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Abstract 
Glioblastoma is the most common malignant brain tumour in adults. Categorised by The 
World Health Organization as a grade IV glioma, it is the most aggressive, invasive form of 
glioma with a median survival time of 14.6 months. The incidence in the United States is 
approximately is two to three per 100,000. Glioblastoma is about 40% more common in 
males than in females and the average age at diagnosis is 64 years. Despite aggressive 
medical intervention including surgical resection followed by radiotherapy and 
chemotherapy, treatment increases survival by a median of only 2.5 months. Tumour 
recurrence occurs in the brain, frequently adjacent to the site of the original tumour. New 
therapies are needed to combat metastatic disease and tumour regeneration after therapy. 
 
Therapeutic resistance is the major cause of death in patients diagnosed with malignant 
tumours. Tumour heterogeneity has emerged as a major player in therapeutic resistance. 
In addition to this, treatments frequently contribute to the evolution of therapy resistance 
by introducing mutations, which provide the cell with mechanisms to survive further rounds 
of treatment. The main aim of this thesis was to identify potential targets within 
glioblastoma that could be exploited to reduce intratumoural heterogeneity and prolong 
progression free survival. 
 
We used three independent processes to interrogate phenotypic and genetic 
heterogeneity within populations of primary human glioblastoma cell isolates. In this first 
experimental chapter, we have investigated whether the cancer stem cell hypothesis may 
explain the heterogeneity observed within our isolates of human glioblastoma. Cancer 
stem cells have been a major focus of research since they were implicated in tumour 
initiation in acute myeloid leukaemia in the 1990s. We tested the cancer stem cell 
hypothesis using glioblastoma cells. We found that glioblastoma contained “slow” and 
“fast” cycling populations of malignant cells. Within the slow cycling stem-like population of 
glioblastoma cells exist a population of cells with superior tumour forming ability. Some of 
the content of this chapter has been published (Brain, 2011. 134, 1331-1343). 
 
The second chapter explored chromosomal heterogeneity using fluorescence activated 
cell sorting (FACS) and Flow cytometry-based assays to demonstrate that the “ploidy” of 
the malignant cells within primary glioblastomas was highly varied and was associated 
with highly discordant behaviour with respect to in vitro growth and proliferation as well as 
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drug resistance. We also showed that hyperdiploid glioblastoma cells were capable of 
tumour formation, more metabolically active and sensitive to glycolysis than their euploid 
counterparts. Some of the content of this chapter has been published (Molecular 
Biosystems, 2014. 10, 741-758) 
 
In the final experimental chapter, we used another platform to interrogate the 
heterogeneity of primary glioblastoma cells. Cell surface proteins have been identified as 
prognostic markers and predictive of response to therapy in a range of human tumours. 
We analysed the expression of 118 cell surface proteins on primary human glioblastoma 
cells and identified a small cohort of proteins, which in concert provide a molecular 
signature of GBM. This data highlights some potential targets for use in the design of anti-
tumour specific therapeutics. 
  
GBM is an incurable heterogeneous tumour with a poor response to treatment. The work 
presented within my thesis identifies a number of potential therapeutic targets that may be 
used to inform novel treatment strategies and targets. In particular, I provide new data that 
may be used to reduce the impact of the highly heterogeneous polyploid populations of 
cells that arise in tumour evolution. Moreover, the targeting of tumour heterogeneity may 
be used to design more effective therapies to reduce side effects, avoid the induction of 
further mutational events caused by current therapies and hopefully extend the 
progression free survival time of patients by slowing tumour growth. 
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1 Introduction 
 
 
 
 
1.1 Foreword 
Cancer accounts for 22% of deaths in the US, a rate exceeded only by heart disease. 
While the 5-year survival rate for cancer has risen from 49% in 1977 to 68% in 2008 
(American Cancer Society, Cancer Facts and Figures. 2013), the death rate from cancer 
overall has remained static for the last 50 years (US National Cancer Institute, 2007). 
Based on previous data, it is estimated that there will be 46,880 deaths from cancer in 
Australia in 2016. The age-standardised mortalilty rate for cancer for the same year will be 
162 deaths per 100,000 persons (Cancer Australia, 2016). Modern medical research has 
been unsuccessful in its goal to effectively cure most cancers despite the growing number 
of available techniques, increasing investment and the enormous amount of time that has 
gone into its study. Target-based study of oncogenic proteins has so far been mostly 
inadequate resulting in therapies incapable of providing long-term survival benefits for 
most cancer patients (Butcher, 2005). A greater understanding of a subset of tumours has 
led to significant improvements in survival demonstrating the benefits of a deeper 
knowledge of the disease and response of tumour cells to targeted therapies. 
Promyelocytic leukaemia is an example of this. Predominantly affecting children, the 
precise chromosomal translocation has been identified and with current therapy the cure 
rate is 80-90% (Tallman & Altman, 2009). Similarly, the cure rate in children with T cell 
acute lymphoblastic leukemia’s (T-ALLs) is 75%. This is the result of the identification of 
distinct molecular subgroups with specific gene expression signatures (Van Vlierberghe & 
Ferrando, 2012). However, the contribution of these statistically high cure rates in overall 
cancer survival statistics is masked by their relatively low incidence. Despite this, the 
success of informed targeted therapies in some malignancies highlights the potential for 
inducing cures in many other cancer types once we have detailed information of their 
underlying pathobiology. A new experimental approach is required to understand the 
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underlying mechanisms of therapy resistance in order to develop effective anti-cancer 
drugs for the majority of tumours that remain incurable today. 
 
Malignant astrocytic gliomas represent 60% of all primary human brain tumours in adults 
(Furnari et al., 2007; Sakariassen, Immervoll, & Chekenya, 2007). Histologically classified 
according to The World Health Organization (WHO), glioblastoma multiforme is 
categorized grade IV, the most aggressive, invasive form of the disease with the poorest 
prognosis (Network, 2008). Patients with GBM have a median survival time of 14.6 months 
(Vescovi, Galli, & Reynolds, 2006). The incidence of glioblastoma is 40% more common in 
men than in women and the average age at diagnosis is 64 years (CBTRUS, 2012). Only 
5% of glioma cases present with a family history of glioma and in the majority of these 
patients there is no known familial genetic abnormality (Wen & Kesari, 2008). Patients with 
primary GBM present with a grade IV glioma and have no previous history of the disease. 
Secondary glioma presents initially as a lower grade tumour either grade I, II or III 
astrocytoma, which subsequently progresses to grade IV. Histopathologically, primary and 
secondary GBM are indistinguishable (Parsons et al., 2008).  
 
Glioblastoma is refractory to treatment despite aggressive medical intervention (Stupp et 
al., 2005). This is partly attributable to the blood brain barrier that presents a physical 
obstruction to the majority of systemically administered chemical compounds, thereby 
reducing treatment response (Sottoriva et al., 2013). Current treatment of GBM is 
aggressive and involves surgery to remove the bulk of the tumour followed by 
chemotherapy and radiotherapy. Surgical debulking is performed to remove pressure on 
surrounding tissues and must be conservative enough to keep post surgical morbidity to a 
minimum (Wen & Kesari, 2008). Radiotherapy in conjunction with the chemotherapeutic, 
temozolomide, is usually administered at 2Gy per day for five days a week over six weeks 
to an area which encompasses the tumour cavity and a small margin of the surrounding 
tissues only, again to reduce damage via post-radiation tissue necrosis (Wen & Kesari, 
2008). In a study of 573 patients with GBM where 50% received radiotherapy alone and 
the other 50% received radiotherapy plus temozolomide, the median increase in survival 
for the radiotherapy plus temozolomide group was only 2.5 months (Stupp et al., 2005). 
Glioblastoma tumour recurrence usually occurs within tissue that has received intensive 
radiation and cytotoxic therapy (Garden et al., 1991). This suggests that a subpopulation 
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of cells is able to evade cytotoxicity and participate in tumour regrowth. Proliferation of 
therapy resistant cells occurs rapidly with previously resected tumours frequently requiring 
further surgical debulking (Chaichana et al., 2013). 
 
The genetic abnormalities most commonly found in GBM involve pathways responsible for 
cell survival, cell cycle control and growth factor signaling (Fomchenko & Holland, 2005). 
These changes result in loss and inactivation of tumour suppressor genes and genes 
responsible for DNA repair mechanisms combined with the amplification or over-activation 
of constitutively activated pathways that function to regulate cell cycle progression and an 
increase in quantity of growth factor ligands and receptor sensitivity that promote cell 
proliferation (Fomchenko & Holland, 2005; Wen & Kesari, 2008). Until recently, the 
common genetic mutations identified in glioma have been used to classify tumours into 
two broad groups, namely, primary and secondary glioma. A recent genomic study that 
identified four tumour subtypes within GBM based on common genetic mutations provided 
a molecular profile that could be used to identify an individual tumour’s potential response 
to therapy and prognosis (Verhaak et al., 2010). 
 
The four subtypes are described in depth elsewhere; key points only will be briefly outlined 
here (Verhaak et al., 2010). The subtype termed ‘classical’ was clearly defined by a 
combination of chromosome 7 amplification with chromosome 10 loss in 100% of cases. 
There was an average fourfold increase in epidermal growth factor receptor (EGFR) 
amplification in 97% of tumours categorised as ‘classical’ with an associated homozygous 
deletion of cyclin-dependent kinase inhibitor 2A (CDKN2A). The ‘mesenchymal’ subtype 
was characterized by neurofibromatosis 1 (NF1) and phosphatase and tensin homolog 
(PTEN) mutations. This group also exhibited an increase in mesenchymal marker 
expression, YKL40/Chitinase-3-like protein-1 (YKL40) and met proto-oncogene tyrosine 
kinase (MET) as well as that of genes in the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκ-B) and tumour necrosis factor pathways although the upregulation 
of these genes was not exclusively identified in this subtype. The ‘proneural’ subtype 
exhibited the highest rate of platelet-derived growth factor receptor alpha (PDGFRA) 
amplifications in association with an increase in gene expression levels. Isocitrate 
dehydrogenase 1 (IDH1) mutations were seen almost exclusively in this group. 
Transformation-related protein 53 (TP53) mutations and loss of heterozygosity (LOH) were 
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also strong features of this subtype. Proneural development genes including the sex-
determining region Y protein (Sry)-related high mobility group box (SOX) genes were a 
feature of this group. The ‘neural’ subtype was identified based on the expression of 
neural markers. Synaptotagmin-1 binds calcium at the synapse triggering neurotransmitter 
release, this along with the neurofilament light polypeptide gene was amongst the genes 
upregulated in the neural group.  
 
No correlation was identified between CpG methylation status of the 06-methylguanine-
DNA-methyltransferase (MGMT) promoter and any of the four subtypes. This study found 
no evidence of transition between subtypes during disease progression. The 
mesenchymal and classical subtypes derived the greatest benefit from treatment in terms 
of survival. The purpose of a profile such as this is to develop biomarkers for each glioma 
subtype that would allow clinicians to tailor treatment to each patient’s tumour by 
predicting points of therapeutic susceptibility and resistance and to aid in prognosis. 
However, in 2013 Sottoriva et al.. published findings that more than one of the subtypes 
identified by Verhaak et al.. can be found within a single GBM tumour simply by sampling 
different regions of the same tumour. This suggests that tumour evolution, from a cell of 
origin, gives rise to an heterogeneous population of malignant cells with varying fitness 
levels responding to a variety of selection pressures including therapy and 
microenvironment resulting in regional differences in genotype and gene expression over 
time (Sottoriva et al., 2013). 
 
Sturm et al., looked at glioblastoma tumour samples of both children and adults and 
identified six subgroups based on mutational status, DNA copy-number aberrations and 
gene expression signatures. They found that mutations in two critical amino acids (K27 
and G34) in the H3F3A gene or mutations in IDH1 occur in both adult and childhood 
glioblastoma and that the two mutant genes were mutually exclusive. In addition to this, 
they were able to map the six subgroups to specific brain regions. This suggests that 
glioblastoma tumour treatment could be specifically designed for different epigenetic and 
biological subgroups from different anatomical brain regions (Sturm et al., 2012). 
 
Therapy resistance is the major problem facing oncologists today. The combination of 
surgery, radiotherapy and chemotherapy, results in removal of the majority of tumour cells. 
However, tumour regeneration following treatment suggests that a population of therapy 
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resistant cells remain to regenerate the tumour. This often leads to the evolution of an 
aggressive chemoresistant cell population that is refractive to further treatment. Tumour 
heterogeneity contributes to therapy resistance making this an important research area in 
the effort to find a cure for cancer. 
 
1.2 Tumour heterogeneity 
Tumour heterogeneity is the term used to describe the existence of cells exhibiting 
different genomic or proteomic profiles or biological activity (Marusyk & Polyak, 2010). 
Tumours from different organs are genetically diverse. This might be explained in part, by 
the specific biological properties of the organ combined with the microenvironment of the 
cells within that tissue. Intertumoural heterogeneity has been partially resolved through 
subgroup classification, which may predict response to therapy and prognosis (Burrell, 
McGranahan, Bartek, & Swanton, 2013). Tumours from the same organ within the same 
individual patient also frequently exhibit genetic differences as well as differences in 
therapeutic response and aggressiveness of disease. This is called intratumoural 
heterogeneity (Burrell et al., 2013). Intratumoural heterogeneity presents the biggest 
obstacle to cancer therapy. It is not simply ‘noise’, that disguises the more frequent 
deleterious changes that have been the focus of genetic studies to identify oncogenic 
genes common to certain cancer types (Heng et al., 2009). Intratumoural heterogeneity 
provides a mechanism of rapid evolution by imparting variation that can overcome a wider 
range of perturbations. Small subpopulations of cells persist with an elevated expression 
of a beneficial protein such as an oncogene, or loss of expression of a detrimental protein 
such as a tumour suppressor gene. These cells exhibit a superior fitness level in a 
cytotoxic environment increasing their chances of survival. For a trait to contribute to 
therapeutic resistance it must be heritable. If a trait is not heritable, it does not contribute to 
the evolvability of a clonal population with the ability to overcome therapy. In some tumour 
types the stage of the cancer progression can be measured by the genetic mutation load 
(Khambata-Ford et al., 2007; McFarland, Korolev, Kryukov, Sunyaev, & Mirny, 2013).  
 
GBM is characterized by marked heterogeneity within the cell population of an individual 
tumour. Cells within a tumour display varying rates of proliferation and migration, a variety 
of cell-cell interactions, variation in sensitivity to therapy and differences in cell size and 
cell surface protein profile. The accumulation of this diversity presents a significant 
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challenge to the development of an effective treatment for the disease. One possible 
solution to this dilemma is to identify subpopulations of cells within a tumour that promote 
disease progression and treat these cell populations with individually targeted therapies.  
 
1.3 Tumour evolution 
Genomic instability refers to an increase in genetic mutations arising in a cohort of cells 
(Shen, 2011). It is a potential source of genetic diversity underpinning progressive tumour 
evolution subject to phenotypic penetrance (Burrell et al., 2013). The presence of a variety 
of different clones within a tumour is generally considered to be generated stochastically 
while the expansion of a clonal population within a tumour is determined by selection 
pressure exerted by external factors, the microenvironment on surrounding cells and cell 
signalling (Inda, Bonavia, & Seoane, 2014).  Mechanisms of genomic instability include 
mismatch repair, telomere loss, double-strand break repair, deregulated DNA replication 
and chromosomal missegregation (Burrell et al., 2013; Pikor, Thu, Vucic, & Lam, 2013). 
These mechanisms are a result of various genetic defects including point mutations, 
chromosomal deletions (loss of heterozygosity) or insertions, chromosomal 
rearrangements and aneuploidy (subdiploid and hyperdiploid) (Abdel-Rahman, 2008; 
Campbell et al., 2010). The phenotypic outcome will vary according to the magnitude of 
the genetic defect, which could be smaller for a point mutation for example than the loss of 
an entire chromosome (Burrell et al., 2013).  
 
Treatment including chemotherapy and radiotherapy can initiate exogenous genomic 
instability introducing new mutations as was demonstrated in patients following treatment 
for AML (L. Ding et al., 2012). Temozolomide is an alkylating agent used in the treatment 
of glioblastoma. Alkylating agents work by inducing adducts on DNA causing mispairing of 
nucleotides.  Normally the mispairing is recognised by the mismatch repair system leading 
to apoptosis (Kondo, Takahashi, Ono, & Ohnishi, 2010).  Mispairing of 06-methylguanine 
with thymine in double stranded DNA is normally recognised by the MSH2/MSH6 
mismatch repair dimers (Hunter et al., 2006). The results of an analysis of human 
malignant glioma tissue and blood samples from 30 patients showed that this system was 
inactivated due to mutations in MSH6 following TMZ therapy (Hunter et al., 2006). 
Tumours, which responded to the initial round of chemotherapy, were insensitive to 
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subsequent treatment due to mismatch repair deficiency and with no system in place to 
prevent cell cycle progression exhibited elevated mutation rates (Hunter et al., 2006).  
 
Environmental conditions can promote tumour progression in individual cohorts of cells. 
Tumour microvascular proliferation, a key feature of glioma is a disorganised process 
leading to inconsistency in perfusion levels across the tumour (Junttila & de Sauvage, 
2013). Variations in distance from vasculature, affects access to supply of nutrients and 
signalling proteins. Nitric oxide is produced in the endothelial cells and plays a role in cell 
signalling (Tredan, Galmarini, Patel, & Tannock, 2007). Variations in nutrient distribution 
and access to signalling proteins contribute to the regional heterogeneity reported when 
biopsies are examined from different geographical locations across a tumour (Tredan et 
al., 2007).  Suboptimal perfusion results in poor drug distribution to some regions of the 
tumour leaving those areas with less than the desired dose (Tredan et al., 2007). 
Exposure to nitric oxide was shown to be associated with tumour formation and 
aggression in mouse models of glioma as determined by endothelial nitric oxide synthase 
protein levels on western blot.  Tumourigenesis was reversed when nitric oxide was 
withdrawn resulting in longer survival time (Charles et al., 2010).  
 
Cellular fitness is context dependent (Junttila & de Sauvage, 2013). A genetic mutation, 
which is advantageous in one environment, may be deleterious in another. This means 
that a mutation might be present in a small subpopulation and subsequently undergo 
clonal expansion in response to a change in the tumour environment such as 
commencement of cytotoxic therapy (L. Ding et al., 2012; Villanueva et al., 2010). In 
addition to this, mutations can be silent, known as cryptic genetic variation, and this cryptic 
variation can be revealed under novel selection pressures and is thought to be responsible 
for rapid evolution (Whitacre, Lin, & Harding, 2012). A mutation that is deleterious in a 
normal environment may, in a hostile environment such as hypoxia, improve the likelihood 
of cell survival, contribute to fitness, undergo positive selection and through clonal 
expansion become a trait that contributes to a therapeutic resistant population (Loeb & 
Loeb, 1999; Tian, Olson, Whitacre, & Harding, 2011). Regional microenvironmental 
differences within a tumour can result in the clonal expansion of different subpopulations 
across the tumour (Junttila & de Sauvage, 2013). 
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Another way in which tumour cells can express heterogeneity is through phenotypic 
plasticity. Tumour cell plasticity is defined as the dedifferentiation of a cell to a different 
phenotype (Friedmann-Morvinski & Verma, 2014). One example of cellular plasticity is 
epithelial to mesenchymal transition (EMT). EMT is a process whereby cells display 
morphological changes including cytoskeletal changes and loss of cell-to-cell signalling 
facilitating invasion and metastasis formation (Creighton, Chang, & Rosen, 2010). EMT 
has been reported in tumours in the breast, lung, pancreatic, head and neck and 
glioblastoma (Ortensi, Setti, Osti, & Pelicci, 2013; Sarkar, Li, Wang, & Kong, 2009; 
Shrivastava et al., 2015; Q. S. Wang, Kong, Li, Yang, & Feng, 2015; Xiao & He, 2010). 
Reversible EMT is the process by which cells undergo EMT followed by mesenchymal to 
epithelial transition (MET) and back again (Luo, Brooks, & Wicha, 2015). This process of 
transitioning between different states has been reported in breast cancer cells (S. Liu et 
al., 2014). MET-like breast cancer cells identified at the tumour centre have been 
recognised as being proliferative while EMT-like cells located at the invasive front were 
quiescent (Luo et al., 2015). In tumours, cellular plasticity can provide additional 
mechanisms for subpopulations of cells within a tumour to respond differently to 
chemotherapy. Cancer metastasis and drug resistance have been shown to be features of 
EMT (Luo et al., 2015; Saunders et al., 2012). Breast cancer cells that underwent EMT 
confirmed by changes in protein expression levels, developed insensitivity to paclitaxel (G. 
Z. Cheng et al., 2007). Similarly, cisplatin resistance correlated with EMT in 
immunohistochemical analyses of head and neck squamous cell carcinoma (HNSCC) 
patient tissue samples (Hsu et al., 2010).  
 
GBM cells have been reported to exhibit EMT characteristics in association with increased 
invasion and therapy resistance following treatment (Piao et al., 2013). Anti-vascular 
endothelial growth factor (VEGF) therapy slows tumour progression by inhibiting 
angiogenesis (Batchelor et al., 2007). Bevacizumab (Avastin; Genentech/Roche) is a 
humanised monoclonal antibody directed against VEGF currently approved for use in the 
treatment of GBM (Piao et al., 2013). Glioma cells with previous exposure to bevacizumab 
developed a mesenchymal-like gene expression signature that was associated with an 
increase in invasion and resistance to further bevacizumab therapy compared with 
parental cell lines with no previous exposure to bevacizumab (Piao et al., 2013).  
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There are two proposed models of tumour heterogeneity contributing to tumour evolution, 
the cancer stem cell model and the clonal evolution model. Both models purport to explain 
therapy resistance in tumours. This thesis investigates each model in human glioblastoma. 
Finally, cell surface protein expression has been used by others, to predict prognosis and 
determine therapeutic response in a variety of tumours. This study analysed cell surface 
protein expression on human GBM cells to identify a subpopulation of cells of clinical 
relevance in GBM tumours. Tumour evolution resulting in increased cellular plasticity and 
heterogeneity is generated by a range of mechanisms leading to a complex set of 
therapeutic responses. To effectively treat a plastic heterogeneous tumour cell population 
a combination of therapies will be required that target different subsets of the tumour with 
unique characteristics. 
 
1.4 The cancer stem cell model 
Stem cells exist throughout the body in many human tissues to generate new cells for the 
dual purposes of ongoing maintenance and repair following injury and disease (Dalerba, 
Cho, & Clarke, 2007). The three defining properties of stem cells are: extensive self-
renewal, generation of a large number of progeny and multi-lineage differentiation 
potential (Piccirillo et al., 2006). Another key characteristic of stem cells is their relative 
quiescence, which is essential to prevent premature stem cell depletion over the lifetime of 
the organism (T. Cheng et al., 2000). 
 
Neural stem cells are generated in the hippocampus, the subventricular zone of the lateral 
ventricles and the olfactory bulbs (Fomchenko & Holland, 2005; Piccirillo et al., 2006). 
Their function is to generate new neurons and glia that can migrate to other brain regions 
to replace damaged and ageing cells throughout the lifetime of the organism (Gage, 
2000). The Neurosphere Assay culture system (NSA) is the method of choice to isolate, 
propagate and culture neural stem cells (NSCs) from embryonic and adult murine and 
human central nervous system (CNS) (Reynolds & Weiss, 1996; Vescovi et al., 1999). For 
this reason, it is the method used in the present study to culture brain tumour cells. 
 
Therapy resistance continues to be the greatest obstacle to achieving complete remission 
in this disease (Ramirez, Weatherbee, Wheelhouse, & Ross, 2013). The cancer stem cell 
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hypothesis states that tumour initiation and maintenance is driven by a rare subpopulation 
of tumour cells that phenotypically mimic the cardinal properties of stem cells. This 
hypothesis was first postulated in the 1990s based on studies of acute myeloid leukaemia 
(AML) (Bonnet & Dick, 1997; Huntly & Gilliland, 2005; Lapidot et al., 1994) and has since 
been strengthened by findings in breast, prostate, lung and mesenchymal tumours (Al-
Hajj, Wicha, Benito-Hernandez, Morrison, & Clarke, 2003; Buzzeo, Scott, & Cogle, 2007; 
Mano et al., 2008). The ability of cells derived from human glioma tissue to generate 
neurospheres in culture, suggests the presence of tumour cells with neural stem cell 
properties within CNS tumours (Hemmati et al., 2003; Ignatova et al., 2002; Singh, Clarke, 
Hide, & Dirks, 2004; Singh et al., 2003), as neurosphere generation is one indicator of the 
presence of NSCs. Further work  (Galli et al., 2004) has demonstrated the isolation, 
propagation and serial transplantation of tumour neural stem cells (tNSCs) that exhibit very 
similar functional properties to neural stem cells. Importantly, following implantation of 
tNSCs, the resulting tumours exhibit the classic in vivo features of human glioblastoma 
multiforme; recapitulating the morphology, genotype and gene expression patterns of 
primary GBMs, as well as having extensive migratory and infiltrative capacity (Engelman et 
al., 2007). This indicates that the in vitro defined brain tumour stem cells faithfully preserve 
the key in vivo features of human GBM. 
 
Results in chronic myeloid leukemia (CML) patients suggest that a small number of 
quiescent, malignant stem cells are extremely refractory to treatment and are responsible 
for patient relapse after therapy (Barnes & Melo, 2006). The short progression free survival 
(PFS) time of patients with glioblastoma is consistent with the hypothesis that an 
analogous population of slow-cycling cancer stem cells also exists in human GBM 
tumours. If this hypothesis is correct, then elimination of slow-cycling, therapy-resistant 
cancer stem cells will be essential for the long-term survival of glioblastoma patients.  
 
1.5 The clonal evolution model 
One of the ways in which tumours exhibit genetic heterogeneity is through variation in 
ploidy (Craig & Foon, 2008; Zuzana Storchova & Pellman, 2004). Polyploidy is the over 
duplication of whole chromosome sets. Polyploidy in mammals is defined as greater than 
two sets of chromosomes (Tovar et al., 2010). An example of this is tetraploidy which 
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refers to the presence of four sets of chromosomes. This can occur when a cell that has 
undergone DNA replication subsequently fails mitosis or cytokinesis (Vitale et al., 2011).  
 
Polyploidy exists in normal development. There are at least three known mammalian cell 
types that utilize polyploidy during development. During placental development, placental 
trophoblast giant cells utilize polyploidization to reach many times the usual diploid content 
by preventing mitosis (Davoli & de Lange, 2011; Ullah, Lee, Lilly, & DePamphilis, 2009). 
Bone marrow megakaryocytes fail to undergo cytokinesis numerous times forming a large 
nucleus following multiple rounds of mitosis and hepatocytes also fail cytokinesis to form 
4N or 8N nuclei (Davoli & de Lange, 2011; Winkelmann, Pfitzer, & Schneider, 1987). 
Numerous variations of polyploidy also exist. 
 
Aneuploidy refers to the presence of an abnormal number of chromosomes which is not a 
precise multiple of the haploid chromosome number for that cell (E. M. Torres, Williams, & 
Amon, 2008). An aneuploid cell can be subdiploid or hyperdiploid, due to the loss or gain 
of one or more chromosomes (Lacroix & Maddox, 2012).  Aneuploidy is a common feature 
of tumours (Y. Li et al., 2010; Z. Storchova & Kuffer, 2008; Tang, Williams, Siegel, & 
Amon, 2011) and is sometimes used to classify tumours and predict prognosis (Y. Li et al., 
2013; Van Wier et al., 2013). Hyperdiploidy is a clinically relevant feature of tumours 
including acute lymphoblastic leukaemia (Paulsson et al., 2010). Hyperdiploidy can also 
contribute to therapeutic resistance by amplification of drug transporters and reducing 
sensitivity to chemotherapeutics (Anand, Penrhyn-Lowe, & Venkitaraman, 2003; Q. Cheng 
& Evans, 2005; Gorre et al., 2001). Studies involving yeast revealed that aneuploidy 
promoted rapid phenotypic evolution and drug resistance to cytotoxic compounds (J. Chen 
et al., 2012). These findings suggest that aneuploid cells could be contributing to therapy 
resistance in cancer and may provide an important therapeutic target for future cancer 
treatments. 
 
1.6 Cell surface proteins 
Tumours are also heterogeneous in their expression of cell surface proteins. A vast 
spectrum of molecules exists on the surface of a single cell and cell types from various 
organs and tissues exhibit differential cell surface molecule expression. The molecules 
represented on the cell surface include proteins, glycoproteins and glycolipids, which 
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function as ligands, receptors, adhesion molecules, and ion channels (Zola et al., 2005). 
Cell surface proteins may span the cell membrane, binding both extracellular and 
intracellular ligands, or alternatively through tethering to the external surface of the 
membrane, trigger protein interactions that promote a cascade of interactions through the 
membrane and into the cytosol. Proteins that reside on the surface of a cell contribute to 
the phenotype of that cell and to the range of functions of which it is capable. Processes 
such as proliferation, apoptosis, invasion, migration, and senescence are initiated through 
the binding of circulating extracellular ligands to cell surface protein receptors that trigger 
downstream signaling to intranuclear transcription factors. Immunophenotyping exploits 
cell surface protein expression to distinguish a subpopulation of cells with a distinct 
molecular signature (Craig & Foon, 2008; van Dongen et al., 2012). 
 
During the 1980’s, the identification of antibodies to leukocyte cell surface molecules by 
immunologists developed rapidly in various laboratories across the globe utilizing a variety 
of techniques. This resulted in antibody reactivity that was often variable and confusion 
with regard to which newly generated antibodies were identical. The human leukocyte 
Differentiation Antigen (HLDA) workshops were initiated in 1982 to provide consensus on 
surface protein identification and a universal nomenclature system (Zola, 2001; Zola et al., 
2005). Some of the same proteins have since been detected in organs and tissues 
throughout the body. Additionally, disease biomarkers and molecular targets for therapy 
have been identified (Zola, 2001). The collective name for these antibodies is now human 
cell differentiation molecules (HCDM) to encompass the expanding range of human tissue 
types that exhibit reactivity to these antibodies. 
 
Cell surface proteins have traditionally been widely used in haematologic malignancies for 
the purposes of diagnosis, monitoring of treatment efficacy and isolation of cancer stem 
cells (Hofmann et al., 2010). Immunophenotyping of acute leukaemic blast cells using CD 
markers has facilitated the identification of the cellular lineage allowing clinicians to predict 
prognosis and response to therapy (Medeiros et al., 2010). Panels of antibodies that 
detect minimal residual disease in leukaemia following therapy are being investigated to 
facilitate early detection of relapse and improve treatment outcomes (X. Li et al., 2010). 
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An increased presence of circulating membranous glycoproteins is thought to be indicative 
of either apoptosis or protein shedding (Alatrash et al., 2010). The shedding of membrane 
spanning glycoproteins into the plasma is a characteristic of malignant cells (Komada et 
al., 1986). Post therapeutic progression free survival and estimation of minimal residual 
disease may soon be possible by assessment of CD expression levels in circulating 
plasma. In chronic lymphoblastic leukaemia (CLL), circulating CD20 is understood to 
reflect a refractory response to therapy (Prevodnik, Lavrencak, Horvat, & Novakovic, 
2011).  
 
Cancer stem cells have been identified in AML as the cancer-initiating cell responsible for 
disease progression and relapse after therapy (Bonnet & Dick, 1997). Immature 
lymphocytes, also known as blasts, proliferate without fully differentiating to the point that 
overcrowding inhibits normal proliferation of other cell types (Bonnet & Dick, 1997). One 
study interrogated leukaemic cells for a cell surface protein expression profile that 
identified them from amongst other primitive cell types and non-cancerous stem cells 
(Lapidot et al., 1994). A small proportion of the overall population of AML cells were 
selected based on their expression of two cell surface proteins, CD34+ and CD38-, which 
when transplanted into immunocompromised mice were able to proliferate and initiate a 
disease state identical to that of the donor (Bonnet & Dick, 1997; Lapidot et al., 1994). 
More recently, monoclonal antibodies targeting CD44, CD47 and CD123 have been 
shown to independently inhibit disease progression in in-vivo models of AML (Majeti & 
Weissman, 2011). 
 
The identification and isolation of tumour initiating cells in leukaemia using a cell surface 
protein expression profile (Bonnet & Dick, 1997; Lapidot et al., 1994), has led to a search 
for a similar phenomenon in solid tissue cancers. Medulloblastoma cells have been shown 
to include a subpopulation of CD133+ expressing cells that exhibit extensive proliferative 
ability, ability to differentiate into the cell types specific to the tumour from which they were 
derived, and in the proportions indicative of that specific tumour type, as well as the ability 
to form neurospheres in the culture system originally designed for neural stem cells (Singh 
et al., 2003). In other work, tumour-initiating cells have been isolated from the total 
population of breast cancer cells using cell surface protein antibodies. A xenograft assay 
involving transplantation of breast cancer cells into immunocompromised mice showed 
that as few as 200 CD44+/CD24-/low cells were capable of tumour formation with 100% 
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efficiency whereas transplantation of 50,000 unsorted breast cancer cells were required to 
achieve 100% tumour formation (Al-Hajj et al., 2003).  
 
CD protein expression profiles have been recognized as corresponding with tumour 
progression and prognosis in a range of solid tumours. The increased expression of the 
tetraspanin protein CD151 has been shown to positively correlate with large invasive 
tumours and metastases while being negatively correlated with overall survival in 
hepatocellular carcinoma patients (Ke et al., 2009). Motility-related protein-1 (MRP-1/CD9) 
is a transmembrane protein found to predict disease free survival (DFS) in patients 
diagnosed with squamous cell carcinoma of the head and neck. CD9 expression was 
negatively correlated with disease free survival (DFS) in a study of 153 patients by 
immunohistochemistry (Mhawech et al., 2004). A small number of cell surface CD proteins 
have been recognized in GBM as contributing to disease progression and prognosis. 
Higher expression of CD44 has been correlated with aggressive glioma tumours as 
determined by immunohistochemistry (Wei et al., 2010).  
 
CD133 expression in glioma has been quite controversial. Initially reported as being a 
putative cancer stem cell marker (Zeppernick et al., 2008), CD133 positivity now appears 
to be environmentally induced rather than inherited (L. K. Donovan & Pilkington, 2012; 
Safa, Saadatzadeh, Cohen-Gadol, Pollok, & Bijangi-Vishehsaraei, 2015). Several labs 
have shown an increase in stem cell marker expression and CD133 expression, 
proliferation and migration in cells exposed to a hypoxic environment, suggesting that cells 
undergoing hypoxia migrate away to regions supplying higher oxygen concentrations 
where they utilize blood vessels to supply nutrients for tumour growth and progression 
(Campos & Herold-Mende, 2011; Ohnishi et al., 2013). McCord et al. showed that GBM 
cells passaged under hypoxic conditions, 7% oxygen, exhibited an increase in CD133 
expression in addition to increased proliferation and self-renewal rates in comparison to 
cells passaged in 20% oxygen (McCord et al., 2009). 
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1.7 Aims and Hypotheses 
The overall aim of my thesis was to interrogate the role of heterogeneity in the 
development of GBM therapy resistance with a view to designing better treatment 
paradigms 
 
1.7.1 Hypotheses 
1. A rare subpopulation of stem like cells exists within human GBM tumours that are 
responsible for the initiation and regeneration of tumours following treatment. 
2. Cell-surface protein expression can be used to identify cell subpopulations of clinical 
relevance in GBM tumours.  
 
1.7.2 Aims 
To address these hypotheses I will pursue the following three aims: 
1. Examine GBM tumours for a subpopulation of stem like cells that exhibit therapeutic 
resistance. 
2. Investigate the relevance of hyperdiploid cells in the evolution of therapeutic resistance 
in GBM. 
3. Identify cell surface proteins of potential clinical relevance in GBM. 
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CHAPTER TWO 
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2 Materials and Methods 
 
 
 
 
2.1 Tumour cell line generation from primary tumour tissue 
All tumour tissue was obtained from glioblastoma patients during surgical resection 
following written informed consent complying with guidelines established by the Princess 
Alexandra Hospital Research Ethics Committee. Tumour tissue was classified by 
neuropathologists as glioblastoma according to WHO guidelines (D. N. Louis et al., 2007). 
Patient tumours were washed and mechanically dissociated before being chemically 
dissociated with trypsin/ethylenediaminetetraacetic acid 0.05% (Gibco) for 10 minutes at 
370C. Cells were then filtered through a 40µm filter to achieve a single cell suspension. 
Cells were counted using Trypan Blue to exclude dead cells and cultured in fresh 
neurosphere media in a 370C incubator. Neurosphere media contained DMEM F12 
(Sigma), 10% NeuroCult Neural Stem Cell Proliferation Supplement (StemCell 
Technologies Inc), human epidermal growth factor (hEGF, 20ng/ml, StemCell 
Technologies Inc.), basic fibroblast growth factor (bFGF, 10ng/ml, StemCell Technologies 
Inc.) and heparin 2μg/ml (Sigma), Penicillin/Streptomycin 2.8ml in 250ml (Life 
Technologies) as described in (S. A. Louis et al., 2008). When spheres reached an 
adequate size ~ 150µm, they were chemically dissociated as described above, counted 
and reseeded in flasks at a density of 50,000 cells per ml. 
 
2.2 Xenotransplantation assays 
All animal work was performed in accordance with the National Health and Medical 
Research Council Guidelines for the care and use of animals for scientific purposes. 
Surgical protocols were approved by The University of Queensland Animal Ethics 
Committee.  All surgery was performed on six to ten week old non-obese diabetic/severe 
combined immunodeficient (NOD/SCID) mice. 
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2.2.1 Mouse subcutaneous injections of human GBM cells 
Cells were chemically dissociated using Trypsin (Gibco) and washed twice in neurosphere 
media. Cells were resuspended in 5µM CFSE in 5ml cold neurosphere media and 
incubated for 10 minutes in the dark. CFSE reaction was inhibited with cold neurosphere 
media containing 10% foetal calf serum. Cells were centrifuged, given two washes in 
neurosphere media, resuspended in complete neurosphere media and a cell count was 
performed. Cells were resuspended at 1 x 106 cells per 100µl in Matrigel (BD Biosciences) 
and neurosphere media 1:1 and stored on ice while mice were prepared. Fur was 
chemically removed from the abdominal region of each mouse using Nair and area 
cleaned. Mice received subcutaneous injections using a Tuberculin syringe containing 
100µl of solution with 1 x 106 cells. Animals were monitored daily and tumours measured 
with a caliper once they became visible. Animals were sacrificed once tumours reached 
1cm in diameter. 
 
2.2.2 Mouse intracranial injections of human GBM cells 
Cells passaged as neurospheres in serum free media were chemically dissociated with 
Accutase (Sigma) for 10 minutes at 370C and centrifuged into a pellet. Cells were 
resuspended in neurosphere media to a concentration of 100,000 cells/µl and stored on 
ice. Mice were anaesthetized with either Ketamine and Xylazine or Isofluorane. Mice were 
positioned in stereotax. Coordinates for stereotactical injections into adult mice were 2mm 
laterally to the midline at the bregma and 3mm dorso-ventrally. A small hole was drilled in 
skull for needle insertion. Mice were injected with 200,000 cells using a 5μl Hamilton 
Syringe. The wound was closed with vetbond. Post-operatively mice were monitored for 
signs of neurological and physical deterioration, including ataxia, lethargy, seizures, weight 
loss, or paralysis. Mice were sacrificed and the tumours removed for further study. 
 
2.3 Flow cytometry 
2.3.1 Loading cells with CFSE 
GBM cells were aspirated from flask and centrifuged. Cells were then resuspended in 
warm Trypsin and incubated for three minutes at 370C, pipette mixing twice during 
incubation and centrifuged. Cells were washed in neurosphere media and centrifuged. 
Staining was performed using 5µM CFSE (Molecular Probes) per 1.0ml cold neurosphere 
media per 4 x 106 cells for 10 minutes protected from light. Adding 5.0ml ice-cold 
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neurosphere media with 10% foetal calf serum stopped the reaction. Cells were 
centrifuged for five minutes at 40C and rinsed twice in ice-cold neurosphere media, 
resuspended in fresh media, counted and seeded into tissue culture flasks at 50,000 cells 
per ml. GBM cells were cultured for five to seven days before analysis.  
 
2.3.2 FACS sorting of CFSE stained cells 
Cells were loaded with CFSE as described above. After CFSE was inhibited cells were 
washed once in PBS and either sorted by fluorescence-activated cell sorting (FACS) or 
fixed for 10 minutes in 4% PFA and kept at 40C until analysis by flow cytometry. Cells were 
separated into top 5% CFSE stained cells and bottom 85% CFSE stained cells with a 10% 
gab in between to prevent contamination of populations. Cell sorting was performed on an 
Influx Cell Sorter. Results were analysed using FLOWJO software. 
 
2.3.3 5-Ethynyl-2’-deoxyuridine incorporation 
Cells were chemically dissociated in Trypsin (Gibco) or Accutase (Sigma) and washed 
twice in PBS. Cells were labeled with EdU (Invitrogen 10µM) for 45 minutes at 370C, 
followed by two washes with neurosphere media and resuspension in complete media. 
Retention was determined at intervals of 24 hours for five days. In preparation for flow 
cytometry analysis, cells were treated with Accutase (Sigma), centrifuged, fixed for 10 
minutes in 4% PFA on ice, pelleted resuspended in ice-cold methanol and stored at -200C. 
Flow cytometry was performed on a BD LSRII. Analysis was performed with FLOWJO 
software. 
 
2.3.4 Cancer stem cell marker and cell cycle analysis by flow cytometry 
Cells were stained with CFSE in NS media as described above and fixed for 10 minutes in 
4% PFA. Cells were washed once in PBS and permeabilized in 100% ice-cold methanol. 
Cells were either stored at -200C or used immediately. For antibody staining, cells were 
washed once in PBS and blocked in 1% BSA (Sigma) in PBS for 30 minutes at room 
temperature in the dark. Cells were counted and 1 x 106 cells were stained per well. 
Primary antibodies: CD15 (BD Biosciences 1:100), CD133 (Miltenyl Biotech 1:50), ABCG2 
(Abcam 1:200), GFAP (Cell Signaling Technology Technology 1:1,500), Sox2 (Cell 
Signaling Technology 1:200), Nestin (Merck Millipore 1:400), MCM2 (Cell Signaling 
Technology 1:200), MCM7 (Cell Signaling Technology 1:100), Cyclin B1 (BD Biosciences 
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1:100), Phospho-Rb (Cell Signaling 1:200) were diluted in 100ul block and cells incubated 
for 60 minutes at room temperature in the dark. Cells then underwent two x PBS washes 
followed by secondary antibody incubation. Alexa Fluor 647 (Life Technologies 1:400) and 
DAPI (1:500) were applied for 30 minutes at room temperature in the dark. At the 
completion of secondary antibody incubation, cells were given one PBS wash and stored 
at 40C until analysis by flow cytometry on a BD LSRII. Analysis was performed using 
FLOWJO software. 
 
2.3.5 Ki67 staining 
GBM cells were aspirated from flask, centrifuged, resuspended in warm Trypsin (Gibco) 
and incubated for three minutes at 370C, pipette mixing twice during incubation, Trypsin 
was then inhibited and cells centrifuged. Cells were washed twice in PBS and fixed for 10 
minutes in 4% PFA then washed twice again in PBS and permeabilized in Saponin 
(Invitrogen) in BSA and PBS for 10 minutes as per manufacturers instructions. Blocking in 
3% BSA in PBS was performed at room temperature for 60 minutes. Staining using Ki67 
(Novocastra 1:100) was performed at room temperature for 60 minutes. Cells were 
washed twice in PBS and incubated in secondary antibody and DAPI for 30 minutes at 
room temperature followed by two PBS washes before analysis by flow cytometry on a BD 
LSRII. 
 
2.3.6 Isolation of hyperdiploid clones and assessment of proliferative ability 
Four GBM tumour cell lines were stained with CFSE and cultured for seven days in 
neurosphere media. Cells were chemically dissociated with Accutase as described above 
and sorted by FACS according to CFSE intensity into two groups, the top 5% CFSE bright 
cells and the bottom 85% CFSE dim cells. Top 5% CFSE bright cells were diluted in media 
and added to wells of a 384 well plate at one cell per 50µl per well. Developing spheres 
were monitored daily. Only spheres generated from a single cell in a well were retained for 
proliferation and further analysis. Clones were amplified into plates from 96 wells through 
to six wells and then flasks. At this stage, clones were DAPI (Invitrogen 4µg/ml) stained 
and analysed by flow cytometry using FLOWJO software to determine ploidy status. Three 
independent hyperdiploid clones were assessed from three primary tumour cell lines for 
the potential to maintain long-term proliferation. Each cell line was sub-cultured for seven 
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days over an eleven-week period at 50,000 cells per ml to observe the maintenance of 
viable, proliferative cultures. 
 
2.3.7 Cell volume measurement 
GBM cells were cultured as tumourspheres as described above and chemically 
dissociated in Accutase (Sigma) and fixed in 4%PFA in PBS, permeabilized in ice-cold 
methanol and stained with propidium iodide (PI) at a final concentration of 1µM in PBS 
RNase solution for 30 minutes at room temperature. Cell volume was measured using a 
Beckman Coulter Quanta SC Flow Cytometer. The instrument software using 10µM latex 
bead size standards calculated cell volume. 
 
2.3.8 Cell surface protein detection by flow cytometry 
Cells were passaged as neurospheres in serum free media as described above for tumour 
cell line generation. When large spheres had formed, spheres were dissociated via 
enzymatic reaction using Accutase (Sigma) for 10 minutes, or Trypsin (Gibco) for three 
minutes at 370C. Cells were placed into a flask of media in 370C for three hours to recover 
before staining. After blocking in 2% BSA in neurosphere media for 30 minutes at room 
temperature, staining was performed in 96 well ‘V’ bottom plates. Live cells were stained 
with LIVE/DEAD Fixable Near Infra-red Dead Cell Stain Kit (Invitrogen) according to 
manufacturers instructions to facilitate isolation of dead cells during flow cytometry 
analysis. To control for non-specific antibody binding cells were incubated in identical 
concentrations of isotype control. During analysis of mouse tumours, neural cell adhesion 
molecule 1 (NCAM-1) (BD Biosciences Alexa Fluor 647 Mouse Anti-Human CD56 1:100) 
was used to identify human cells and exclude cells of mouse origin. In analyzing primary 
human tumours, CD45 was used to exclude leukocytes (Violet 450 1:50). CD3 was used 
as an additional negative control. All CD antibodies and isotype control were purchased 
from Becton Dickinson unless stated otherwise below in ‘Cell surface antibodies’. Cells 
were incubated for 30 minutes in the dark at 370C in CD antibodies diluted in block 
conjugated to either phycoerythrin (PE) (1:100) or flourescein isothiocyanate (FITC) (1:50). 
This was followed by fixation in 4% PFA for 10 minutes and two PBS washes. Cells were 
resuspended in PBS and flow cytometry was performed on either a BD LSRII or a 
Beckman Coulter Gallios. Results were analysed in FLOWJO software. 
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2.3.9 Cell surface antibodies 
CD antibodies purchased from BD Biosciences unless stated otherwise were conjugated 
to either PE or FITC (1:100): CD2, CD3, CD4, CD5, CD7, CD8, CD9, CD11a, CD11b, 
CD11c, CD13, CD14, CD15, CD16, CD16b, CD18, CD19 (BD Horizon), CD20, CD23, 
CD24, CD25, CD26, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD38, 
CD40, CD44, CD45, CD45RA, CD45RB, CD45RO, CD49a, CD49c, CD49d, CD49f, CD54, 
CD55, CD56, CD58, CD59, CD61, CD62L, CD62P, CD63, CD69, CD79a, CD79b, CD80, 
CD81, CD86, CD87, CD88, CD90, CD95, CD103, CD104, CD105 (abcam), CD106, 
CD110, CD111 (Beckman Coulter), CD117, CD128a, CD128b, CD133 (Miltenyl Biotech), 
CD134, CD135, CD138, CD140a, CD140b (BD Transduction Laboratories), CD141, 
CD142, CD146, CD152, CD161, CD163, CD164, CD165, CD166, CD171 (eBioscience), 
CD183, CD184, CD200, CD206, CD220, CD230 (eBioscience), CD235a, CD243, CD271, 
CD273, CD274, CD338, HLA-DR (347367), HLA-DR (555561), HLA-DR (555809), HLA-
DR (555812), NGFR. 
 
2.4 In vitro assays 
2.4.1 Sphere forming assay 
To determine sphere-forming frequency, cells were chemically dissociated using Accutase 
(Sigma) for 10 minutes at 370C. Cells were resuspended in media and seeded into a 384 
well flat bottom plate usually 10,000 cells per ml, 50μl per well. In the experiment to 
assess response to temozolomide treatment, cells were seeded at 2,000; 1,000; 500 cells 
per well and passaged for seven days before counting spheres. Sphere forming frequency 
was determined by dividing the number of observed gliomaspheres by the number of cells 
plated initially. 
 
2.4.2 Colony forming assay 
To determine colony-forming ability 1000 cells were suspended in 2.0ml of semi-solid 
media per well of a six well plate. Media consisted of: MegaCult-C 1.7ml (StemCell 
Technologies Inc.), NeuroCult Neural Stem Cell Proliferation Supplement 330µl (StemCell 
Technologies Inc.), EGF 6.6µl (human EGF, 10µg/ml, StemCell Technologies Inc.), basic 
FGF 3.3µl (bFGF, 10µg/ml, StemCell Technologies Inc.) and heparin 3.3µl (0.2% Sigma), 
penicillin/streptomycin 32µl and Collagen (StemCell Technologies Inc.) 1.3ml. Collagen 
was kept on ice and added after all other components. The assay continued for three 
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weeks and colonies were fed fresh media once every seven days. Weekly feeds of 
60µl/well consisted of neurosphere media 900µl, EGF 50µl and FGF 25µl and heparin 
25µl. Colonies were measured and counted by eye using a grid under a Zeiss Axio 
Observer. 
 
2.4.3 Cell division rate assay 
To identify different cell proliferation rates and isolate a population of slowly dividing cells 
human glioblastoma cells were loaded with CellTrace CFSE green fluorescent dye 
(Molecular Probes) and cultured for seven days in neurosphere media. Slow cycling cells 
were identified by flow cytometry based on their increased fluorescence due to greater dye 
retention. CFSE is divided equally between daughter cells at cell division resulting in weak 
fluorescence in cells that have undergone more cell divisions and brighter fluorescent 
intensity in cells that have undergone few cell divisions. The cells with strong fluorescent 
intensity, CFSE bright cells (top 5%) dilute the dye at a slower rate than the overall 
population (bottom 85%). Staining was quantified by flow cytometry (BD LSRII) and 
FLOWJO software. 
 
2.4.4 2-DG assay 
2-Deoxy-D-glucose (2-DG, Sigma) was diluted to a final concentration of 4mM and added 
to cells plated into 96 well plates at 5000 cells per 100ul per well. Cell viability was 
measured after seven days. Cells were incubated at 37°C for 2.5 hours in 10µl colorimetric 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolim bromide (MTT) assay (5mg/ml, Sigma) 
per well. Media was aspirated and 100µl solubilization solution (0.1N HCl, 10% TritonX in 
isopropanol) added before reading. Colorimetric analysis was performed at 690nm & 
570nm using a standard microplate reader. The background absorbance of multiwell 
plates at 690 nm was subtracted from the 570nm measurements; the data was plotted in 
Prism and reported as the mean normalized to the vehicle control vials. The drug 
response assays were performed in triplicate for each cell line per assay with biological 
replicates per cell line. The data plotted represent the standard error of the mean from 
three independent experiments. 
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2.4.5 Temozolomide MTT assay 
Cells were plated into 96 well plates at 5000 cells per 100ul media per well, with or without 
temozolomide (Sigma) to determine resistance to therapy. Temozolomide (TMZ, Sigma) 
was diluted to final concentration of 60µM in 100µl of media. MTT assay was performed as 
described above. 
 
2.4.6 L-Lactate metabolic assay 
GBM parent and clonal variants passaged under neurosphere conditions were chemically 
dissociated into a single cell suspension using trypsin and seeded at a density of 1 x 106 
cells per ml into a flat bottom 96 well plate and incubated for 24 hours at 370C. L-Lactate 
assays were performed according to manufacturers instruction (Eton Bioscience kits). L-
Lactate was added to wells at 50µl/well for a 30-minute incubation at 370C. Adding 50µl of 
0.5M glacial acetic acid per well stopped the reaction. Absorbance was measured at 
490nM using a microplate reader. 
 
2.4.7 Immunohistochemistry 
Haematoxylin and eosin staining was used to confirm tumour formation in tissue sections 
from mouse xenograft tumours. Human GBM cells were identified using an anti-human 
Nestin antibody (Millipore 1:500) alone or in combination with CD133 (Abcam 1:300). A 
human-specific MCM2 antibody (Santa Cruz 1:200) was used to identify human GBM cells 
that were competent to divide. Immunocomplexes were visualized in 3,3’-
diaminobenzidine using the ABC-Elite peroxidase method (Vector laboratories) or using 
secondary antibodies conjugated to Alexflour 488 or 568 (Invitrogen 1:500) with DAPI 
(Invitrogen 1:1000). 
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3 Tumour initiation is associated with label retention in 
human glioblastoma 
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Gabrielli, B. Osborne, G. Vescovi, A. Reynolds, B. A. Evidence for label-retaining tumour-
initiating cells in human glioblastoma. Brain, 2011, 134, 1331-1343. 
 
 
 
 
3.1 Introduction 
Cancer stem cells are widely believed to be responsible for the formation and ongoing 
maintenance of tumours in a number of malignant conditions including CML (Barnes & 
Melo, 2006; Bonnet & Dick, 1997; Holyoake, Jiang, Eaves, & Eaves, 1999; Lapidot et al., 
1994), pancreas (Dembinski & Krauss, 2009; L. Li & Neaves, 2006), head and neck 
cancers (Prince & Ailles, 2008), melanoma (Roesch et al., 2010) & breast cancer (Al-Hajj 
et al., 2003). Cancer stem cells have been reported in glioblastoma (Bao et al., 2006; Das, 
Srikanth, & Kessler, 2008) however controversies exist due to a lack of established 
functional markers for neural stem cells (Chojnacki, Mak, & Weiss, 2009). 
 
One of the defining characteristics of somatic stem cells is their infrequent cell division due 
to cell cycle arrest, which is essential to prevent premature stem cell depletion over the 
lifetime of the organism (T. Cheng et al., 2000). As it is well established that cell cycle 
arrest protects cells from irradiation (Mohrin et al., 2010) and cytotoxic agents (Dean, Fojo, 
& Bates, 2005), it follows that the slow-cycling cancer stem cells will be resistant to 
conventional therapeutic approaches (Reya, Morrison, Clarke, & Weissman, 2001). 
Several groups have also utilized the propensity of label-retention to identify tumor-
initiating cells from solid tumors such as in breast (Krishnamurthy, Wang, Rokhfeld, & 
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Bieberich, 2008; Pece et al., 2010), skin (Roesch et al., 2010) and pancreatic (Dembinski 
& Krauss, 2009) cancer. 
In light of these observations, I hypothesised that post-therapy tumour regrowth is initiated 
from a subpopulation of slow cycling chemo/irradiation-resistant cancer stem cells that 
exhibit the basic stem cell-like property of self-renewal. Cancer stem cells that evade 
toxicity could then generate a separate population of rapidly dividing progeny that are 
responsible for repopulating the tumour bulk, much like somatic stem cells generate a 
rapidly dividing pool of precursor cells to replace damaged tissue. I predict that elimination 
of slow-cycling, therapy-resistant cancer stem cells is essential for the long-term survival of 
glioma patients. This subpopulation therefore represents a critical therapeutic target for the 
treatment of malignant gliomas.  
 
Here, I describe the isolation and characterization of an infrequently cycling (i.e. CFSE 
retaining), tumor-initiating subpopulation in human glioblastoma cells that may represent a 
target to improve response to therapy.    
 
3.2 Results 
3.2.1 Slow cycling cells exist in vitro in primary human GBM cell cultures 
Fluorescent labels are commonly used in the study of cancers to identify quiescent cancer 
stem cells. The fluorescent label used in this study was the prodrug carboxyfluorescein 
diacetate succinimidylester (CFSE), which passively diffuses into cells and following 
cleavage by intracellular esterases, covalently binds to cellular proteins (Quah, Warren, & 
Parish, 2007). CFSE is equally divided between daughter cells at each cell division, thus 
providing information about the comparative division rates of all the cells within a 
population allowing the researcher to quantify the relative frequency of cell division over 
time based on CFSE staining intensity (De Boer, Ganusov, Milutinovic, Hodgkin, & 
Perelson, 2006; Hawkins et al., 2007). I chose CFSE because of its extensive use both in 
vitro and in vivo as a functional readout of cell division in immunology and cancers (Fei et 
al., 2010; Hawkins et al., 2007; Quah et al., 2007; Rodel et al., 2005).  
 
All cell lines were generated from primary human GBM tissue, chemically dissociated and 
seeded as a single cell suspension into serum free neurosphere media (S. A. Louis et al., 
2008). Human GBM cells passaged in vitro in neurosphere culture conditions maintain the 
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genotype and phenotype of the original tumour (J. Lee et al., 2006). To test whether 
staining intensity correlated with cell division in primary human GBM cell culture, I 
analysed human GBM tumour cell lines established from primary patient tumour tissue. 
Cells were stained with CFSE and the subsequent reduction in fluorescence was 
measured by flow cytometry for six consecutive days. The profile of CFSE staining in 
figure 3.1A shows a progressive decrease in CFSE concentration in human GBM cells 
from right to left, with unstained cells represented on the far left. This data shows that in 
human GBM cells, CFSE can be used to track cell divisions over time, and may therefore 
be a suitable tool to enrich for slow-cycling cancer stem cells in human GBM cell culture 
systems. 
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Figure 3-1 Identification of slow cycling human GBM cells in vitro. (A) Human GBM cells, 
established from primary patient GBM tumors were incubated in 5µM CFSE. CFSE is divided 
equally between daughter cells during cell division. The histogram shows the decreasing CFSE 
concentration in human GBM cells over six days of proliferation. (B) Tumoursphere formation by 
human GBM cell lines was observed after cells were stained with 5µM CFSE and allowed to 
proliferate in neurosphere culture media over 5-10 days. Developing tumourspheres were 
observed daily under a brightfield microscope. (C) The histograms indicate EdU incorporation and 
retention by human GBM cells. Cells were stained with CFSE and incubated for 45 minutes in 
EdU. During flow cytometry analysis, the first gate on CFSE retention established two populations, 
the top 5% CFSE high population which were called the slow cycling population and the bottom 
85% CFSE low cells called the fast cycling population. The histograms show an overlay of the EdU 
incorporation by the slow cycling cells indicated by the red peak and the fast cycling cells indicated 
by the blue peak at various times post EdU pulse in hours. The incorporation and retention of EdU 
into the CFSE bright cells indicates that they are cycling and have undergone fewer cell divisions 
than the bulk of the population. (D) The figure demonstrates a typical distribution of CFSE levels in 
a human GBM neurosphere culture that was loaded seven days earlier. Above the flow cytometry 
histogram are representative cells showing different CFSE staining intensities. A slow-cycling 
population of cells was identified and isolated based on their capacity to retain CFSE (top 5%). To 
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the right a 10% gap has been used between populations of cells collected to minimize cross 
contamination between top 5% and bottom 85%. (E) The histograms show 10 human GBM cell 
lines. In each line, a slow cycling top 5% and fast cycling bulk 85% was identified based on CFSE 
retention. 
 
Next, single cells derived in our lab from primary human GBM tumour tissue were loaded 
with CFSE, and the decrease in CFSE retention was monitored in developing 
neurospheres over six consecutive days. Neurosphere formation by the CFSE labelled 
human GBM cells was observed using a combination contrast microscope. In Figure 3.1B 
slow cycling cells can be seen in developing neurospheres when the majority of 
surrounding fast cycling cells have diluted out the CFSE marker over a number of cell 
divisions. These results show that CFSE retaining human GBM cells exist in vitro in 
proliferating cells cultured as neurospheres.  
 
5-bromo-2’-deoxyuridine (BrdU) retention has been used to identify tumour-initiating 
cancer stem cells from breast tumours (Pece et al., 2010).  5-ethynyl-2-deoxyuridine (EdU) 
is a thymidine analogue and like BrdU is incorporated into DNA during strand synthesis 
(Chehrehasa, Meedeniya, Dwyer, Abrahamsen, & Mackay-Sim, 2009). Detection of EdU 
doesn’t require the harsh DNA denaturation necessary with BrdU that can distort cell 
structure resulting in loss of the target antigen (Lin et al., 2009). To determine whether 
CFSE label retention correlates with a second, established label retention protocol, I 
double labelled GBM cells with EdU and CFSE and analysed this by flow cytometry. EdU 
labelling was performed for 45 minutes and retention was determined at intervals of 24 
hours for five days by flow cytometry. The histogram in figure 3.1C shows that the top 5% 
slow cycling cells, as identified by CFSE-retention, did incorporate EdU and retained more 
EdU over time than the fast cycling 85% CFSE-low population. Increased EdU retention in 
the slow cycling cells provides a second, independent confirmation that slow cycling cells 
have undergone fewer cell divisions, and in combination with Pece et al. verifies the use of 
CFSE to monitor cell division rates in human GBM cells (Pece et al., 2010). 
 
Utilizing the ability of flow cytometry to sort cell populations based on relative fluorescence, 
human GBM cells were divided into two populations. A CFSE high top 5% population of 
slow cycling cells and a bottom 85% CFSE low population of fast cycling cells with a 10% 
gap between the two to avoid contamination. To the right of the histogram in figure 3.1D a 
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small percentage of cells exhibit high fluorescent intensity in contrast to the cells to the left 
of the histogram that show decreasing fluorescence. The cells inserted above the 
histogram indicate decreasing CFSE concentrations with subsequent cell divisions 
throughout neurosphere formation. This is representative of the progressive reduction in 
fluorescent intensity associated with each cell division.  We were able to identify a CFSE 
high, top 5% population in all our human GBM lines. Figure 3.1E shows the CFSE 
fluorescent intensity in 10 human GBM lines. 
 
3.2.2 Slow cycling cells exist in vivo in mouse human GBM tumours 
The tumour microenvironment is known to play a key role in tumour development 
(Hoelzinger, Demuth, & Berens, 2007). In particular, hypoxic regions within the tumour are 
thought to drive cells into a quiescent state and contribute to therapy resistance (Axelson, 
Fredlund, Ovenberger, Landberg, & Pahlman, 2005). To test whether slow cycling human 
GBM cells are quiescent in vivo, two xenograft models of GBM tumours were used, an 
intracranial model, and a subcutaneous model. Human GBM cells were stained with CFSE 
and immediately injected into the striatum of NOD-SCID mice. Figure 3.2A shows the 
distortion of the tumour bearing cerebral hemisphere caused by the progressive 
enlargement of a GBM tumour. Six weeks after human GBM cells were injected into the 
mouse brain, CFSE bright cells can be seen within the bulk of the tumour in tissue 
sections using immunofluorescence  (Figure 3.2B). This result confirmed the legitimacy of 
our strategy to use in vivo mouse models to study slow cycling cells in GBM and provides 
further evidence that slow cycling CFSE-retaining cells persist in vivo. 
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Figure 3-2 Slow cycling cells exist in orthotopic xenograft mouse tumours.  
(A) Injections of 200,000 human GBM cells were administered into the striatum of anaesthetized 
mice and animals monitored for signs of deteriorating health during tumour formation, usually three 
- six months. The arrow indicates the tumour bearing cerebral hemisphere is enlarged and 
distorted below the site of tumour cell injection. (B) Mouse brain section showing CFSE bright 
cells. CFSE retaining cells can be identified in proliferating mouse brain tumours in vivo six weeks 
post-transplant of 200,000 CFSE stained human GBM tumour cells into the striatum. The scale bar 
represents 50µm. 
 
3.2.3 Slow cycling human GBM cells form tumours in vivo 
Several studies have confirmed that slow cycling cell populations in other tumours are 
enriched for tumour-initiating cells (TICs). We next sought to confirm whether slow cycling 
cells are able to form tumours in vivo.  To determine the capability of human GBM cells to 
form orthotopic xenograft mouse tumours, 2 x 105 human GBM cells were injected into the 
striatum of SCID mice. This technique resulted in 100% success in generating large 
tumours that eventually resulted in death.  
 
Next we wanted to compare the tumour forming capabilities of slow cycling cells compared 
with fast cycling cells. To examine this in human GBM tumours we injected either 2 x 105 
slow cycling cells or 2 x 105 fast cycling cells into the striatum of SCID mice using three cell 
lines, Line 0, Line 1 and Line 2, and we observed tumour formation in 100% of mice 
injected. This was followed by limiting dilution assays, where reducing numbers of cells 
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were injected into mouse brains to determine tumour initiation efficiency. In limiting 
dilution, only one of three mice injected with 25,000 fast-cycling cells developed a tumour 
while six out of six mice injected with 25,000 slow-cycling cells developed tumours. When 
10,000 slow-cycling cells were injected into mice, tumour initiation was successful in 50% 
of mice injected (Figure 3.3A and 3.3B). This data shows that tumour initiation is a feature 
of both the slow cycling and fast cycling cells and not a distinctive feature of slow-cycling 
human GBM cells. However, slow cycling cells display a small but statistically significant 
increase in tumour initiation frequency (TIF). These data suggest that slow cycling cells 
are not quiescent, senescent or terminally differentiated since they are still capable of 
cycling and tumour initiation and this population is somewhat enriched for cells able to 
initiate tumours in vivo. 
 
 
 
 
200 000 100 000 50 000 25 000 10 000
Overall population 11.1 +/-  0.5 12.3.+/- 0.3 13.8 +/- 1 12 ND
Slow cycling cells 19.1 +/-  0.9 15.5 +/- 4.1 19 +/- 1.5 17.3 +/- 0.8 23
cells per injection
Time for tumour formation (weeks)
A 
B 
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Figure 3-3 Slow cycling cells show an increase in orthotopic xenograft tumour initiation 
frequency. (A) In limiting dilution assays, NOD-SCID mice injected intracranially with 200,000, 
100,000, 50,000, 25,000 and 10,000 (slow-cycling only) fast-cycling and slow-cycling primary 
patient human GBM cells were monitored for tumour formation. (B) The tumour initiating frequency 
is shown for the overall population and the slow cycling cell population. The time-frame for tumour 
development is shown as average ±	 SEM. 
 
3.2.4 Sphere and colony formation are not characteristics exclusive to slow cycling 
human GBM cells 
The neurosphere assay can be used to measure sphere formation and has been shown to 
be a predictor of GBM disease progression (Laks et al., 2009). To determine the sphere-
forming frequency of slow cycling cells, CFSE-labelled cells were sorted according to 
CFSE intensity into top 5% and bottom 85%, and identical numbers of viable sorted cells 
were seeded into 384 well plates to assess sphere-forming frequency. Figure 3.4A shows 
that in two human GBM lines both the slow cycling and fast cycling cells were able to 
proliferate and form spheres although the slow cycling cells formed fewer spheres and at a 
slower rate. This experiment was performed in triplicate. This finding suggests that both 
cell populations are capable of tumour formation and that sphere formation is not a 
characteristic unique to or enriched in slow cycling cells.   
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Figure 3-4 Sphere and colony formation are not characteristics exclusive to slow cycling 
human GBM cells in vitro. (A) Two human GBM lines showing sphere formation in slow cycling 
and fast cycling cells. Cells were seeded into 384 well plates 50µl per well at a density of 10,000 
cells per ml. Twenty wells were seeded per row per condition. This was done in triplicate. The 
mean and SEM were calculated for each, as shown. (B). The image shown is of a typical colony of 
human GBM cells formed by a cell with extensive self-renewal capabilities in semi-solid media. (C) 
Colony forming assays representing number and size of colonies generated by the fast cycling 
cells and slow cycling cells of two human GBM cell lines, Line 0 and Line 4 over three weeks. Cells 
were seeded in a single cell suspension into six well plates at 1000 cells/ml, two wells per 
condition. Mean and SD shown. 
 
Similarly, the ability of somatic neural stem cells to form large colonies when grown in solid 
collagen growth conditions has been established as a robust assay for quantitating the 
abundance of neural stem cells from culture and primary mouse brain cells (S. A. Louis et 
al., 2008). To assess the ability of slow cycling cells to proliferate and form large colonies 
we seeded single cells into a semi-solid collagen media (Figure 3.4B). The formation of 
large colonies indicates extensive proliferative ability, which is a characteristic of stem 
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cells. In our colony-forming assay the average colony size was larger in fast cycling cells 
than slow cycling cells. We also noticed that slow cycling cells formed fewer colonies 
compared to that of the fast cycling cells (Figure 3.4C). This result shows that fast cycling 
cells are more proliferative than slow cycling cells and therefore colony formation is not an 
exclusive characteristic of human GBM slow cycling cells.  
 
3.2.5 Slow cycling human GBM cells are dissimilar to somatic stem cells in their 
cell cycle progression 
Infrequent cell division was used to enrich for cancer stem cell-like cells for two reasons. 
First, somatic stem cells are predominantly quiescent (that is, in the G0 phase of the cell 
cycle), and if cancer stem cells (CSC) phenotypically mimic somatic stem cells, a 
significant proportion of CSCs should also be quiescent and therefore cycle infrequently. 
Second, identification of a quiescent human GBM CSC subpopulation has important 
therapeutic implications, as many chemotherapeutic agents target actively cycling cells 
and quiescent cells are therefore less susceptible to those therapies, as has been 
observed in CML (T. Cheng et al., 2000; Komarova & Wodarz, 2007). Thus quiescence 
provides a potential mechanism for the reported resistance to radiotherapy in human GBM 
cancer stem cells (Bao et al., 2006).  By discriminating between the slow and fast cycling 
cells in human GBM we were able to directly test whether these two distinct populations 
differed in their sensitivity to radiation treatment. 
 
Quiescent cells pause during the cell cycle; consequently, identifying quiescent cells 
requires the use of multiple markers, as this subpopulation is defined by the absence of 
markers. I define quiescence as a reversible state of dormancy during which the cell has 
temporarily withdrawn from the cell cycle (Cheung & Rando, 2013). Three markers were 
selected in addition to CFSE to determine if the slow cycling cell population was quiescent. 
1) DNA content, which can be used to identify 2n peak, 2) Ki67 which is not expressed by 
cells in the G0 phase of the cell cycle (Scholzen & Gerdes, 2000), and is used clinically to 
determine the proliferative potential of patient glioma specimens, to grade tumours and to 
predict patient prognosis (P. C. Burger, Shibata, & Kleihues, 1986; Karamitopoulou, 
Perentes, Diamantis, & Maraziotis, 1994) and, 3) EdU which can identify cells actively 
replicating their genome (Chehrehasa et al., 2009). I define quiescent G0 cells as CFSE-
retaining cells that have 2n DNA content and are negative for both Ki67 and EdU.  
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Initially, somatic mouse adult neural stem cell cultures were examined. Figure 3.5A shows 
the DNA content and cell cycle distribution of adult mouse somatic neural stem cells and 
human GBM cells. Incorporation of EdU indicates the presence of actively cycling cells. 
Ki67 is only expressed by proliferating cells (Scholzen & Gerdes, 2000). Figure 3.5B 
shows fast cycling mouse adult neural stem cells overlayed with the slow cycling cells and 
the relative incorporation and expression of EdU and Ki67 as assessed by flow cytometry. 
The fast cycling mouse neural stem cells expressed Ki67 and incorporated EdU in contrast 
to the deficit seen in the slow-cycling cells reflecting a rapid proliferation rate. The mouse 
label-retaining neural stem cells have all the hallmarks of quiescent, G0 cells, an absence 
of proteins expressed by cycling cells.   
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Figure 3-5 Slow cycling human GBM cells are dissimilar to somatic stem cells in their cell 
cycle progression. (A) DNA staining shows cell cycle profiles for total population and slow cycling 
mouse adult neural stem cells (mANSC) and human GBM cells. Cells passaged in neurosphere 
culture conditions were first stained with 5µM CFSE then passaged for five days. Spheres were 
chemically dissociated and DAPI stained at 4µg/ml with 1 x 106 cells per well in a 96 well ‘V’ 
bottom plate. During flow cytometry analysis a gate isolating the top 5% CFSE-bright cells was 
used to identify the slow cycling population. DNA content for each population was determined 
according to DAPI staining intensity. The red histogram shows the total population, the blue 
histogram the slow‐cycling (top 5% CFSE high) population. There are two peaks in the histograms. 
The first peak indicates cells in the G0/G1 phase of the cell cycle and 2n DNA content and the 
second peak indicates the G2/M phase and 4n DNA content. (B) Human GBM and mANSC were 
incubated for 10 minutes in 5µM CFSE then passaged for five days. CFSE labeled cells were 
chemically dissociated and incubated for 45 minutes in 10µM 5-ethylnyl-2’-deoxyuridine (EdU), 
fixed in 4% formaldehyde in PBS and permeabilized in ice-cold methanol. Analysis was performed 
by flow cytometry. Approximately 250,000 cells were analysed per tube. The red histogram shows 
the bulk of the population, bottom 85%, CFSE diluting, fast cycling cells. The blue histogram shows 
the slow cycling, top 5%, CFSE retaining cells. The fast cycling adult mouse NSC retain more EdU 
and express more Ki67 than the slow cycling adult mouse NSC. Slow and fast cycling human GBM 
cells incorporate EdU and express Ki67 at approximately the same rate. (C) The figure shows 
expression of proliferation markers MCM2 and MCM7 in the 2n populations of slow and fast 
cycling human GBM cells after normalizing for DNA content.  
 
Having confirmed that the CFSE-retaining cell population of our somatic neural stem cells 
was enriched in cells displaying a quiescent phenotype, we next sought to confirm that the 
human GBM CFSE-retaining, slow cycling cell population was also enriched in quiescent 
cells. Surprisingly, and in contrast to our somatic neural stem cell control, human GBM 
slow cycling cells are not quiescent (G0), as slow cycling human GBM cells expressed 
Ki67 and incorporated EdU at rates that approximated that of fast cycling cells. 
Intriguingly, there was consistently more 4n (G2/M peak) and 4n+ (hyperdiploid) cells in 
the slow cycling cell population than in the fast cycling population for all lines tested.  
 
Minichromosome maintenance complex (MCM) proteins are only expressed by actively 
cycling cells. To extend the cell cycle analysis of slow cycling human GBM cells, MCM2 
and MCM7 protein expression was assessed for human GBM cells. The MCM2-7 complex 
activated during S-phase is essential for the separation of the double-stranded DNA at the 
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replication fork (Vijayraghavan & Schwacha, 2012). After normalizing for DNA content, the 
MCM protein expression was the same for the fast and slow cycling cells (Figure 5C). This 
data provides further experimental evidence showing that slow cycling GBM cells are not 
quiescent but are actively cycling. 
 
In conclusion, the results presented here reveal that CFSE-retention does enrich for 
quiescent cells in somatic neural stem cell cultures. This confirms that the neurosphere 
culture system, where long-term proliferation is driven by somatic neural stem cells, does 
maintain a quiescent subpopulation. In contrast, human GBM cultures grown under 
identical culture conditions either do not have a quiescent cell population or it is 
significantly reduced compared to the neural stem cell control.  
 
3.2.6 Hyperdiploid human GBM cells exhibit an increase in stem cell marker 
expression 
During analysis the cell cycle progression of slow and fast cycling cells we noticed that the 
slow-cycling CFSE-retaining top 5% population of cells contained proportionately more 
hyperdiploid cells than the human GBM cell population overall (Figure 3.6A and B).  
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Figure 3-6 Slow cycling human GBM cells do not exhibit stem-like cell characteristics. (A) 
Cell cycle analysis shows the DNA content of the total cell population in red and the slow cycling 
population in blue for four human GBM cell lines. (B) The slow cycling human GBM cell population 
is enriched with a subpopulation of hyperdiploid cells. Human GBM cells were chemically 
dissociated into a single cell suspension and incubated in DAPI at 4µg/ml before being fixed in 4% 
formaldehyde and DNA content analysed. The percentage of cells containing 8n DNA was 
identified for the total population and the slow cycling population in four independent experiments 
using gating during flow cytometry. An average 2.9% of the total cell population and 17.4% of slow 
cycling cells fell within the 8n gate (p value = 0.0059).  
 
Several studies have reported the use of cell surface protein expression to identify and 
enrich for brain cancer stem cells (Mao et al., 2009; Ogden et al., 2008). Hyperdiploidy 
gives rise to cells that display elevated levels of protein expression due to gene 
amplification and changes in transcriptional programming (Pavelka et al., 2010). Therefore 
we hypothesised that hyperdiploid GBM cells may display increased expression of cell 
surface markers commonly used to identify cancer stem cells. If true, enrichment 
0 50K 100K 150K 200K 250K
GBM L2 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L3 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L4 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L8 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L2 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L3 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L4 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L8 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L2 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L3 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L4 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L8 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L2 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L3 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L4 
0
20
40
60
80
100
%
 o
f 
M
a
x
0 50K 100K 150K 200K 250K
GBM L8 
0
20
40
60
80
100
%
 o
f 
M
a
x
DNA DNA 
DNA DNA 
%
 o
f M
ax
 
%
 o
f M
ax
 
GBM L2 GBM L3 
GBM L8 GBM L4 
2n 
4n 
4n+ 
2n 4n 
4n+ 
2n 
4n 
4n+ 
2n 
4n 
4n+ 
Total DNA Slow Cycling DNA 
!
"8
n"
#$
%%&
"
Total 
population 
Slow  
cycling 
B A 
''"
41 
 
strategies based on cancer stem cell marker expression would enrich for viable 
hyperdiploid cells, and these cells could therefore be contributing to the cancer stem cell 
phenotype reported in these studies. To test this hypothesis, we selected a panel of six 
stem cell markers (Table 3.1) and compared the cancer stem cell marker expression in the 
4n+ hyperdiploid population to the bulk population of three passaged human GBM lines. 
 
Table 3-1 Known stem cell functions. Table describes the known functions of stem cell markers 
in the analysis. 
 
Marker Protein Function References 
ABCG2 ATP binding 
cassette 
membrane 
transporter/ 
membrane 
pump 
An efflux pump that utilizes ATP to 
move small substances, including 
toxins across the cell membrane 
providing protection.  Particularly 
active in brain endothelial cells 
contributing to the blood brain 
barrier and in neoplastic cells. 
Bleau, A. 
M. 2009. 
CD15 Stage-
specific 
embryonic 
antigen 1 
(SSEA-1) 
Cell-cell adhesion particularly 
astrocytes. 
Mao, X. G. 
2009. 
Pruszac, J, 
2009. 
CD133 Prominin-like 
1 
Located in the cytoplasm and on 
the cell surface in human neural 
stem cells. Function unknown. 
Possibly associated with migration 
and polarity.  CD133 antigen with 
the glycosylated epitope AC133 is 
only expressed by stem cells. 
Bao, S. 
2006. Dell 
'Albani. J. 
2008. 
GFAP Glial fibrillary 
protein 
The most specific protein used to 
identify astrocytic cells. An 
astrocytic intermediate filament 
protein. Phosphorylation of GFAP 
regulates polymerization and 
depolymerization of filaments in 
mitosis. 
Das, S. 
2008. 
Imura,  T. 
2006. 
Nestin A cytoplasmic 
intermediate 
filament 
protein 
Expressed in undifferentiated cells 
and radial glia during development. 
Nestin phosphorylation  in mitosis 
facilitates dissociation of 
intermediate filaments. It is down 
regulated at differentiation. 
Reexpression has been seen in 
reactive astrocytes associated with 
injury and ischaemia. 
Zhang, M. 
2008. Park, 
C. H. 1971. 
Kornblum, 
H. I. 2001 
Sox2 SRY (sex 
determining 
region Y box 
2) 
A transcription factor that maintains 
neural stem cells, it’s lost at neural 
differentiation. Sox2 is 
overexpressed in glioma. 
Brazel, C. 
Y. 2005. 
Pevny, L. 
H. 2010. !
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The markers selected were CD15, CD133, ATP-Binding Cassette, sub-family G (white), 
member 2 (ABCG2), Glial fibrillary acidic protein (GFAP), Nestin and Sox2. The ABCG2 
drug transporter is widely understood to export chemotherapeutic substances from stem 
cells and cancer stem cells and is reportedly expressed at high levels in numerous 
cancers including glioma (Bleau, Huse, & Holland, 2009; X. Li et al., 2010). CD133 is 
reputed to be a marker for both stem cells and brain cancer stem cells and to confer 
radioresistance to glioma cells that express it on the cell surface (Bao et al., 2006; 
Dell'Albani, 2008). CD15 is a known stem cell marker and more recently purported to be a 
marker of brain tumour stem cells (Mao et al., 2009; Pruszak, Ludwig, Blak, Alavian, & 
Isacson, 2009). The intermediate filament protein GFAP is expressed on stem cells in the 
nervous system (Das et al., 2008; Imura, Nakano, Kornblum, & Sofroniew, 2006). Nestin is 
recognized as an intermediate filament protein and commonly used stem cell marker 
because of its expression by cells in the developing neural tube (Kornblum & Geschwind, 
2001; Park, Bergsagel, & McCulloch, 1971; M. Zhang et al., 2008). Sox2 is a well-
recognized marker of adult neural stem cells and has been identified both in vitro and in 
vivo (Brazel et al., 2005; Pevny & Nicolis, 2010). We analysed the expression of these six 
potential cancer stem cell markers in human GBM cells by flow cytometry.  Interestingly 
when the hyperdiploid cells were compared with the diploid cell population, an increase in 
stem cell markers was apparent in the hyperdiploid population (Figure 3.7). Stem cell 
markers are used in other cancers to identify the tumour initiating cell population. As the 
4n+ population of human GBM cells lies within the label retaining group, previous studies 
may have overlooked this population, attributing the traits of a hyperdiploid minority of cells 
to a cancer stem cell population. 
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Figure 3-7 Hyperdiploid primary human tumour cells express higher levels of stem cell 
markers. Cells from three primary human GBM tumours were stained with antibodies for six 
recognized stem cell markers: Sox2, ABCG2, CD15, CD133, GFAP and Nestin. During flow 
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cytometry analysis, gating isolated the hyperdiploid cells in each cell population so that antibody 
labelling could be directly compared. 
 
Strikingly, in all lines tested and for all cancer stem cell markers, the hyperdiploid 
subpopulation displayed elevated expression of cancer stem cell markers relative to the 
bulk population. These results indicate that hyperdiploid tumour cells will be enriched in 
strategies designed to isolate putative cancer stem cells, and suggests the intriguing 
hypothesis that many of the clinically relevant phenotypes linked with cancer stem cells 
(such as tumour initiation and therapy resistance) could in fact also be displayed by 
hyperdiploid GBM tumour cells. 
 
3.3 Discussion 
The notion that a self-renewing, infrequently cycling, cancer stem-like cell population is 
responsible for tumor initiation is well established in leukemias (Graham et al., 2002; 
Holyoake et al., 1999). While an infrequently cycling compartment has been described in 
solid tumors such as breast cancer (Krishnamurthy et al., 2008; Pece et al., 2010), 
pancreas adenocarcinoma (Dembinski & Krauss, 2009) and melanoma (Roesch et al., 
2010) a similar population has yet to be identified in brain tumors.  
 
3.3.1 CFSE can be used to identify slow cycling cells 
Here we identified a subpopulation of label-retaining cells within human GBM that 
exhibited slower progression through the cell cycle, compared to the bulk of the tumor 
cells as well as an enhanced ability to form tumors in vivo; features that are consistent with 
a tumor-initiating cell. To track cell divisions and identify slower cycling cells, we used 
functional labeling with the lipophilic, non-fluorescent precursor, CFDASE. The probe is 
activated by intracellular esterase activity converting it to fluorescent CFSE while 
covalently coupling it to amino groups where it becomes cell permanent and is diluted in 
half at each cell division (Lyons, 2000). Cells exhibiting higher CFSE epifluorescence over 
time corresponded to slow dividing cells, which was confirmed using nucleoside analog 
incorporation of EdU followed by a chase period, correlating label-retaining cells with 
CFSE intensity (Golmohammadi et al., 2008). This shows that CFSE retention directly 
correlates with EdU retention (Figure 2B), providing direct confirmation for the hypothesis 
that a subset of human GBM cells cultured as tumorspheres retain CFSE due to reduced 
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cell division. In sum, these results, together with the extensive literature using CFSE to 
track cell division (Graham et al., 2002; Lyons, 2000; Moore, Houghton, & Lyle, 2012), 
demonstrate CFSE labeling as a valid approach to identify and isolate sub-fractions of 
cells based on frequency of cell division. 
 
3.3.2 CFSE retaining cells are actively cycling 
Although the primary aim of this study was the enrichment of quiescent cancer stem cells, 
our data provided a series of unexpected findings that are not consistent with the classical 
cancer stem cell model. A basic cell cycle analysis yielded the surprising result that in 
GBM tumoursphere cultures and in vivo GBM tumours, slow cycling cells were not 
enriched in quiescent cells but in fact were enriched in cells harboring a 4n DNA content 
that were positive for EdU and Ki67, and therefore actively cycling, although at a slower 
rate. This is unlikely to be due to experimental artifact, as CFSE has been extensively 
characterized in vitro and in vivo as a marker for cell division (De Boer et al., 2006; 
Hawkins et al., 2007). In addition, in our hands and using identical culture conditions, 
somatic adult neurosphere cultures revealed that CFSE retention does enrich for cells 
displaying all the hallmarks of cellular quiescence (i.e. 2n DNA content, Ki67 negative and 
EdU negative). These results confirm that in cultures containing quiescent cells, CFSE-
retention does enrich for the G0 sub-population. To provide additional experimental 
evidence that the slow cycling human GBM cells were not quiescent, we tested them for 
expression of the replication licensing proteins MCM2 and MCM7, which are absent from 
quiescent cells and expressed only in cycling cells that have been licensed to replicate 
their genome (Blow & Gillespie, 2008). CFSE retaining GBM cells expressed both MCM2 
and MCM7, confirming that the majority of CFSE-retaining cells are licensed to replicate 
their genome and therefore not in a quiescent state. Altogether these data suggest that 
unlike CML, where a quiescent cancer stem cell population has been identified using 
CFSE retention, the CFSE retaining human GBM cell population does not contain a 
significant number of quiescent cells. 
 
3.3.3 Slow cycling human GBM cells do not exhibit superior sphere or colony 
forming ability 
To extend this unexpected outcome, we then used functional assays to assess the 
enrichment of cancer stem cells from GBM using CFSE retention. The frequency of sphere 
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formation under neurosphere culture conditions correlates with the presence of somatic 
neural stem cells and progenitor cells (Azari, Rahman, Sharififar, & Reynolds, 2010). If 
CFSE retention does enrich for cancer stem cells, then one prediction would be a 
commensurate increase in the sphere forming frequency due to an increase in the number 
of cancer stem cells and progenitor cells within the CFSE retaining population. The slow 
cycling human GBM population displayed a significantly reduced sphere forming capacity 
to the tumour bulk. To extend these findings we used a second functional readout for stem 
cell function, the colony-forming assay. In this system, only somatic stem cells can 
generate large colonies during culture due to the stem cell property of self-renewal that is 
absent from the progenitor and differentiated subpopulation. In our hands, human GBM 
cultures were incapable of generating the large colonies found in somatic neural stem cell 
cultures invalidating this assay system for the identification of GBM cancer stem cells. 
However, when comparing the slow cycling population with the tumour bulk, the slow 
cycling population always generated significantly fewer colonies than the tumour bulk. This 
is the opposite of what would be expected if the slow cycling population were enriched in 
cancer stem cells. However, this result could be due to a number of factors. Within a 
heterogeneous cell population cell cycle times may vary resulting in a greater contribution 
from some cells than others. Some cell divisions may be asymmetrical giving rise to a 
subpopulation of cells incapable of proliferation. 
 
3.3.4 Slow cycling cells were more proficient at tumour formation and harbor a 
hyperdiploid subpopulation with increased stem cell marker expression 
In contrast to the predictions of the stem cell hypothesis, when we injected 50,000 of either 
slow or fast-cycling cells into the striatum of NOD-SCID mice, tumours formed in all mice. 
However, the slow-cycling cells were more proficient at tumour formation, requiring fewer 
injected cells than fast-cycling cells. Upon injection of 25,000 cells, slow-cycling cells 
formed tumours 100% (n=6) of the time while the total cell population formed tumours at a 
rate of 1:3 (n=3) at this dilution. With the intracranial injection of 10,000 cells, the slow-
cycling cell population was capable of tumour formation in 50% of cases (3/6). In isolation, 
this finding might suggest support for the cancer stem cell hypothesis. When taken in 
combination with our data showing that increased levels of stem cell markers are 
expressed in the population of label retaining cells that exhibited a DNA content of 4n+, we 
hypothesize that the hyperdiploid cells within the top 5% CFSE retaining cells are the 
tumour initiating cells. 
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3.3.5 Slow cycling cells have an advantage during tumour regeneration.  
The finding that slow cycling cells are more proficient at tumour formation than fast cycling 
cells is counter intuitive. It seems logical that a population of fast cycling cells would 
normally generate a tumour faster than a slow cycling cell population and as a result, be 
the cohort that were more proficient at tumour formation. However, tumour regeneration 
following surgery, radiotherapy and chemotherapy is believed to be the result of a small 
number of therapy resistant cells that are capable of replication and go on to form another 
tumour, often adjacent to the site of the original tumour. Our findings that fewer slow 
cycling cells were required for tumour formation than fast cycling cells suggest that the 
slow cycling cells have an advantage during tumour regeneration.  
 
3.3.6 Hyperdiploid cells may have superior survival capabilities.  
Our data revealed a feature of slow cycling cells. Within the slow cycling cell population 
there was a cohort of cells with an increased DNA content. The finding that slow cycling 
cells were more proficient at tumour formation suggests that extra copies of genes could 
provide a cell with the ability to withstand a harsh environment by supplying nutrients or 
overcome cell cycle inhibition mechanisms to evade cell death. We wanted to investigate 
further the potential role and advantageous characteristics of slow cycling 4n+ DNA cells 
in GBM.  
 
3.4 Conclusions 
The distribution of CFSE staining within human GBM cultures reveals that cells within the 
human GBM culture have varied rates of proliferation. This finding suggests that CFSE-
retention can be used to isolate infrequently cycling cancer cells based on a functional 
marker (dye retention).  The slow-cycling cell population in GBM do not exhibit the typical 
stem cell characteristics of quiescence and recognised stem cell marker presentation. 
They do not form larger colonies than their fast-cycling counterparts or exhibit superior 
sphere formation.  
 
However, the slow-cycling cell population exhibited superior tumour forming ability in vivo. 
The greatest challenge facing cancer researchers, clinicians and patients today is tumour 
regeneration following therapy. These findings suggest that fewer slow cycling cells are 
48 
 
required at the completion of therapy for efficient tumour regeneration. Within the slow 
cycling cell population we identified a cohort of cells with a hyperdiploid DNA content that 
displayed elevated expression of cancer stem cell markers relative to the bulk population 
implicating hyperdiploid cells within the slow cycling fraction as a population of interest for 
further study. A deeper understanding of the potential points of fragility of this cohort is 
required to be able to begin to identify therapeutic candidates.  
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4 Hyperdiploid glioblastoma cells are capable of tumour 
formation and show increased sensitivity to metabolic 
inhibition 
 
 
This work contributed to the following publication: 
Donovan, P. Cato, K. Legaie, R. Jayalath, R. Olsson, G. Hall, B. Olson, S. Boros, S. 
Reynolds, B. Harding, A. Hyperdiploid tumour cells increase phenotypic heterogeneity 
within glioblastoma tumours. Molecular Biosystems, 2014. 10, 741-758. 
 
 
 
 
4.1 Introduction  
Therapeutic resistance is one of the most challenging obstacles thwarting the efforts of 
researchers involved in the development of anticancer drugs today. The development of 
therapeutic resistance mechanisms is widespread across cancer types and progressive 
throughout the course of the disease (Garraway & Janne, 2012; Szakács, Paterson, 
Ludwig, Booth-Genthe, & Gottesman, 2006). The potential mechanisms underpinning 
GBM resistance to conventional therapy are diverse. Therapy resistance can be mediated 
by microRNA expression (Besse, Sana, Fadrus, & Slaby, 2013), receptor tyrosine kinase 
amplification and activation (Hatanpaa, Burma, Zhao, & Habib, 2010; Khalil, Jameson, 
Broaddus, Lin, & Chung, 2013; Osuka et al., 2012), activation of signal transduction 
pathways (Chautard et al., 2010; Golding et al., 2009; Kim et al., 2012; H. F. Li, Kim, & 
Waldman, 2009; J. Wang et al., 2010), nuclear erythroid-related-factor-2 expression (Nrf2) 
(P. K. Sharma & Varshney, 2012), enhanced DNA repair and homologous recombination 
(Bao et al., 2006; Lim et al., 2012; Naidu, Mason, Pica, Fung, & Pena, 2010), hypoxia and 
tumour microenvironments (Hardee et al., 2012; Jamal, Rath, Tsang, Camphausen, & 
Tofilon, 2012; Yang, Lin, Wang, Guo, & Wang, 2012), expression of heat shock proteins 
(Brondani Da Rocha et al., 2004; Fedrigo et al., 2011), and generation of a cancer stem 
cell phenotype (Eyler & Rich, 2008).  
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An emerging tumour subpopulation that has been shown to contribute to therapy 
resistance in a variety of solid tumours are tumour cells that contain elevated levels of 
genomic DNA (i.e. hyperdiploid cells) (Balsas, Galan-Malo, Marzo, & Naval, 2012; 
Castedo et al., 2006; Lagadec, Vlashi, Della Donna, Dekmezian, & Pajonk, 2012; S. 
Sharma et al., 2013; Q. Wang et al., 2012). Based on results where we identified that 
hyperdiploid cells were enriched in the CSFE-retaining, slow cycling population, we sought 
to determine whether GBM-hyperdiploid cells represent a therapy-resistant subpopulation 
within adult brain tumours. This data identified a slow cycling, tumourigenic hyperdiploid 
tumour cell population present within GBM patients that can initiate and maintain tumour 
growth in vivo, and are resistant to conventional therapy. These results revealed a GBM 
hyperdiploid tumour cell subpopulation that has the phenotypic potential to contribute to 
the evolution of therapy resistance in patients. In this chapter, I show that GBM 
hyperdiploid tumour cells are larger and more metabolically active than euploid tumour 
cells, and that hyperdiploid tumour cells are vulnerable to therapies targeting tumour 
metabolism. Together, these results support the hypothesis that hyperdiploid tumour cells 
are a clinically relevant GBM tumour cell subpopulation that contributes to the phenotypic 
heterogeneity present within GBM patient tumours. Recent work is beginning to identify 
hyperdiploid specific drugs (A. J. Lee et al., 2012; Marxer et al., 2012; Rello-Varona et al., 
2009; Roh, van der Meer, & Abdulkadir, 2012; Vitale et al., 2007), which may provide a 
therapeutic opportunity to deplete hyperdiploid cell subpopulations from solid tumours. 
 
4.2 Results 
4.2.1 Slow cycling human GBM cells are not delayed in G2/M 
In multiple lines in vitro, CFSE-retaining, slow cycling cells display a significant increase in 
4n DNA content. Figure 4.1A shows the 4n DNA content in passaged primary human GBM 
cells, orthotopic xenograft mouse models, and fresh primary human GBM cells from 
patient tumours. Passaged cells amplified from primary patient tumour tissue exhibited 
levels of 4n+ DNA varying between patients from 1.5% -12% of the total population (Figure 
4.1B). This is consistent with our hypothesis that a proportion of slow cycling cells are 
delayed or arrested during G2 and/or mitosis.  
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Figure 4-1 Hyperdiploid cells exist in primary patient tumour tissue, passaged human GBM 
cells, and xenograft tumours. DNA content was determined using DAPI. (A). The panel on the 
left shows the DNA content of GBM tumour cells cultured as tumourspheres. The gate isolates the 
cells with a 4n DNA content. The 4n DNA population shown in the panel to the left represents 
21.5% of the total cell population in cells cultured from a patient tumour. The centre panel shows 
the DNA content of a mouse xenograft tumour where the 4n cell population makes up 30.2% of the 
total tumour cell population. The panel on the right shows the DNA content of fresh primary human 
glioblastoma tumour cells. The subpopulation of 4n cells shown is 18.9% of the total tumour cell 
population. (B). Cells cultured as tumourspheres from primary patient tumour tissue exhibited 
levels of hyperdiploidy varying between 1.5% and 12%. Six patient lines are shown. (C). The 
histograms show cyclin B1 expression in cells from five human GBM tumours passaged in vitro. 
The 2n population was negative for cyclin B1 and the 4n population was positive, confirming that 
the 4n population contained cells in G2 phase while the 2n population did not. Cyclin B1 
expression was normal for all five tumours assessed validating the use of cyclin B1 levels for 
identification of a delay in G2M progression. (D). The 4N population of the fast cycling cells 
expressed higher levels of cyclin B1 than the 4n population of the slow cycling cells which is 
inconsistent with a G2 checkpoint arrest in the slow cycling cells. 
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To test this hypothesis, the slow cycling population was screened for increased expression 
of cyclin B1. Cyclin B1 is required for mitotic regulation. Expression accumulates 
throughout G2 phase and reaches a peak during mitosis. Cyclin B1 binds to cyclin 
dependent kinase 1 (CDK1) the primary driver of mitosis (Boxem, 2006). Analysis of a 
diploid cell population would usually reveal an initial absence of cyclin B1 and following 
DNA synthesis, cyclin B1 should be present in the 4n population. A delay in G2M 
progression would be recognized by overexpression of cyclin B1 in the cells undergoing 
DNA replication in G2, as they accumulate before mitosis. To first verify the staining profile 
of our antibody, cyclin B1 expression in the total tumour cell population was compared with 
the 2n (G0/G1 sub-population) and the 4n (G2/M sub-population) (Figure 4.1B). These 
results for five primary human GBM cell lines indicate that while the 2n population is 
negative for Cyclin B1, the 4n population is positive, confirming that cyclin B1 levels 
increased during G2/M as expected and validating the cyclin B1 antibody under the 
experimental conditions routinely used in our lab for flow cytometry analyses.   
 
Next, cyclin B1 expression was compared between the slow cycling cells and the fast 
cycling cells. Cyclin B1 expression was absent in the 2n population of the slow cycling and 
fast cycling cells. Strikingly, and in the same experiment, when we compared the cyclin B1 
staining of the slow cycling 4n cells with the 4n fast cycling cell population, the slow cycling 
cell population expressed less cyclin B1 than the fast cycling population (Figure 4.1C & D). 
This is the opposite of what would be expected for a G2/M accumulation and is 
inconsistent with a G2 or mitotic checkpoint arrest. A population arrested in G2/M would be 
expected to express higher than usual levels of cyclin B1. This suggests that the 4n 
population of the slow cycling cells were actively replicating their genome and not in G2 
arrest. 
 
Hyperdiploidy in tumour cells can lead to cellular senescence initiated by DNA-damage 
checkpoint response activation (DDR) (Di Micco et al., 2006). The DDR once initiated, 
slows progression through the cell cycle while DNA replication is performed correctly and 
completely and DNA strand repair is carried out. If the DDR is unable to achieve this the 
cell normally enters replicative senescence or is redirected to the apoptosis pathway (B. B. 
Zhou & Elledge, 2000). For a cell to contribute to tumour progression it must be capable of 
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DNA replication and be actively cycling. It is therefore important to determine whether 
hyperdiploid tumour cells are actively cycling and capable of contributing to tumour growth. 
 
The finding that slow cycling cells contain an increase in the 4n and 4n+ cells that are not 
in G2/M phase suggests two possibilities. First, these are tumour cells that have failed 
cytokinesis but did not die, are senescent, and gradually accumulate in the slow cycling 
subpopulation over time. Second, these cells are a viable, hyperdiploid, tumour cell 
population that cycle less frequently but nevertheless are viable and therefore may play a 
non-trivial role in GBM disease. We next sought to determine whether the 4n population of 
the slow cycling cells were proliferating and therefore capable of contributing to disease 
progression. 
 
4.2.2 Proliferating hyperdiploid cells exist in tumoursphere lines derived from 
patient tumours 
To ascertain whether the hyperdiploid cells were actively cycling or senescent, Ki67 
expression levels were analysed in cells cultured as tumourspheres. Ki67 is expressed 
exclusively by cycling cells and absent in senescent cells (Scholzen & Gerdes, 2000). Ki67 
labeled cells were stained with DAPI and the 4n+ cells were analysed to determine Ki67 
expression. Gating on the 4n+ population revealed that a proportion of GBM hyperdiploid 
tumour cells expressed Ki67, indicating they were actively replicating their genome. Figure 
4.2 shows the expression of Ki67 in the 2n, 4n, and 4n+ populations of human GBM cells 
indicating that all three populations are actively proliferating.  
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Figure 4-2 Proliferating hyperdiploid cells exist in tumoursphere lines derived from primary 
patient tumours. Ki67 labeled cells were stained with DAPI. Gates isolated the 4n+ population to 
assess Ki67 expression in the hyperdiploid subpopulation of cultured human GBM cells. The figure 
shows Ki67 protein expression for four human GBM cell lines. The upper panels show cells 
containing 2n DNA, overlaid with the hyperdiploid population (4n+), as assessed by DAPI staining. 
The lower four panels show an overlay of cells containing 4n DNA with hyperdiploid cells. 
 
The proportion of 4n+ GBM cells expressing Ki67 indicates that this sub-population was 
clearly not senescent, however it is possible that these cells routinely fail cytokinesis due 
to defects in G2/M progression and are therefore not a viable sub-population. Cytokinesis 
failure has a number of potential outcomes. Activation of the tumour suppressor p53 
induces a checkpoint arrest in G1 resulting in cells that either undergo apoptosis or are 
simply unable to divide and contribute to tumour progression (Lacroix & Maddox, 2012). 
Another possible outcome of failed cytokinesis is the formation of binucleate cells and 
aneuploidy (Sagona & Stenmark, 2010).  
 
4.2.3 Hyperdiploid clones can maintain long–term growth under tumoursphere 
culture conditions 
To confirm that GBM hyperdiploid cells are capable of long term proliferation CFSE-
retaining cells were sorted from the bulk population by flow cytometry and seeded 96 well 
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dishes at a density of one single cell per well. Nine days post-seed, wells containing a 
single sphere were identified (i.e. clonal population) and these clones were amplified for 
cell cycle analysis. Over 100 clones were screened from four separate GBM parent lines. 
Hyperdiploid clones were isolated from three of the patient lines and amplified as 
tumourspheres. Only clones with a hyperdiploid DNA profile, as assessed by DAPI 
concentration, were maintained in culture. Figure 4.3A compares the DNA content of three 
hyperdiploid clones with the diploid parent cell line.  
 
 
Figure 4-3 Hyperdiploid clones exhibit an increase in DNA content. (A). Clonal cell lines were 
generated from three primary human GBM tumours. The parent GBM tumour cell line and clonal 
cell lines were dissociated into single cells, the parent population was stained with CFSE for easy 
identification, and all cells were fixed and permeabilized. Each clonal cell line was spiked with 
CFSE labeled parent cells as a control and all the cells were stained with DAPI to assess DNA 
content. The parent cell line was isolated from the clonal lines during flow cytometry based on 
CFSE fluorescence. All the clonal lines shown in blue, exhibited hyperdiploidy as indicated by the 
increase in DNA content over that of the parental line, shown in red. (B). Hyperdiploid cells are 
viable and capable of long-term proliferation in vitro. The charts show three parent lines (L0, L4, 
L25) in blue and three clones of each parent line shown in red over 10 passages. 
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To formally assess the ability of hyperdiploid clonal lines to proliferate long term in culture 
conditions, three clones from each line were compared to their parental control 
populations with respect to their ability to maintain long-term growth under tumoursphere 
culture conditions. Parental and clonal lines were passaged under tumoursphere 
conditions for seven days when spheres were dissociated and cell counts performed, this 
continued for 10 passages. All of the hyperdiploid clones isolated were able to maintain 
long-term growth, and therefore expressed one of the key hallmarks of cancer, unbridled 
proliferation (Hanahan & Weinberg, 2000). While the hyperdiploid cell populations 
exhibited long-term proliferative capacity, they did not proliferate with the same efficiency 
as the parent cell lines (Figure 4.3B). These results confirm that a proportion of 4n and 
4n+ GBM cells are viable as evidenced by the ability to maintain a tumoursphere culture in 
vitro, and suggest the hypothesis that these cells may play an active role in GBM disease.  
 
4.2.4 Viable hyperdiploid cells are present in mouse xenograft tumours and 
primary patient tumours 
It was crucial to confirm that the presence of hyperdiploid cells was not an artifact of tissue 
culture. To do this we attempted to identify a subpopulation of hyperdiploid cells in 
xenograft mouse brain tumours. NOD SCID mice were anaesthetized and 200,000 
hyperdiploid cells amplified in sphere cultures and dissociated into a single cell suspension 
were injected into the striatum of each mouse. When large brain tumours had formed, they 
were surgically removed and chemically dissociated. Near infrared live-dead stain was 
used to exclude dead cells from our analysis. Human specific CD monoclonal antibody 
CD56, which recognized human glioblastoma cells but not mouse cells, was used to 
isolate human cells from surrounding and infiltrating mouse cells in xenograft experiments.  
 
Figure 4.4A shows the gating strategy used to isolate human GBM cells within orthotopic 
xenograft tumours. Human GBM cells were isolated from freshly resected primary human 
brain tumours using a similar gating strategy. CFSE staining intensity was used to isolate 
control cells, near infrared live/dead stain was used to exclude dead cells, and DAPI was 
used to analyze the DNA profile (Figure 4.4B).  
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Figure 4-4 Gating strategy used to isolate human GBM cells in orthotopic xenograft 
tumours and primary human brain tissue. (A) The figure shows the gating strategy used for 
mouse xenograft tumour cells. CFSE staining was used to isolate control cells from tumour cells. 
To isolate the live cells, near infrared live–dead stain was used to exclude dead cells that take up 
the fluorescent label. CD56 labels neural cell adhesion molecule 1 (NCAM-1) which is present on 
the surface of human neural and glial cells. It was used to isolate human tumour cells from 
surrounding and infiltrating mouse brain cells. The DNA content of live human tumour cells was 
detected according to DAPI staining intensity. (B) Shows the gating strategy used for fresh primary 
human tumour cells. CFSE staining was used to isolate control cells from tumour cells. To isolate 
the live cells, near infrared live–dead stain was used to exclude dead fluorescently labeled cells. 
The DNA content of live human tumour cells was detected according to DAPI staining intensity. 
 
Figure 4.5A shows the DNA content of primary patient GBM cells that have been 
passaged as tumourspheres. The gate isolates the 4n+ population. In this tumoursphere 
culture, 5.88% of cells fall within this gate. Figure 4.5B shows the DNA content of an 
orthotopic xenograft tumour analysed by flow cytometry using DAPI. The 4n+ cells 
constituted 7.88% of the tumour cell population in this mouse.  
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Figure 4-5 Hyperdiploid cells exist in primary patient tumour tissue and passaged cell lines 
and xenograft tumours. The DNA content was determined using DAPI. (A) Shows the DNA 
content of a GBM tumour cell line passaged as tumourspheres. The gate isolates the aneuploid 
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cell population, which represents 5.88% of the total cell population. (B) Shows the DNA content of 
a mouse xenograft tumour where the aneuploid cell population makes up 7.88% of the total tumour 
cell population. (C) The DNA content of primary human glioblastoma tumour cells is shown where 
a subpopulation of aneuploid cells shown is 4.89% of the total tumour cell population. Cell cycle 
analyses of all primary GBM tumours identified a viable subpopulation with an elevated DNA 
content. (D) The box and whisker plot indicates the aneuploid cell distribution in a single cell 
suspension of human glioblastoma tumours, cultured tumoursheres, and xenograft mouse 
tumours. (E) The figure shows the gating strategy used for comparing DAPI staining in parents and 
clones. GBM Line 4 is shown with one of the clones derived from it. The clone was stained with 
CFSE to enable both populations to be analysed in the same tube. The figure shows the DAPI 
content of each separately and then as an overlay. The clone, shown in green, clearly consists 
mostly of 4n and 8n DNA. 
 
Finally, we analysed the ploidy status of fresh primary patient tumour tissue using DAPI by 
flow cytometry. Primary glioma tissue contained a subpopulation of cells with an increased 
DNA content as assessed by DAPI concentration shown in figure 4.5C. All the human 
GBM tumours we analysed harbored a hyperdiploid subpopulation. In the tumour shown 
the hyperdiploid cell population was 4.89% of the total cell population. The box and 
whisker plot in figure 4.5D shows the percentage of hyperdiploid cells in passaged 
tumourspheres, primary patient tumours, and orthotopic xenograft tumours. Combined, 
these results confirm the presence of viable, proliferative hyperdiploid cells in passaged 
tumourspheres, xenograft tumours, and primary patient glioma tissue. 
 
Donovan et al., contains a CGH analysis of three hyperdiploid clonal cell lines and the 
corresponding parent line generated in our lab. All three clones displayed chromosomal 
gains and losses compared to the parental bulk population. The clones exhibited almost 
double the DNA content of the euploid parent. CGH analysis revealed that all three clones 
were hyperdiploid with near-tetraploid chromosomal content. Overall, 1297 genes with 
copy number variations were identified, however, only 16 genes were affected in all of the 
three clones. A subsequent analysis of the functional networks over-represented in the 
cohort of 16 genes affected across all three clones identified that “Cellular Growth and 
Proliferation”, “Cancer”, “Cell Cycle”,  “Cell Death and Survival” and “DNA Replication, 
Recombination and Repair” were the networks affected (P. Donovan et al., 2014). 
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4.2.5 Hyperdiploid cells are capable of forming tumours in vivo which have the 
hallmarks of high grade glioma 
The gold standard assay to assess tumourigenic potential of cells for brain cancer is the 
intracranial xenograft disease model (Morton & Houghton, 2007). Therefore, we used a 
xenograft tumour model to determine whether hyperdiploid cells were capable of driving 
disease in vivo. Figure 4.5E shows the gating strategy used to assess the DNA content of 
our hyperdiploid clones. We injected 200,000 hyperdiploid cells passaged as 
tumourspheres into the striatum of NOD SCID mice exactly as described in (Deleyrolle et 
al., 2011). Figure 4.6A is a schematic of the GBM mouse models we generated in vivo. We 
injected a total of 29 mice consisting of L0 Parent: N=8, L0 Clone: N=5, L4 Parent: N=4, 
L4 Clone: N=6, L25 Parent: N=3, L25 Clone: N=3. Mice were monitored daily for signs of 
disease and were sacrificed when they began to lose weight and/or displayed symptoms 
of disease in line with our animal ethics protocol. The survival data generated was used to 
generate a Kaplan-Meir survival curve. Figure 4.6B shows the survival data for mouse 
orthotopic xenograft tumours for three parent cell lines and a corresponding clonal variant 
of each. The median survival time was longer for mice injected with hyperdiploid clonal 
lines than parental lines, however, the difference was shown to be insignificant in all cases 
using the log-rank test. These data show that hyperdiploid clones are capable of driving 
disease progression similar to that of the bulk tumor population.  
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Figure 4-6 Hyperdiploid human GBM cells can initiate tumour formation in vivo and exhibit 
variations in genomic stability in xenograft tumours. (A) Schematic of xenograft tumour 
initiation in mice. Cells from three hyperdiploid clonal variants and the three-matched parent diploid 
controls were dissociated from tumoursphere cultures into single cell suspensions and injected into 
the striatum of SCID mice (2 x 105 cells per mouse). When large tumours formed, they were 
surgically removed and mechanically and chemically dissociated. (B) Kaplan-Meier survival curve 
showing mouse survival following striatal tumour cell injection of hyperdiploid clonal cell lines and 
matched parental controls. We injected a total of 29 mice consisting of L0 Parent: N=8, L0 Clone: 
N=5; L4 Parent: N=4, L4 Clone: N=6; L25 Parent: N=3, L25 Clone: N=3. (C) Stability of 
hyperdiploidy in orthotopic xenograft tumour cells. The DNA content of human GBM diploid parent 
tumour cells, hyperdiploid cultured clones and hyperdiploid xenograft tumour clones was 
determined according to DAPI staining intensity using flow cytometry analysis as described in the 
Materials and Methods. The clone derived from patient Line 0 (upper panel) showed a marked loss 
of DNA content in vivo. The tumour generated from the hyperdiploid clone generated from patient 
Line 4 (centre panel), maintained an approximate two-fold DNA content in vivo despite some 
genetic drift. Two separate populations evolved from the tumour generated from the hyperdiploid 
clone derived from patient Line 25 (lower panel), one of which displayed a marked loss in DNA 
content and a second separate population that maintained a two-fold DNA content in vivo. 
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To determine the ploidy of the parent and hyperdiploid clonal orthotopic xenograft tumors 
we analysed the DNA content by flow cytometry. Mouse brain tumours were diced and 
chemically dissociated before fixation; DAPI staining intensity was assessed to determine 
DNA content. In both parent and hyperdiploid clonal lines there was 100% tumour 
formation in vivo. Tumours generated from parental cell lines maintained a near diploid 
DNA content and a similar proportion of hyperdiploid DNA content to their corresponding 
tumoursphere cultures. In contrast, the ability of clones to maintain a hyperdiploid DNA 
profile after in vivo tumour formation varied from cell line to cell line. Hyperdiploidy was lost 
in vivo in the tumour that developed from the clone of patient Line 0 resulting in a 
subdiploid DNA content evident during flow cytometry analysis. The tumour generated 
from the clone of patient Line 4 maintained a relatively stable hyperdiploid state in vivo 
despite some genetic drift. The tumour generated by the clone from patient Line 25 
developed two populations in vivo, one hyperdiploid and the other subdiploid. (Figure 
4.6C). This data is illustrative that maintenance of the hyperdiploid state in vivo is variable 
across different patient tumours being stably maintained in some and lost in others.   
 
Next, we examined the histopathological features of the xenograft tumors following 
haematoxylin and eosin staining. Figure 4.7 shows histological sections of xenograft 
tumours from parental cell lines and hyperdiploid clonal lines that are consistent with the 
histopathological features of high-grade human glioma. Parental and hyperdiploid clonal 
variants both exhibited pleomorphic (variable shape and size of cell/nucleus) astrocytic 
tumour cells with marked nuclear atypia and brisk mitotic activity (more than 20 
mitoses/ten high power fields). This data confirms the use of orthotopic xenograft models 
of glioblastoma in immunocompromised mice with regard to the histopathology of the 
tumours generated using this method.  
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Figure 4-7 Haematoxylin and eosin (H&E) staining of xenograft tumours generated from 
diploid parent cells and hyperdiploid clonal cells. Histopathological features of high-grade 
glioma were identified by a pathologist in H & E stained sections of paraffin embedded tumour 
tissue. Pleomorphic (variation in cell/nuclear size, shape, staining) astrocytic tumour cells can be 
seen with marked nuclear atypia and brisk mitotic activity (more than 20 mitoses/ten high power 
fields). Representative atypical mitotic figures are indicated by yellow arrows. 
 
From this data I concluded that the xenograft tumour model I established shows that 
hyperdiploid cells are capable of tumour formation in vivo and that mouse brain tumours 
that develop from hyperdiploid glioma cells exhibit features consistent with primary patient 
GBM tumours. In one patient line, the hyperdiploid cell is a stable cell state, maintained 
during both serial passaging and growth in vivo. In two other patient lines, the hyperdiploid 
state is a pseudo-stable cell fate, with hyperdiploidy being maintained during long-term 
passaging in vitro but lost during in vivo disease. 
 
4.2.6 Hyperdiploid cells show resistance to conventional therapy 
Hyperdiploid cells present in other solid tumors including colon cancer, breast cancer and 
ovarian cancer (Kusumbe & Bapat, 2009; Paulsson et al., 2013) display resistance to 
cytotoxic therapies (Castedo et al., 2006; Moore et al., 2012; Senovilla et al., 2012; Vitale 
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et al., 2011). We therefore predicted that GBM hyperdiploid cells might be resistant to the 
conventional cytotoxic treatments.  
 
To this end, cells were treated with the chemotherapeutic currently used in first line 
management of GBM to determine whether hyperdiploid cells exhibited resistance and 
were therefore capable of contributing to disease recurrence after therapy. Temozolomide 
(TMZ) is a chemotherapeutic DNA methylation agent currently in use to treat GBM. To 
assess the response of hyperdiploid cells to TMZ, hyperdiploid clones were seeded into 
media containing TMZ. The colourimetric MTT assay was used to determine the response 
to chemotherapy. The response was compared to that of the bulk of the overall tumour 
population. Hyperdiploid cells showed a reduced sensitivity to TMZ when passaged in the 
drug for five consecutive days in comparison to the overall tumour cell population (Figure 
4.8). This data shows that the hyperdiploid cell population exhibited relative therapeutic 
resistance when compared to the parent population in response to one of the current first 
line treatments in clinical use for glioma.  
 
 
Figure 4-8 Hyperdiploid cells show therapeutic resistance. Cell viability was assessed using 
the MTT assay following treatment with temozolomide. Tumoursphere cultures from Line 0 (N=3) 
and 3 aneuploid clonal lines derived from Line 0 (N=3 per clone) were treated with 60µM 
temozolomide and assessed for viability seven days after treatment. The three hyperdiploid clonal 
lines were significantly more resistant to temozolomide than the parental control line. * Denotes 
significance as determined by ANOVA with Tukey post-test; **** p ≤ 0.0001, *** p ≤ 0.001, ** p ≤ 
0.01, * p ≤ 0.05. 
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4.2.7 Hyperdiploid tumour cells cycle less frequently than euploid tumour cells 
Experimental data from yeast (Rancati et al., 2008; Eduardo M Torres et al., 2007), 
mammalian cell culture (Williams et al., 2008) and tissue (Gentric, Celton-Morizur, & 
Desdouets, 2012) all indicate that polyploidy reduces cellular proliferation. Consistent with 
a reduced proliferative phenotype, we have shown that GBM hyperdiploid cells represent a 
subpopulation in primary tumor culture, mouse xenograft tumors, and primary patient 
tumors. To formally address the replicative phenotype of GBM polyploid tumor cells, we 
analysed the cell cycle distribution of the parent and tetraploid cells grown under 
tumorsphere culture conditions. Consistent with a reduced frequency of entering the cell 
cycle, the hyperdiploid clonal tumorsphere cultures had a reduction in cells in the G2/M 
phase of the cell cycle with a commensurate increase in the G0/G1 peaks (Figure 4.9A).  
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Figure 4-9 Slow cycling cells exist in in vitro GBM cell culture and exhibit a higher DNA 
content than the bulk of the population. (A) Hyperdiploid clonal tumoursphere cultures exhibited 
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a pronounced reduction in cells in the G2/M phases of the cell cycle with a commensurate increase 
in the G0/G1 phases. (B) The expression levels of two proliferation markers, phosphorylated 
Retinoblastoma (phospho-Rb) protein and Ki67 were analysed in hyperdiploid clones and the 
matched parental control. Parental cells and hyperdiploid clones were grown under tumorsphere 
conditions for five days, then dissociated into a single cell suspension and the parental population 
was incubated in CFSE for identification during flow cytometry analysis. All cells were fixed, 
permeabilized, and blocked and each clonal population was mixed in with the corresponding CFSE 
labeled parent control. Then the mixed populations were stained in the same tube to achieve 
identical staining conditions for phosphorylated Rb (y axis) and Ki67 (x axis). Phosopho-Rb (1:50 
Cell Signalling). Ki67 (1:100 Novocastra). In the clonal populations, an increase in double negative 
non-cycling cells (phospho-RB-/Ki67-, lower left quadrant) corresponded with a decrease in double 
positive proliferating cells (phospho-Rb+/Ki67+, upper right quadrant), relative to the matched 
parent control population. 
The retinoblastoma (Rb) tumour suppressor gene produces a protein which blocks entry 
into S phase, initiating the G1 checkpoint (Harbour & Dean, 2000). Rb binds to E2F 
preventing transition from G1 to S phase through repression of gene transcription (Giacinti 
& Giordano, 2006). Three Rb states have been identified, namely, unphosphorylated, 
hypophosphorylated and hyperphosphorylated. Rb is unphosphorylated in early G1  
(Narasimha et al., 2014). In the hyperphosphorylated state the protein is inactive. Rb 
proteins are phosphorylated by cyclin D- and cyclin E-dependent kinases allowing 
progression into S phase (Nevins, 2001). The hyperphosphorylated form of Rb is 
expressed in late G1, S, G2 and M phases of the cell cycle (Giacinti & Giordano, 2006). We 
chose phosphorylated Rb (phospho-Rb) and Ki67 to determine the relative proliferation 
rates of parental and hyperdiploid clonal cultures. Ki67 protein is highly expressed in 
cycling cells and rapidly degraded once cells exit the cell cycle (Scholzen & Gerdes, 
2000). A comparison of the hyperdiploid clones with the parental controls revealed a 2.97 
fold increase in non-cycling cells in the hyperdiploid clones. Cells that were negative for 
both Ki67 and phospho-Rb (p value = 0.0008) were deemed non-cycling (Figure 4.9B). 
This data indicates that the hyperdiploid cells cycle less frequently due in part, to the 
presence of a G0/G1 checkpoint delay in hyperdiploid human GBM cells. 
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4.2.8 Hyperdiploid cells are larger and exhibit increased metabolic activity and 
glycolysis inhibition sensitivity compared to euploid tumour cells  
Increased DNA content is associated with an increase in overall cell size, and a direct 
correlation exists between ploidy status and increases in cell size (Williams et al., 2008). 
We hypothesized that increased cell size is a conserved phenotype across the entire 
hyperdiploid cell population and that this attribute could be exploited in the development of 
anti-aneuploid therapeutics.  
 
The total cell volume of hyperdiploid clones was compared with the parental cell line to 
determine the relative cell size differences between the euploid bulk population and the 
hyperdiploid clones. The results confirmed those of previous work by others (Cavalier-
Smith, 2005; Chan & Marshall, 2010; Gregory, 2001; Jorgensen et al., 2007; Neumann & 
Nurse, 2007; Petrov, 2002), our hyperdiploid cells were approximately double the size of 
the parent euploid cells (Fig. 4.10).  
 
 
Figure 4-10 Hyperdiploid cells are larger than euploid tumour cells. Aneuploid clones and 
parent cell lines were passaged as tumourspheres. DNA content was analysed by DAPI 
concentration and cell volume using BD Quanta flow cytometer. DNA content was used to identify 
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cells in G0/G1. Electronic volume of parent and clonal line in G0/G1 was calculated from 10,000 
cells. In the histograms, the electronic volume distribution shown in red represents the parent 
population and the hyperdiploid clones are shown in blue. The mean cell volume was calculated 
using 10,000 cells based on 10µm diameter beads. 
 
There are a number of possible cellular adaptations required to compensate for an 
increase in DNA content including a corresponding increase in metabolic demand 
associated with an increase in organelle activity and protein production. An increase in 
these activities would place an increased demand on the glycolytic pathway. To assess 
whether this was occurring in hyperdiploid cells L-Lactate production was measured, which 
is an established method for assessment of metabolic pathway activity in tumour cells 
(Jain et al., 2012). L-lactate production is the result of an intracellular accumulation of 
pyruvate as a consequence of glycolysis, increased lactate dehydrogenase activity, or 
disturbances in mitochondrial function (Williams et al., 2008). As predicted, the increase in 
size of the hyperdiploid tumour cells corresponded with an increased level of L-Lactate 
production when compared to the parental euploid population (Figure 4.11A).  
 
 
Figure 4-11 Hyperdiploid cells exhibit increased metabolic activity and glycolysis inhibition 
sensitivity compared to euploid tumour cells. (A). Parent and hyperdiploid clonal cell lines were 
seeded at 1 x 106 cells/ml and passaged as tumourspheres for 24 hours. The relative L-Lactate 
production shown in the figure represents the results of three independent cultures per line. 
Significance was determined using ANOVA with Tukey post-test, *** p≤ 0.001. (B). Parental 
tumourspheres (N=3) and hyperdiploid clonal cultures  (N=3 per clone) were treated with 4mM 2-
Deoxy-D-glucose (2-DG). Viability was assessed seven days after treatment. The three aneuploid 
71 
 
cultures were significantly more sensitive to 2-DG than the parental control line. *Denotes 
significance as determined by ANOVA with Tukey post-test; ****p≤ 0.0001, *** p≤ 0.001. 
 
To determine whether the demand for an increase in metabolism in hyperdiploid cells was 
a potential therapeutic target, cells were treated with an inhibitor of glycolysis. Treatment 
with 2-deoxy-D-glucose (2-DG), an established inhibitor of glycolysis (S. Gupta, Farooque, 
Adhikari, Singh, & Dwarakanath, 2009; Kalia, Prabhakara, & Narayanan, 2009; F. Zhang & 
Aft, 2009) had a significantly greater effect on cell viability in the hyperdiploid clonal lines 
than on the euploid parental population (Figure 4.11B). The results of this assay showed 
that administration of the optimal dose of 2-DG reduced sphere formation in the euploid 
parental cells while at the same time eliciting a more dramatic response from the 
hyperdiploid clones. This data supports our hypothesis that hyperdiploid GBM cells are 
larger in size and exhibit an increased metabolic demand compared to their euploid 
counterparts. Additionally, the finding that hyperdiploid GBM cells are more sensitive to 
glycolysis inhibition than euploid tumour cells suggests that this is a possible therapeutic 
target with the advantage of cellular specificity. 
 
4.3 Discussion 
Genomic instability and aneuploidy are common characteristics of tumours (Wodarz & 
Gonzalez, 2006) (Korzeniewski, Spardy, Duensing, & Duensing, 2011; E. M. Torres et al., 
2010). In the process of monitoring patients diagnosed with Barrett’s oesophagus for 
progression to oesophageal adenocarcinoma, surgeons regularly perform endoscopic 
examinations and tissue biopsies. This enables oncologists to observe disease 
progression at a cellular and subcellular level. Galipeau et al., identified an unstable 4n 
intermediate cell population in premalignant oesophageal adenocarcinoma tissues in vivo 
that progressed to aneuploidy as a result of continued genomic instability ((Galipeau et al., 
1996). Vitale et al., studied the effects of nocodazole or cytochalasin D (a cytokinesis 
inhibitor) on p53-/- human colon carcinoma HCT116 cells in vitro. The initial response was 
an increase in the number of polypolid cells and a reduction in cell death compared to the 
control p53 competent cells. Cells were FACS-purified to establish a tetraploid population 
and amplified in vitro. Notably, p53-/- tetraploid cultures accumulated a population of cells 
with an ~2n DNA content. Videomicroscopy revealed that p53-/- underwent multipolar cell 
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divisions with a higher frequency than p53+/+ control cells and that the resulting sub 
tetraploid cells were capable of normal bipolar cell divisions thereafter (Vitale et al., 2010). 
 
Despite the observation that almost all cancers have degrees of aneuploidy, the 
contribution of genetic imbalance to the pathophysiology of cancer remains an ongoing 
question in cancer research. Direct experimental evidence supporting a pivotal role for 
aneuploidy in tumor initiation has been provided in a series of seminal studies (Castillo, 
Morse, Godfrey, Naeem, & Justice, 2007; Davoli & de Lange, 2012; Fujiwara et al., 2005; 
Zheng et al., 2012), however the role of aneuploidy in advanced disease is less well 
understood. It was first hypothesized by Boveri (Boveri, 1902) that aneuploidy may cause 
the uncontrolled proliferation of cancer cells. Here we have identified a hyperdiploid tumor 
cell subpopulation of potential clinical significance that is present in adult brain GBM 
tumors. These cells are viable, stably hyperdiploid, able to maintain long-term proliferation 
and drive tumor growth in vivo, and are resistant to conventional therapy. 
 
This hypothesis has been countered with experimental observations showing that 
hyperdiploidy, in particular polyploidy, reduces cellular proliferation. For example, studies 
of hyperdiploid yeast strains have widely reported that aneuploid strains have a 
proliferative disadvantage (Rancati et al., 2008; Eduardo M Torres et al., 2007). The 
growth disadvantage of hyperdiploidy has also been demonstrated in mammalian cells 
derived from aneuploid mice, where hyperdiploid cells showed proliferation defects under 
standard tissue culture conditions (Williams et al., 2008). In tissues, polyploidy is 
associated with a markedly decreased replicative capacity (reviewed in (Gentric et al., 
2012)). Consistent with the idea of polyploidy providing a growth disadvantage in adult 
brain cancer, GBM hyperdiploid clonal cultures were less proliferative than the parental 
tumor cell population. Cell cycle analyses confirmed that hyperdiploid tumor cells cycle 
less frequently than the euploid tumor bulk, which is caused (at least in part) by a delay in 
G0/G1. Altogether, our data and historic studies all support the hypothesis that 
hyperdiploidy comes with the fitness cost of decreased replicative capacity. 
 
The reduced proliferative capacity of aneuploid tumor cells would be predicted to provide a 
selective disadvantage in the competitive tumor environment; a prediction borne out by the 
observation that aneuploid cells represent a relatively small cell subpopulation within 
patient and xenograft tumours as well as during growth under tumorsphere cell culture 
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conditions. However, this situation can change during the therapeutic selection pressures 
that occur as a result of treatment. We have shown here that GBM hyperdiploid cells are 
resistant to the DNA damaging therapy commonly in use to treat GBM, temozolomide. 
These results are consistent with tetraploid models of colon carcinoma, in which 
tetraploidy (a specific form of polyploidy) was shown to provide resistance to DNA-
damaging agents (Castedo et al., 2006).  
 
Infrequent cell cycle is a well-established drug resistance mechanism, and provides a 
plausible explanation as to why GBM aneuploid tumor cells are resistant to temozolomide. 
Quiescent (G0) haematopoietic stem cells (HSCs) are resistant to the anti-proliferative 
chemo-therapeutic agent 5-fluoro-uracil (5-FU) (Randall & Weissman, 1997; Wilson et al., 
2008), and become sensitive to 5-FU treatment when they are forced from G0 into a 
proliferative state by treatment with IFNα (Essers et al., 2009). Further, HSCs can be 
protected from the effects of irradiation by increasing the proportion of HSCs in G0 through 
a variety of treatments in vivo (Davis, Mungunsukh, Zins, Day, & Landauer, 2008; Forristal 
et al., 2013; Johnson et al., 2010). In cancer, the chemo-protective effect of cell cycle-
mediated drug resistance is well established (Shah & Schwartz, 2001). For example, 
Schmidt and colleagues demonstrated that colon adenocarcinoma cells arrested in G1 by 
over-expression of p27Kip1 are significantly more resistant to a variety of chemotherapeutic 
agents, including temozolomide (Schmidt et al., 2001). Using a mouse xenograft model, 
Naumov et al. showed that the DNA intercalating compound doxorubicin (DXR) effectively 
reduced the metastatic tumor burden but spared non-cycling tumor cells, which persisted 
during therapy and subsequently developed into metastases after DXR therapy was 
discontinued (Naumov et al., 2003).  
 
More recently, label-retention has been used to phenotypically identify infrequently dividing 
cells that are resistant to chemotherapy from a variety of tumor types (Dembinski & 
Krauss, 2009; Fillmore & Kuperwasser, 2008; Kusumbe & Bapat, 2009; Moore et al., 
2012). Studies examining the cancer stem cell phenotype have also shown that 
quiescence provides protection against cell death induced by DNA-damage agents (G. 
Chen, Bradford, Seidel, & Li, 2012; Y. Chen et al., 2012) and chemotherapy (Kobayashi et 
al., 2012). Recently, a landmark study by Kreso et al. revealed how chemotherapy selects 
for minor, infrequently cycling subpopulations using lineage tracking in mouse models of 
cancer evolution (Kreso et al., 2013). Collectively these studies provide strong support for 
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the hypothesis that infrequent cell cycle contributes to the evolution of therapy resistance 
in cancer, and here we identify hyperdiploidy as an additional mechanism to generate 
slow-cycling cell subpopulations within solid tumors.  
 
Why do aneuploid tumor cells cycle less frequently? One intriguing possibility is that the 
difference in cell size between aneuploid and diploid cells determines the frequency of cell 
division. This study found that GBM hyperdiploid tumor cells have a two-fold larger cell 
volume compared to their diploid counterparts. Cell growth, cell size and cell division are 
co-regulated to ensure cells are large enough to divide at mitosis (Turner, Ewald, & 
Skotheim, 2012). Studies in yeast revealed a size requirement for G1-S transition, with 
smaller cells delaying in G1 until a sufficient size was reached to maintain viable progeny 
after cell division (Johnston, Pringle, & Hartwell, 1977; Martin-Castellanos, Blanco, de 
Prada, & Moreno, 2000). Complementary studies in animal cells show that mammalian 
cells also delay in G1 to allow an appropriate cell size to be achieved (Dolznig, Grebien, 
Sauer, Beug, & Mullner, 2004; Kafri et al., 2013). Thus, one plausible hypothesis is that 
the larger aneuploid tumor cells arrest during G0/G1 to allow sufficient growth to occur 
before committing to division.  
 
In human development, aneuploidy is a normal mechanism contributing to organ 
development. Trophoblast giant cells (TGCs) are required for placental development 
following embryo implantation. Endoreplication in TGCs produces polyploid nuclei thought 
to facilitate an increased capacity for synthesis of secreted proteins including hormones, 
cytokines, adhesion molecules and extracellular matrix proteins in addition to promotion of 
angiogenesis and invasion during placental development (D. Hu & Cross, 2010). 
Polyploidy is maintained in TGCs through endoreplication by preventing M phase after 
completion of S phase (Elledge, 1996). Unhavaithaya et al. studied glial cells in normal 
development of the model organism Drosophila melanogaster. Polyploidy of glial cells is 
required to maintain a functioning blood brain barrier during larval brain development in 
Drosophila (Unhavaithaya & Orr-Weaver, 2012). Polyploid neurons have been found 
throughout the mammalian brain during normal brain development. While their functions 
have not been fully elucidated, it is postulated that chromosome gains could contribute to 
developmental processes (Kingsbury et al., 2005). It is conceivable, given that 
hyperdiploidy is required for normal organ development in insects and mammals that the 
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contribution to tumour progression is the adaptation of an evolutionarily conserved 
mechanism to maintain organ function. 
 
Hyperdiploidy may contribute to therapy resistance through additional mechanisms other 
than cell cycle effects. Both temozolomide and ionizing radiation can inhibit the 
proliferative capacity of tumor cells by inducing senescence (Hirose, Berger, & Pieper, 
2001; Jinno-Oue et al., 2010; Knizhnik et al., 2013). A recent study has shown that 
aneuploid cells preferentially escape from therapy-induced senescence, providing another 
mechanism for aneuploid tumor cells to resist the effects of conventional therapy (Q. Wang 
et al., 2012). Aneuploidy also generates phenotypic changes through changes in gene 
expression (Galitski, Saldanha, Styles, Lander, & Fink, 1999; Pavelka et al., 2010), and 
there is a growing body of evidence suggesting that aneuploid-dependent phenotypic 
changes provide adaptive advantages during therapy in a wide range of clinical settings. In 
fungal pathogens, chromosomal gains are thought to be responsible for anti-fungal drug 
resistance and immune-evasion (reviewed in (Kronstad et al., 2011; Selmecki, Forche, & 
Berman, 2010)). In experimental yeast models of therapy resistance, chromosomal gains 
provide a selective advantage under chemotherapeutic, cytotoxic, and anti-fungal drugs 
(G. Chen et al., 2012; Pavelka et al., 2010). Bortezomib (Velcrade) is an important drug for 
the treatment of multiple myeloma (MM). In a myeloma cell line model of cancer therapy 
resistance, polyploid myeloma cells displayed a five-fold resistance to the proteasome 
inhibitor bortezomib (Velcade) that is associated with over-expression of the proteasome 
subunit PSMβ5, the cellular target of bortezomib (Balsas et al., 2012). It is also possible 
that aneuploid cells are more resistant to genomic toxins due to simple gene duplication, 
which could preserve gene function through redundancy mediated genetic buffering 
(Elena, Carrasco, Daros, & Sanjuan, 2006).  
 
It must also be noted that genotoxins such as TMZ and γ-radiation directly cause the 
generation of hyperdiploidy within GBM patients, based on the classic study by Yung and 
colleagues (Yung, Shapiro, & Shapiro, 1982) and more recent results obtained in breast 
cancer (Lagadec et al., 2012). Lagadec and colleagues increased the prevalence of 
polyploidy using radiation or pharmacological induction and showed that the resulting 
polyploid tumor cells display a pluripotent, tumor-initiating phenotype (Lagadec et al., 
2012). These data support the provocative hypothesis that radiotherapy increases the 
aggressiveness of a patient tumour by elevating the frequency of hyperdiploid cells within 
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the surviving tumor cell population (Lagadec et al., 2012). Altogether there is a growing 
body of literature that provides a strong precedent for the ability of aneuploid cells to 
contribute to the evolution of therapy resistance and disease recurrence in a variety of 
solid tumors, and this study provides support for the idea that this hypothesis also holds 
true for adult brain cancer.  
 
A number of lines of evidence suggest that aneuploid tumour cells can be specifically 
targeted with drugs that have little or no impact on normal euploid cells. Tumour cells 
exhibited heightened sensitivity when treated in vitro with 5-Aminoimidazole-4-
carboxamide-1-β-4-ribofuranoside (AICAR) compared with non-cancerous cells (Jose et 
al., 2011). AICAR is an AMP kinase activator that regulates cellular responses to 
metabolic stress (Rattan, Giri, Singh, & Singh, 2005). AICAR treatment resulted in a dose 
dependent reduction in tumour cell viability and proliferation, and an increase in apoptosis 
in contrast with little effect on non-cancer cells (epithelial cells and fibroblasts) (Jose et al., 
2011). Jose et al. showed that AICAR sensitivity was increased in cells with a low steady-
state ATP and a rapid proliferation rate. In another study, single chromosome gains in 
mouse embryonic fibroblasts were used to model the response of aneuploid cells to 
chemical compounds inducing genotoxicity, proteotoxicity, and energy stress. Aneuploid 
cells treated with AICAR and 17-allylamino-17-demethoxygeldanamycin (17-AAG) 
underwent apoptosis at doses that had minimal toxic effects on euploid cells (Tang et al., 
2011). 17-AAG interferes with protein folding through its inhibition of HSP90 
(Krishnamoorthy et al., 2013). These data show that drugs targeting already disrupted 
cellular functions have the potential to selectively inhibit aneuploid cell proliferation and 
tumour progression. 
 
One strategy being actively pursued to overcome tumor heterogeneity is the identification 
of tumor subpopulations most likely to contribute to therapy resistance, followed by the 
development of new drug regimes that specifically target these subpopulations. This 
approach aims to decrease the adaptive capacity of the tumor to maintain the efficacy of 
the primary targeted or chemotherapeutic regimes for longer periods of time. Several 
independent groups have made inroads into the development of therapeutic strategies that 
specifically target aneuploid tumor cells (A. J. Lee et al., 2012; Marxer et al., 2012; Rello-
Varona et al., 2009; Roh et al., 2012; Vitale et al., 2007). Extensive genetic heterogeneity 
could impede the development of general therapeutic strategies targeting the aneuploid 
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subpopulation of cells. We have shown that hyperdiploid tumor cells have a two-fold 
increase in cell volume that is proportional to their doubled genome. As the positive 
relationship between genome size and cell volume has been evolutionarily conserved 
throughout eukaryotes (Cavalier-Smith, 2005; Chan & Marshall, 2010; Gregory, 2001; 
Petrov, 2002), a larger cell volume may be a common phenotype within the hyperdiploid 
tumor cell subpopulation, which may increase the sensitivity of hyperdiploid tumors cells to 
inhibitors of tumor metabolism. Consistent with this hypothesis, hyperdiploid clonal 
cultures were more metabolically active than the diploid lines, and showed an increased 
sensitivity to inhibition of glycolysis.   
 
Cancer cells rely on the glycolytic pathway to maintain their metabolic function resulting in 
high glucose requirements, known as the Warburg Effect (Warburg, 1956a). The increased 
glucose metabolism in tumour cells is facilitated by greater expression of the Glut1 
transporter than normal cells (Birnbaum, Haspel, & Rosen, 1987). 2-DG is an inhibitor of 
glucose metabolism (Aft, Zhang, & Gius, 2002). Breast cancer cells exhibit a higher 
glucose uptake when treated with 2-DG thereby increasing 2-DG uptake after which they 
undergo apoptosis (Aft et al., 2002). When hyperdiploid GBM cells with 2-DG in this study, 
sphere formation inhibition was inversely proportionate to 2-DG dose. While euploid GBM 
counterparts were also inhibited by 2-DG, the effect on the hyperdiploid cells was far 
greater. This suggests that careful optimization of drug dose has the potential to maximize 
the effect of 2-DG on hyperdiploid GBM cellular metabolism while having a minimal impact 
on the metabolism of normal healthy cells.  
 
4.4 Conclusions 
Interestingly, hyperdiploidy appears to confer inhibition to proliferation, hindering tumour 
progression and gene amplification (Rexer & Arteaga, 2012), facilitating therapy resistance 
(Corcoran et al., 2010). Hyperdiploid cells cycle more slowly than their euploid 
counterparts and therefore exhibit slower tumour development. Conversely, chromosome 
duplication can potentially contribute to drug resistance by facilitating the emergence 
phenotypic diversity leading to a selective advantage during cellular stress. These results 
suggest that tumor metabolism may be a point of fragility within hyperdiploid tumor cells 
that can be therapeutically exploited to target this subpopulation within patient tumors. Our 
hope is that this insight will contribute to the development of anti-hyperdiploid treatments, 
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which can be used to reduce cellular heterogeneity in solid tumors and improve the 
efficacy of frontline therapies. 
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5 A small cohort of cell surface proteins emerge as viable 
therapeutic targets in glioblastoma 
 
 
 
 
5.1 Introduction 
Two studies published approximately two decades ago, identified a small cohort of cancer-
initiating cells from the total cancer cell population based on their cell surface marker 
expression (Bonnet & Dick, 1997; Lapidot et al., 1994). Using mouse models of acute 
myeloid leukaemia (AML), limiting dilution assays revealed that the majority of AML cells 
exhibited limited proliferative ability in vivo (Bonnet & Dick, 1997; Lapidot et al., 1994). 
When cell surface marker expression of tumor-initiating cells was analysed, both groups 
found that only CD34+/CD38- AML cells possessed extensive proliferative ability capable 
of reproducing the original cancer in mouse models (Bonnet & Dick, 1997; Lapidot et al., 
1994). Mice intravenously injected with CD34+/CD38- leukaemic cells developed 
leukaemia in contrast to mice injected with CD34- or CD34+/CD38+ cells that did not 
(Lapidot et al., 1994). Bonnet et al., compared normal and leukaemic cells in AML to 
identify the cells capable of producing leukaemic clones. Primitive normal stem cells were 
identified as being the targets of leukaemic transformation rather than progenitors because 
consistent with the results of the study performed by Lapidot et al. only CD34+/CD38- cells 
were capable of extensive proliferation and tumour initiation in immunocompromised mice 
(Bonnet & Dick, 1997; Lapidot et al., 1994).   
 
The initial identification and isolation of tumour initiating cells in leukaemia, has led to a 
search for a similar phenomenon in solid tissue cancers. A molecular signature identifying 
cells capable of tumour initiation could be used to identify a population of clinical interest 
when designing targeted treatments for therapeutically resistant cell populations (Ke et al., 
2009; McClelland, Zhao, Carskadon, & Arenberg, 2009; Rorive et al., 2010; Shim, Oishi, & 
Fujii, 2009; Taran, Kobos, Sitkiewicz, & Sporny, 2007; Teicher & Fricker, 2010). In breast 
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cancer studies, tumour-initiating cells have been isolated from the total population of 
breast cancer cells using CD antibodies. A xenograft assay involving transplantation of 
breast cancer cells into immunocompromised mice showed that as few as 200 
CD44+/CD24-/low cells were capable of tumour formation with 100% efficiency whereas 
transplantation of 50,000 unsorted breast cancer cells were required to achieve 100% 
tumour formation (Al-Hajj et al., 2003). This study suggests that cell surface proteins can 
be used to identify cells within a tumour that possess tumour-initiating capabilities in solid 
tumours (Al-Hajj et al., 2003). Another more recent study in 2013 also identified 
CD44+/CD24low+ breast cancer cells as exhibiting superior tumour initiation ability 
compared to CD44+/CD24-/low cells in limiting dilution assays in immunocompromised 
mice (Azzam et al., 2013). 
 
The identification of stem cells in the adult mammalian brain in 1992 (Reynolds & Weiss, 
1992) has led to the hypothesis that a population of brain tumour stem cells could be 
responsible for tumour initiation and progression in the central nervous system (Reynolds 
& Weiss, 1992; Vescovi et al., 2006). Over the past decade, CD133 has been widely 
reported as a putative cancer stem cell marker (Jamal et al., 2012; Singh et al., 2003). 
CD133 positivity now appears to be environmentally induced rather than inherited. A 
recent study found that a hypoxic environment increased CD133 expression in 
glioblastoma cells in vitro resulting in a more stem-like tumour cell phenotype (Kolenda et 
al., 2011). This suggests that stem-like properties may not be fixed but may depend upon 
environmental cues. This is consistent with a recent study showing that breast cancer cells 
possess considerable plasticity in vitro in which the cancer cells can transition between 
stem-like states and various differentiation states (P. B. Gupta et al., 2011). Digoxin has 
been shown to inhibit hypoxia inducible factors in vitro and in vivo. HIF1α and CD133 were 
inhibited in mice with flank GBM xenografts treated with intraperitoneal injections of 
digoxin. Digoxin inhibited HIF1α (63%) and CD133 (72%) as analyzed by western blot of 
biopsy tissue (Bar, Lin, Mahairaki, Matsui, & Eberhart, 2010).  
 
In addition to identifying tumour-initiating cells, CD proteins are aberrantly expressed in a 
wide range of cancers and have been recognized as useful prognostic markers in 
predicting disease progression and selecting between treatment options. For example, the 
increased expression of the tetraspanin protein CD151 has been shown to positively 
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correlate with large invasive tumours and metastases while being negatively correlated 
with overall survival in hepatocellular carcinoma patients (Ke et al., 2009). Motility-related 
protein-1 (MRP-1/CD9) is a transmembrane protein found to predict disease free survival 
(DFS) in patients diagnosed with squamous cell carcinoma of the head and neck. CD9 
expression was negatively correlated with DFS in a study of 153 patients using 
immunohistochemistry on formalin fixed paraffin embedded tissue (Mhawech et al., 2004). 
CD44 expression levels positively correlated with disease recurrence and poor prognosis 
in head and neck squamous cell carcinoma (HNSCC) in a study analyzing cells extracted 
from mouse xenografts of human tumour cells by flow cytometry (Joshua et al., 2012). 
Additionally, CD44 expression was found to be involved in metastasis formation in 
osteosarcoma through in vivo experiments using CD44 knockout mice (Weber et al., 
2002). These studies indicate that cell surface proteins are useful markers of disease 
progression in a range of human solid cancers. 
 
There are only a few published studies examining CD expression in various brain cancer 
types. These studies have found similar relationships between select CD protein 
expression and disease outcome. Moreover, these studies have also shown that the 
expression of various CD proteins may also contribute to disease development and 
progression. Read et al., found that approximately 35% of medulloblastomas contained 
CD15+ cells analysed by immunohistochemistry and flow cytometry. They identified CD15 
as a marker for tumour-propagating cells in a mouse model of medulloblastoma (Read et 
al., 2009). There are currently only a small number of CD proteins with known correlations 
to glioma disease progression and prognosis. Higher expression of CD44 has been 
correlated with aggressive glioma tumours as determined by immunohistochemistry (Wei 
et al., 2010). CD63 is a tetraspanin protein that complexes with integrins to mediate 
binding although little is currently known about the effects of this on tumour progression 
(Pols & Klumperman, 2009). It is a known independent prognostic marker of disease 
progression and reduced survival times in astrocytoma (Rorive et al., 2010). In glial 
tumours, CD63 is more highly expressed in higher-grade tumours and correlated with 
shorter survival times in GBM (Rorive et al., 2010). Interestingly, a study using tissue 
microarrays revealed that CD90 expression was higher in human GBM tissue than in 
healthy brain (He et al., 2012). Subsequent neurosphere analysis in vitro showed that 
CD90+ cells possessed superior sphere forming ability when compared with CD90- cells. 
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Additionally, CD90+ cells accumulated in regions of vascularity in GBM tissues (He et al., 
2012). These results suggest the possible involvement of CD90+ cells in tumour growth 
and progression. Collectively, these studies support the hypothesis that cell surface 
proteins that are upregulated in glioma tumour cells could be contributing to disease 
progression. 
 
5.2 Hypothesis 
Cell-surface protein expression can be used to identify cell subpopulations of clinical 
relevance in GBM tumours.  
 
5.3 Aims 
The aim of this study was to identify a panel of glioma-specific CD proteins that can be 
used to identify tumour cell populations of clinical interest. Identification of specific tumour 
cell populations is a prerequisite for further studies on the relative contribution of specific 
CD proteins to the phenotypic properties (e.g. proliferation, apoptosis, drug resistance) of 
glioma cells in patients. 
 
5.4 Results 
 
5.4.1 Development of a robust flow cytometry screening platform to quantitate CD 
expression in GBM cells 
In the first instance, a robust screen was developed that was capable of analyzing a large 
number of live cells by flow cytometry, while at the same time excluding false positives. As 
the population of interest may be attributable to a small subpopulation of cells, it was 
important to be able to assay large numbers of cells and then progressively i) exclude 
dead cells, ii) exclude cell clumps iii) determine the level of non-specific background 
staining, iv) exclude cells from other tissues (non-tumour cells).   
 
Live tumour cells were isolated using a gating strategy that excluded dead cells based on 
fixable live-dead staining (Svendsen et al., 2011). Here, live cells with intact plasma 
membranes exclude the fluorescent dye, whereas dead cells have lost plasma membrane 
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integrity and take up the dye (Life Technologies LIVE/DEAD® Fixable Near-IR Dead Cell 
Stain Kit). Traditionally propidium iodide has been used for this purpose (Crissman & 
Steinkamp, 1973) but to facilitate the identification of multiple cell populations in a single 
experiment it was necessary to use a fluorophore that would not overlap with any others in 
use and would be retained following fixation (Crissman & Steinkamp, 1973; Hudson, 
Upholt, Devinny, & Vinograd, 1969). This was achieved by using a near infra-red 
fluorescent dye that fluoresces upon binding to free amines released when cell 
membranes break down producing intensely fluorescent cells with compromised 
membranes and minimal fluorescence in intact cells, resulting in a 50 fold difference in 
fluorescence intensity between live and dead cells (Perfetto, Ambrozak, Nguyen, 
Chattopadhyay, & Roederer, 2006) (Figure 5.1A). The live-dead stain had to be far 
enough away from other fluorophores that no overlap in excitation/emission spectra would 
occur. The excitation spectra for near infrared is 633/635nm and the emission is ~780nm. 
This will not overlap with fluorescein isothiocyanate FITC (Ex: 495– Em: 530nm), PE (Ex: 
496 - Em: 578) or violet (Ex: 405nm - Em: 450nm) fluorophores (Figure 5.1B).  
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Figure 5-1 Cell surface markers were used to identify populations of interest. (A) Gating 
strategy used to exclude dead cells. The histogram shows near infrared (NIR) Live/dead fixable 
cell stain (Invitrogen). Dead cells exhibit strong fluorescence, live cells mild fluorescence. (B) 
Spectral viewer (generated using the Invitrogen web site) showing absorption and fluorescence 
emission spectra of fluorophores selected to achieve minimal overlap. Violet (450/40) used to 
exclude lymphocytes, Near IR (760/780) to exclude dead cells, PE (575/26) and FITC (530/30) 
were used to identify populations of interest. (C) Shows the gating strategy used in flow cytometry 
analysis of primary human GBM cells. Forward scatter and side scatter on the Becton Dickinson 
LSRII were used to isolate the live, single cells. The first panel on the left shows exclusion of dead 
cells and debris. The second panel shows the single cell gate, which was used to exclude 
doublets. The third panel shows the fixable Live/dead Near infrared stain, which is taken up by 
dead cells that have compromised membranes and is excluded by cells with intact membranes. 
Panel 4 shows CD45 used to exclude lymphocytes. The last panel shows the isotype control, in 
green, used at identical concentrations to the antibodies to exclude non-specific staining and an 
example of the PE positive expression of a protein of interest, shown in red. (D) Gating strategy 
used for mouse xenograft tumours. Forward scatter and side scatter shown were used to exclude 
dead cells and debris and isolate the live cell population shown in the first panel on the left. The 
second panel shows the single cell gate that excludes doublets. The third panel shows the fixable 
Live/dead Near infrared stain that is excluded by live cells. Panel 4 shows the human cell gate. 
CD56, which is only expressed on human cells, was used to exclude mouse cells from xenograft 
tumour cell populations. The isotype control shown in panel 5 was used at identical concentrations 
to the antibodies of interest to determine the level of non-specific staining for exclusion. The last 
panel shows an example of the isotype control and the PE positive expression of a protein of 
interest. 
 
Clumps were excluded using Time of Flight on the Beckman Coulter Gallios or forward 
and side scatter on the Becton Dickinson, LSRII. Time of flight is a function of cell size and 
is determined by the duration of the passage of the cell through the point where the laser 
beam intersects with the stream of cells in the flow cytometer, whereby cells with a larger 
diameter take longer to pass through the beam than smaller cells. Using this method, 
clumps of cells can be excluded based on size using the Beckman Coulter Gallios 
(Sleeman, Kendrick, Ashworth, Isacke, & Smalley, 2006). Forward scattered light is used 
to detect cell surface area. Side scattered light is used to detect granularity. These 
parameters allowed detection and exclusion of debris and clumps and isolation of live, 
single cells using the Becton Dickinson LSRII (Loken & Herzenber, 1975; Tzur, Moore, 
Jorgensen, Shapiro, & Kirschner, 2011) (Figures 5.1C and D).  
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Antibodies can bind non-specifically to cells due to protein-protein interactions, as well as 
binding Fc receptors on the cell surface (Hulspas, O'Gorman, Wood, Gratama, & 
Sutherland, 2009; Krutzik & Nolan, 2003). To quantify the level of non-specific background 
staining, cells were also incubated in identical concentrations of an isotype control (Figures 
5.1C and D). This was used to determine the lower limits of positive staining. The majority 
of the proteins analysed were directly conjugated to either PE or FITC. The gating strategy 
used excluded cells that fell outside of our population of interest so that only the human 
brain tumour cells remained for analysis. To identify tumour and non-tumour cells in vivo 
and in primary patient tumours, cell surface markers were used to identify proteins 
expressed on cells we wanted to include or exclude. CD56, known as (NCAM) is a marker 
of human cells and is not expressed by murine cells (Figure 5.1D). CD56 was used to 
identify human cells in murine subcutaneous and intracranial tumours excluding cells that 
did not express CD56. All fresh primary human cells were stained with CD45 to gate out 
and therefore exclude lymphocytes from further study (Figure 5.1C).  
 
5.4.2 Identification of a preliminary CD panel based on the screening of glioma 
tumoursphere cell lines for protein expression levels of a large cohort of cell 
surface proteins 
Using the gating strategy described above, the expression levels of 118 cell surface 
proteins in primary tumoursphere cell lines derived from ten patient tumours were 
analysed by flow cytometry (Figure 5.2). Tumour cell lines were passaged from primary 
human tumours obtained directly from surgery at the Princess Alexandra Hospital 
Brisbane with patient consent and human ethics approval. Cells were cultured as 
tumourspheres, as this has been shown to more closely preserve the original genotype 
and phenotype of the cell than cells cultured in serum (J. Lee et al., 2006). Maintaining cell 
lines in a state as close as possible to the cells of the original tumour was important as the 
initial results would determine which proteins would be selected for further study.  
87 
 
 
Figure 5-2 A panel of 118 cell surface proteins was analysed using ten human GBM 
passaged cell lines to select a subset for further study. Human GBM cell lines were passaged 
as tumourspheres, chemically dissociated into single cells, incubated in cell surface protein 
antibodies and fixed prior to flow cytometry analysis.  From this initial screen a subset of proteins 
were selected for further study. The X-axis represents the cell surface proteins and their names 
expressed as a CD. The Y-axis represents the percentage of cells that were positive for the 
protein. 
 
There are two methods for measuring protein expression. The level of protein expression 
can be calculated based on the overall fluorescence intensity of a population. Alternatively, 
protein expression can be defined based on the threshold of fluorescence intensity 
determined by the isotype control. We used the latter method. The advantage of using this 
method was that the result is not affected by experimental variation such as relative 
fluorescence. Staining intensity is significantly affected by variables such as cell number. 
The inclusion of an unstained control for each experiment each time was designed to 
improve accuracy and consistency when determining the percentage positive. This 
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provides a quantitative number that can be used across experiments. Using an isotype 
control, a threshold value for non-specific staining was determined by drawing a gate 
around the cells positively expressing the isotype control. Based on this threshold, any cell 
with staining fluorescence above this was deemed positive. Within the 118-CD screen, the 
proportion of positive cells ranged from 0-100% within each cell line (Fig 5.2). In addition, 
there was significant variation of CD protein expression within a subset of CD proteins 
across cell lines, while others were highly expressed across all lines studied. Some CD 
proteins were not expressed in any of the human GBM patient lines. 
 
Some potentially useful patterns were suggested from this initial screen. First, CD markers 
exist that may be uniformly expressed in all GBM tumour cells and are therefore constant 
across GBM patients. These CD proteins can be used as a positive control for CD staining 
in experiments and potentially in assessing clinical samples. Second, a subset of CD 
proteins exists whose expression is highly variable. This subset of CD markers may be 
differentially expressed between tumour cell sub-populations, and may therefore be used 
to identify specific tumour cell sub-populations of clinical interest. 
 
5.4.3 Selection of a small panel of cell surface markers for validation of results 
From the initial panel of 118 cell surface proteins screened, 26 were selected to study 
further to determine the level of experimental variation with two additional proteins that 
served as negative and positive controls. The selection of each of the 26 proteins to 
continue studying was based on positivity for one or more of the following three factors.  
 
1. Significant expression across all lines analysed. Significant was defined as 75 % of cells 
in a tumour expressed the protein. Within this 75% of positive cells, variation in fluorescent 
intensity from individual cells reflecting more or less protein on one cell than another was 
not used to include or exclude cells. A small number of proteins were consistently highly 
expressed across all lines tested in each experiment.  
 
2. Some proteins were highly expressed in some lines but not all lines. Because one 
characteristic of human GBM is the existence of a very heterogeneous cell population it 
was important to include proteins that were strongly expressed in some lines even though 
they may have been only weakly expressed in other lines, as this may still be 
representative of an important cell population in different subsets of glioma patients. This 
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is consistent with the findings by Verhaak et al. that a number of subtypes exist within 
GBM exhibiting different genetic and molecular profiles (Verhaak et al., 2010). 
 
3. Proteins that exhibited less than 10% expression in all lines were excluded from the 
study unless they were previously identified as prognostic markers or as being involved in 
tumour progression in glioma or other cancers by other research groups. The proteins we 
selected to continue studying based on published relevance to tumours are listed in table 
4.1. We included these in our analysis particularly as the tumoursphere culture system, 
although the best in vitro tumour model available to us may differ from in vivo tumours and 
from primary tissues due to important tumour microenvironment conditions that are not 
easily replicated in vitro. Therefore, the inclusion of CD’s identified as potential drivers of 
disease in other cancers increases the probability of identifying a prognostic panel of CD 
markers.  CD133 is one example of a protein that was rarely expressed in the patient lines 
used in the initial screen, but which was included for further analyses because a number of 
research groups had reported links between CD133 expression and stem like cancer cells 
in GBM and other tumours (G. Liu et al., 2006; Singh et al., 2003; Zeppernick et al., 2008). 
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Table 5-1 CD proteins selected based on identification by others. Some CD proteins had 
previously been identified by other researchers as prognostic markers in cancer. These proteins 
were included in the study specifically because they were reported to be clinically relevant in 
glioma or other cancers in work by other research groups.  
 
CD Tumour Association Authors
Increased expression was seen in more advanced gastric 
cancer
Souyer, S. 2009.
Expression was an independent prognostic factor in SCC of 
head & neck
Mhawech, P. 
2004.
9
Upregulated in more aggressive head & neck tumours Benzion, J. 2010.44
High serum levels were associated with poor response to 
treatment in non-Hodgkin's lymphoma
Ristamaki, R. 
1977.
Increased expression was associated with reduced overall 
survival in AML.
Majeti, R. 2009.
Upregulated in human & murine myeloid leukaemia Jaiswal, S. 2009.
47
An indicator of poor prognosis in colon cancer Hashida, H. 200249c
DiGuiseppe, J. A.  
2009.
Detected in ALL cells but absent in control cells. Expresssion 
increased following treatment.
49f
Strongly expressed in adenocarcinoma of the prostate & 
associated with disease progression & poor prognosis.
Xu, C. 2005.59
63 Strong expression correlated to shorter survival times in GBM & 
lower levels in lower grade glioma.  
Rorive, S.  2010.
Higher expression levels correlated to shorter survival times in 
AML
Buccisano, F. 
2004.
90
Higher levels in patients with disease recurrence & shorter 
progression free survival in patients with laryngeal carcinoma.
105 Marioni, M. 2010.
133 Higher expression levels were associated with shorter survival 
times & an increase in tumour grade in glioma. 
Zeppernick, F.  
2008. 
Increased levels corresponded with an increase in tumour 
grade & shorter survival times.
Zhao, P. 2010.
Kristiansen, G. 
2005.
Expression was a prognostic marker of relapse in prostate 
cancer.
166
Higher levels associated with shorter survival times in prostate 
cancer
Fritsche, F. R. 
2008.
146
Zhu, G. H. 2010.Over-expression seen in pancreatic andenocarcinoma.151
Huang, X. Y.  
2010.
Over-expression was correlated with metastasis & invasion in 
intrahepatic cholangiocarcinoma.
A marker of poor prognosis in epithelial ovarian cancer. Aldovini, D. 2006.
200 Found to promote metastasis in SCC. Stumfova, M.  
2010.
171 Upregulation seen between the stages of benign nevi & 
malignant melanoma. 
Fogel, M. 2002. 
Speetjens, F. M. 
2009.
High levels of CD184 in the nucleus was an independent 
predictor of poor survival in colorectal cancer.
184
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To increase the statistical confidence of the initial analysis 12 patient human GBM lines 
were screened twice each for expression of the 26 cell surface proteins selected for the 
smaller panel (Figure 5.3). This data led to the conclusion that the constant CD’s were 
constant across all GBM lines, supporting the hypothesis that these CD proteins were 
universally expressed.  
 
 
Figure 5-3 Twenty-six cell surface proteins were selected for further study. The x-axis titles 
are the cell surface protein names. The numbers below each column on the X-axis represent the 
cell line names. Protein expression, shown as the percentage positive appears on the Y-axis. The 
figure represents 12 passaged cell lines and 22 experiments as some cell lines were analysed in 
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duplicate (L0x2, L1x2, L2x2, L3x2, L4x2, L5x2, L6x2, L7x2, L8x2, L11x2, L23x1, L25x1). CD3 was 
used as a negative control and CD56 as a positive control. 
 
Two of the proteins that were invariant were selected to serve as internal controls to 
highlight experimental noise and assess staining efficiency when replicating experiments. 
CD3 was either not expressed at all or expressed at very low levels so this was selected 
as a negative control. CD56 was used as a positive control for passaged cell lines to 
determine the level of experimental variability and was consistently strongly expressed in 
all cell lines analysed with around 99% of cells in all lines expressing the protein. A small 
cohort of proteins was consistently strongly expressed in all cell lines tested. The 
remaining CD’s were variable across all lines with no obvious patterns suggesting the 
possible involvement of other factors such as environmental conditions. 
 
This data confirmed the original selection of 26 proteins for further study as the majority of 
proteins selected were moderately or strongly expressed in at least some of the lines 
analysed. One exception to this was CD133 that was weakly expressed but had been 
selected originally because of its reported expression in glioma studies undertaken by 
other researchers. We chose to retain it despite its poor expression levels because of the 
large quantity of literature on GBM referring to its relevance (He et al., 2011; Jamal et al., 
2012). 
 
The majority of cell surface proteins examined were highly varied across all cell lines. This 
was assessed by comparing the average number of percentage positive cells in each cell 
line for a set of proteins (Figure 5.3). In some cases, the variability was very high however, 
five proteins analysed, consistently exhibited very little variability, these were CD47, CD58, 
CD59, CD63, and CD90. 
 
Most cell surface proteins analysed expressed great variability even within a single cell 
line. This was noticeable when two separate experiments compared the cell surface 
protein expression of a single cell line. To confirm this result, four human GBM lines were 
selected for study in triplicate to ascertain whether consistent CD protein expression could 
be seen when the same line was analysed on three separate occasions. Consistent with 
all previous results, cell surface protein expression was variable and the standard 
deviations ranged between small and large. These results were consistent with the results 
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seen between different lines (Figure 5.4). The standard deviation was very large in some 
of the proteins examined. This could be due to environmental effects. Culturing cells for 
different lengths of time in different sized flasks could affect oxygen and nutrient 
availability to cells within spheres. Cells on the outer edge of a large sphere may be able 
to access greater quantities of oxygen and nutrients in media compared to cells located at 
the centre of a sphere. Environmental variation could potentially change the expression 
levels of some proteins in cells within a flask. It was therefore important to determine and 
compare the cell surface protein expression of proliferating cells in vivo.  
 
 
 
Figure 5-4 Cell surface protein expression varies within a cell line. The figure shows the 
percentage of cells that were positive for the 26 proteins in the small panel across four human 
GBM lines all performed in triplicate. The standard deviation for each protein is shown. 
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5.4.4 Potential CD markers identified in vitro are also expressed in vivo 
The tumour micro-environment is a critical player in tumour initiation and disease 
progression (M. Hu & Polyak, 2008), and therefore may regulate the expression of cell 
surface proteins, either through epigenetic, transcriptional or post-translational effects 
(these combined effects are here-after referred to as plasticity), or through natural 
selection increasing the frequency of clonal subpopulations that display elevated fitness 
within in vivo selection conditions (Greaves & Maley, 2012). To confirm the protein 
expression levels seen in vitro, in vivo surface protein expression was analysed using 
established NOD-SCID xenograft GBM tumour models (Deleyrolle et al., 2011).  
 
Two mouse models were used to look at the in vivo expression of these same 26 proteins. 
NOD/SCID mice were chosen because they have no adaptive immune response and 
would therefore tolerate the implantation of foreign cells. The next experiment was 
designed to assess the variation in protein expression of xenograft tumours generated 
from a single cell line on a single day. This was done to exclude variations in protein 
expression due to differences in passage number, days in culture media and flask size. 
Injections of 1,000,000 cells of a single GBM cell line, line 0, were performed 
subcutaneously on the same day, into the flank of eight mice. In addition to this, three 
mice were injected with cells from L2 and L4. The cells were harvested on different days 
because tumours were removed according to their size so that there were sufficient cells 
for analysis by flow cytometry. Not all tumours reached a sufficient size at the same time 
due to differing tumour growth rates.  
 
Tumours were measured regularly to determine size. When a tumour of 1cm diameter had 
developed, the mouse was euthanized. The tumour was removed, diced and cells 
chemically dissociated for analysis by flow cytometry in the same manner as the passaged 
cell lines. All cells were incubated in a human-specific CD monoclonal antibody (CD56) 
that recognizes 100% of human GBM cells and does not recognize mouse cells in addition 
to the panel of CD proteins. Only CD56 positive cells were included in the analyses to 
exclude invading or surrounding mouse cells from the analysis. The cell surface protein 
expression pattern of the subcutaneous mouse tumours from a single cell line was 
remarkably consistent with the results obtained using many passaged cell lines. Protein 
expression overall was highly variable, except for CD47, which remained invariant; and 
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CD59 and CD90, which were strongly expressed by each mouse tumour. Figure 5.5 
shows the results of protein analyses of eight subcutaneous tumours generated from the 
same passaged human tumour cell line injected into the mice on the same day and two 
additional lines with three tumors each generated from Line 2 and Line 4. Overall, the 
standard deviations are indicative of very variable CD protein expression within a cell line 
in the subcutaneous mouse tumours. This data suggests that variability in protein 
expression was not a direct result of in vitro passaging techniques, as it remained a 
feature of in vivo xenograft tumours. 
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Figure 5-5 Cell surface protein expression is very variable in xenograft tumours. Due to 
differences between in vitro assays and in the in vivo microenvironment, cell surface protein 
expression was analysed on cells from subcutaneous tumours generated on the flank of mice. 
Subcutaneous injections delivered 1,000,000 human GBM cells from three cell lines of the same 
passage number on the same day into NOD/SCID mice and large tumours were allowed to form. 
Line 0 n=8 tumours, Line 2 n=3 and Line 4 n= 3. Tumours were harvested independently when 
each tumour had reached sufficient size for analysis of all or most proteins in the panel. In order to 
exclude cells of mouse origin, only CD56+ cells were included in the analysis. 
 
The cell surface proteins in the previous experiment were differentially expressed in 
subcutaneous tumours even though they all originated from the same cell line, injected 
into the mice on the same day. However, tumours were harvested at different time points 
due to variation in growth. Tumours were only resected when they reached sufficient size 
to be assessed by flow cytometry, which requires a large number of cells for analysis. To 
confirm that variable cell surface protein expression was not due to the differing periods of 
time individual tumours took to reach sufficient size, we injected two mice subcutaneously 
using line 0 on the same day. The resulting tumours were harvested on the same day, 165 
days later, cells counted and stained with the same aliquot of antibody. Analysis of these 
results, shown in Figure 5.6 confirmed that a high degree of variation in CD expression 
exists even under these stringent experimental conditions. This data suggests the 
hypothesis that CD protein expression is highly plastic, and dynamically regulated 
depending on a wide range of factors including environmental conditions and/or stochastic 
effects (Heddleston et al., 2011). 
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Figure 5-6 Cell surface protein expression is variable in xenograft tumours generated from 
the same cell line at the same time. To minimize the effects of variation caused by differences in 
cell line, passage number, and length of time to tumour formation, cells were injected into two mice 
on the same day and tumours harvested and analysed 165 days later. 
 
5.4.5 In vivo confirmation of in vitro assays using intracranially injected glioma 
cells 
Although the subcutaneous model is a widely used approach to study tumour biology in 
vivo, GBM rarely metastasizes from the brain, and the brain microenvironment is different 
to in vitro tumoursphere and subcutaneous environments. As discussed above, 
differences in microenvironments may significantly alter CD expression. To ascertain the 
influence of the brain environment on cell surface protein expression during tumour 
development 200,000 passaged human tumour cells were injected intracranially into the 
right striatum of anaesthetized mice positioned in a stereotax. When the mice showed 
signs of physical deterioration as a result of large tumour formation, (weight loss, tenting of 
skin due to dehydration, scruffy fur, changes in posture or gait, fits or behavioural 
changes) they were euthanized and the brain was removed. Fifteen tumours generated 
from 10 human GBM lines were analysed (Figure 5.7). Protein expression was analysed 
by flow cytometry. Upon analysis, expression of the selected cell surface proteins in 
intracranial xenograft tumours was highly variable with consistently large standard 
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deviations. CD56 was used to exclude cells of mouse origin from the analysis and ensure 
that only cells of human origin were analysed (Deleyrolle et al., 2011). Consistent with the 
results of the subcutaneous tumours, cell surface protein expression in intracranial 
xenograft tumours was highly variable and CD47 was the most consistently highly 
expressed protein in orthotopic xenograft tumours. This shows that CD47 is strongly 
expressed by human GBM cells in the brain microenvironment and that our earlier results 
were not simply an artifact of tissue culture. 
 
 
Figure 5-7 Expression of most cell surface proteins is very variable in mouse intracranial 
tumours. To determine the effects of the brain microenvironment on cell surface protein 
expression. Ten human GBM cell lines were injected intracranially into 15 mice (five lines were 
performed in duplicate). On some occasions, due to small cell numbers, less than the full CD panel 
of 26 proteins was analysed after tumour harvest. 
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5.4.6 Confirmation of cell surface protein expression profiles using primary glioma 
tumour tissue 
Finally, to confirm that the panel of CD proteins was also expressed in patient tumours, 
fresh primary brain tumour cells straight from surgery at the Princess Alexandra Hospital 
were analysed. Cells were immediately dissociated and red blood cells were lysed using a 
red cell lysis buffer. CD45 that recognizes white blood cells was used to exclude these 
from the analysis. CD56 was used as a positive control. Six primary human tumours were 
used for this analysis. CD47 expression remained consistently high between patients, as 
predicted from the in vitro and in vivo tumour models described above. CD expression 
profiles overall varied significantly between patients (Figure 5.8). Average protein 
expression between patients tended to have a large standard deviation with the notable 
exception of CD47. 
 
Figure 5-8 Expression of some cell surface proteins is very variable in primary human 
tumour tissue. The figure shows the percentage of cells that exhibited positive cell surface protein 
expression. Six primary patient tumours were analysed immediately following surgical removal. 
Red blood cells were lysed in red cell lysis buffer. Cells were diced and chemically dissociated into 
a single cell suspension prior to incubation in antibodies and fixation for flow cytometry analysis. 
CD45 was used to exclude lymphocytes. 
 
Regardless of whether the cells were cultured in vitro or proliferated as part of a xenograft 
tumour or primary human tumour, cell surface protein expression overall was variable. 
These results suggest that with regard to the majority of proteins studied here, rather than 
being associated with a specific cell type, cell surface protein expression is very plastic. 
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Interestingly though, three proteins were consistently highly expressed in all tumour 
models we analysed. CD59 is also known as compliment regulatory protein. It controls cell 
lysis by inhibiting the formation of the membrane attack complex (Madjd et al., 2003). 
CD90 is also known as Thy-1 cell surface antigen and is an adhesion molecule used as a 
marker for stem cells and axonal processes on mature neurons (Buccisano et al., 2004). In 
a recent publication, CD90 exhibited increased expression levels in high-grade gliomas 
when compared to low-grade glioma and normal brain tissue and was associated with 
increased sphere forming ability leading to the conclusion that it was a potential marker for 
high-grade glioma (He et al., 2011). 
 
CD47 is known as integrin associated protein and interacts with thrombospondin-1 (TSP-
1) and signal regulatory protein alpha (SIRPα). SIRPα is expressed on macrophages and 
upon activation capable of inhibition of phagocytosis. For this reason CD47 has been 
dubbed the ‘don’t eat me’ signal (Willingham et al., 2012). In addition, TSP-1 anti-
angiogenic activity is reportedly inhibited in cancer cells by the presence of high levels of 
CD47 (Kalas et al., 2013). 
 
5.4.7 CD47 is expressed in GBM. 
Blocking CD47 binding to it’s ligand SIRPα has the potential to expose tumour cells to 
circulating immune cells with the ability to remove the tumour cells using the body’s natural 
defense system (Willingham et al., 2012). When we looked at the distribution profile of 
CD47, we noticed that in addition to consistently high expression levels, in all tumour 
models analysed CD47 displayed a tight distribution. Figure 5.9 shows the percentage of 
cells expressing CD47 in eight passaged cell lines and the distributions in each. 
Expression levels are all above 98% and distributions are small.  
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Figure 5-9 CD47 is strongly expressed in human GBM cell lines. Expression is shown for 
passaged human GBM cell lines from nine different patient tumours. CD47 was consistently 
expressed in above 98% of cells. 
 
We confirmed these results in xenograft subcutaneous mouse tumours shown in Figure 
5.10. Here we have used two replicates of three human cell lines injected to form 
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subcutaneous tumours in mice. CD47 expression levels shown are all above 96% with 
narrow distributions.  
 
 
 
Figure 5-10 CD47 is strongly expressed in subcutaneous xenograft tumours. One million 
human GBM cells from three patient tumours were injected into two mice each and allowed to 
proliferate until large tumours had formed. CD47 in subcutaneous mouse tumours was consistently 
expressed in over 95% of cells. 
 
The same analysis applied to eight orthotopic xenograft tumours is shown in Figure 5.11 
where CD47 expression was consistently above 86% and distributions remained small. 
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Figure 5-11 CD47 is strongly expressed in orthotopic xenograft tumours. NOD/SCID mice 
received intracranial injections of 200,000 human GBM cells into the right striatum under general 
anaesthetic and were monitored until large brain tumours formed. The x-axis represents the 
human GBM cell line injected into the mouse brain. The figure shows the percentage of cells 
expressing CD47 in eight mouse brain tumours. CD47 was expressed on above 86% of tumour 
cells. 
 
  Finally, fresh brain tumour tissue removed from patients during surgery was analysed to 
determine whether these results were consistent with that of patient tumours or simply an 
artefact of cell culture conditions. Figure 5.12 shows that CD47 expression across six 
patient tumour lines was above 90% and the size of distributions were inversely correlated 
with the percentage of overall CD47 positivity. Normal human brain tissue is very difficult 
to obtain as it is rarely surgically removed and therefore our lab was not able to use 
normal healthy brain cells as a control in our study. Work by others suggests that CD47 is 
variably expressed in normal tissue and could provide a viable target for anti-cancer 
therapeutics that would enable glioma cells to be recognized and removed by the immune 
system with minimal impact on healthy tissue (Willingham et al., 2012). 
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Figure 5-12 CD47 is strongly expressed in primary patient human GBM tumours. The figure 
shows CD47 expression in six primary human tumours. 
 
5.4.8 Gene expression levels of five cell surface proteins are higher in GBM 
tumours than normal brain tissue 
As we had been unable to obtain normal human brain cells to compare to the primary 
human brain tumour cells we studied in vitro and in vivo, we used publically available gene 
expression data to determine differences in gene expression levels between normal brain 
tissue and GBM tumours. We analysed the gene expression data of the 26 cell surface 
proteins we had previously selected for further study using the TCGA database. Ten 
normal brain tissue samples were compared to 524 GBM tumours. The GBM tumours 
have been divided between four subtypes identified by Verhaak et al. based on the TCGA 
data (Verhaak et al., 2010). The four subtypes were proneural (n=137), mesenchymal 
(n=159), neural (n=87) and classical (n=146). Five of the 26 proteins were significantly 
more highly expressed in all four GBM subtypes compared to normal human brain tissue. 
The five proteins were CD9, CD44, CD63, CD164, and CD184 (Figure 5.13). The proteins 
identified are all receptors known to be involved in functions including cell adhesion, 
migration, and activation. Of the five proteins, four are known to functionally interact with 
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another protein within the group. The functions and interactions are briefly outlined in 
Table 5.2.   
 
 
 
Figure 5-13 Comparison of CD gene expression data from the publically available TCGA 
database. The TCGA database analysed normal human brain tissue (n=10) and tumour tissue 
(n=524) which was divided into four subtypes by Verhaak et al. Gene expression of five proteins 
from the subset of 26 that I selected for further study was significantly higher in all GBM subtypes 
than in normal brain tissue.   
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Table 5-2 Table lists known functions of five cell surface proteins upregulated in GBM. The 
table briefly lists known functions of five cell surface proteins that are significantly upregulated in all 
four GBM subtypes compared to normal brain tissue. The analysis was performed on publically 
available TCGA gene expression data for GBM. Functions were obtained from the references 
within the table and The Human Protein Atlas, UniProt and the Atlas of Genetics and cytogenetics 
in Oncology and Haematology. 
 
 
To determine whether the five genes that were significantly more highly expressed in GBM 
were similarly upregulated in other solid tumour types, we analysed the TCGA microarray 
data of three solid tumour types. Mircoarray data with organ specific controls was only 
available for breast cancer, rectal adenocarcinoma, and colon adenocarcinoma. We found 
that CD44 was the only protein of the five that was upregulated in other tumour types and 
it was upregulated in just two of the three solid tumours we analysed; colon 
adenocarcinoma (normal n=19, tumour n=155) and rectal adenocarcinoma (normal n=3, 
tumour n=69) (Figure 5.14).  
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Figure 5-14 CD44 is significantly upregulated in two other solid tumour types. The micro 
array data on the TCGA database revealed that CD44 was significantly more highly expressed in 
two other solid tumour types, rectum adenocarcinoma (normal n=3, tumor n=69) and colon 
adenocarcinoma (normal n= 19, tumour n=155). 
 
5.5 Discussion 
Cell surface markers have been identified in a variety of tumour types as contributing to 
disease progression (Joshua et al., 2012) and as prognostic indicators (Ke et al., 2009). 
We analysed glioma cells to determine whether CD proteins could be used to identify a 
subpopulation of cells of clinical relevance in GBM. We screened ten human GBM lines to 
determine the expression levels of 118 CD proteins by flow cytometry. The purpose of this 
study was to identify subpopulations of cells of clinical relevance in GBM as potential 
future therapeutic targets. Of the 118 cell surface markers screened, we selected 26 to 
study in more depth based on several features. Some were selected due to strong 
expression across multiple cell lines interrogated. Other proteins were interesting because 
they were highly expressed in some lines although not in all lines. Some proteins were 
chosen because they had been identified as proteins of interest in other tumour types by 
other investigators.  
 
5.5.1 Three cell surface proteins were consistently highly expressed in vitro and in 
vivo 
The cell surface expression of the majority of the proteins analysed was variable whether 
the cells were obtained from passaged cell lines, xenograft tumours or unpassaged fresh 
primary tumour tissue straight from the human brain. A prognostic marker must be 
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expressed consistently at some stage or in a particular subtype to be useful in diagnosis or 
prognosis. CD56 was consistently highly expressed and used as a positive control for 
identification of human cells in xenograft models. Throughout this analysis, three proteins 
of interest were consistently highly expressed in passaged cell lines, xenograft tumours 
and fresh primary human glioma cells. CD47, CD59, and CD90 have all been reported to 
provide benefits to glioma cells promoting tumour development and therapeutic resistance 
(He et al., 2012; Maenpaa, Junnikkala, Hakulinen, Timonen, & Meri, 1996; Willingham et 
al., 2012).   
 
5.5.2 CD59 provides protection against complement lysis 
CD59 is a known regulator of complement (Cai et al., 2014). Complement system proteins 
are produced in the liver and circulate in the serum component of blood, and reside on 
plasma membranes as cell surface receptors in an inactivated form as pro-proteins 
(Carroll, 2004). Cleavage of the inactivated proteins leads to formation of the membrane 
attack complex (MAC). The complement system/innate immune system does not adapt 
like the adaptive immune system but can be recruited by it (Kopp, Hebecker, Svobodova, 
& Jozsi, 2012). The complement system acts in a few ways: boosting phagocytosis of 
antigens, recruiting macrophages and neutrophils, promoting lysis of foreign cells. The cell 
surface protein CD59 also known as protectin or membrane inhibitor of reactive lysis 
inhibits formation of the membrane attack complex (Cashman, Ramo, & Kumar-Singh, 
2011).  
 
Immunohistochemical staining of normal human nervous system tissue revealed that 
CD59 was present on endothelial cells as well as neurons and glia in the CNS (Vedeler et 
al., 1994). Increased CD59 expression in the human brain is associated with the normal 
process of myelination and in reactive astrocytes in disease states in the CNS (Zajicek, 
Wing, Skepper, & Compston, 1995). These data suggest that CD59 has a role in 
regulation of complement during normal brain development. It is expressed on all major 
neuronal cell types providing protection during crucial developmental processes. In 
addition to this CD59 is activated during reactive astrocytosis, occurring as a result of 
injury and disease (Pekny, Wilhelmsson, Bogestal, & Pekna, 2007). 
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Tumours have been shown to exhibit increased levels of complement-regulatory proteins 
including CD59 enabling them to withstand attack by complement (Durrant & Spendlove, 
2001). CD59 is strongly expressed in glioma cell lines and primary glioma tumours 
providing remarkable protection against complement lysis in comparison to other cell lines 
(Maenpaa et al., 1996). Antibody therapy that targets membrane complement regulatory 
proteins including CD59 in vivo significantly enhanced the cytotoxic effects of Herceptin on 
lung cancer cells (W. P. Zhao, Zhu, Duan, & Chen, 2009). Administration of a human 
monoclonal antibody, which neutralizes CD59 in vivo, enhanced the therapeutic effect of 
rituximab in B-lymphoma (Macor et al., 2007). In combination with other strategies, the 
ability to disable CD59 and therefore resistance to complement, could slow aggressive 
tumour development following initial treatment by rendering cancer cells sensitive to 
complement cell lysis.  
 
5.5.3 CD90: a potential cancer biomarker 
CD90 is a glycophosphatidylinositol (GPI) anchored cell surface antigen. GPI proteins are 
synthesized as precursor proteins that insert into the extracellular aspect of the membrane 
(Mayor & Riezman, 2004). Also known as Thy-1, CD90 is expressed on human 
thymocytes, neurons, endothelial cells, fibroblasts, and T-cells. It is involved in a range of 
functions including cell adhesion, migration and death, neurite outgrowth, and tumour 
development (Rege & Hagood, 2006). 
 
A number of lines of evidence suggest a contribution of CD90 protein expression to both 
solid and liquid tumour progression. Strong expression of CD90 correlated with invasion 
and metastases in hepatocellular carcinoma (B. Q. Cheng, Jiang, Li, Fan, & Ma, 2012). 
Studies by True et al. found that while benign prostate tissue showed limited CD90 protein 
expression, protein expression was upregulated in prostate cancer stromal cells (True et 
al., 2010). They concluded that in contrast to other proteins that showed no increase in 
expression in tumour tissue, CD90 was a potential cancer biomarker. Other work that 
focused on identifying prognostic biomarkers in 148 elderly patients with AML by flow 
cytometry revealed that increased CD90 expression predicted shorter survival times and 
correlated with unfavourable cytogenetics or unfavourable drug resistance profiles 
(Buccisano et al., 2004). 
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Recently CD90 was reported by He et al., to be a prognostic marker for aggressive 
gliomas. Detected on a variety of cells but predominantly on endothelial cells on tissue 
microarrays it was referred to as a cancer stem cell marker. Exhibiting strong expression 
on glioma tissues with increased expression surrounding vessels it was very weakly 
expressed in normal brain tissue on tissue microarrays. Additionally, CD90+ cells exhibited 
a superior sphere forming ability when compared with CD90- cells in vitro (He et al., 2012). 
These findings are consistent with our results, which showed that the expression of CD90 
on the surface of glioma cells was usually above 80% ranging between 60% and 100%.  
 
5.5.4 CD47 is integral to normal nervous system development 
In the brain CD47 resides on the surface of neurons, microglia, myelin, oligodendrocytes 
and schwann cells while the SIRPα receptor is situated on the surface of microglia. 
Microglia are derived from macrophages that integrate into the central nervous system 
during development and like microglia express both the CD47 ligand and SIRPα receptor 
(Gitik, Liraz-Zaltsman, Oldenborg, Reichert, & Rotshenker, 2011). Microglia typically 
contain a small soma and long processes, which extend and retract to scan the local 
environment. The role of microglia is in leading a reconnaissance mission in search of 
pathogens, damaged tissue or other indicators of changes to environmental homeostasis 
(Kierdorf & Prinz, 2013). After detection of a disruption to the normal environment by 
receptor activation, microglia commence phagocytosis and initiate recruitment of other 
immune cells, to assist with clearance of dying cells, pathogens etc. Damage to the 
integrity of the vasculature where injury or tissue distortion occurs facilitates the entry of 
circulating macrophages that further assist with phagocytosis (Kierdorf & Prinz, 2013).  
 
5.5.5 The “Don't eat me” signal 
CD47 is known as the “don't eat me” signal because one of its functions is cellular 
protection from phagocytic cells by self-recognition, which is established through receptor 
interaction (Azuma, Nakagawa, Dote, Higai, & Matsumoto, 2011). CD47 is expressed on 
the surface of both cancerous and noncancerous cells (Barclay & van den Berg, 2013; Y. 
Liu et al., 2002). However, higher CD47 expression was seen on cancer cells than on 
normal healthy cells (Majeti et al., 2009; Tseng et al., 2013). CD47 interacts with a number 
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of receptors expressed on the cell surface including integrins, signal regulatory protein-α 
(SIRPα) and thrombospondin-1. SIRPα is expressed on macrophages and dendritic cells 
(Legrand et al., 2011). The binding of CD47 with SIRPα inhibits phagocytosis by initiating 
a signaling cascade following phosphorylation of the cytoplasmic tail of the SIRPα receptor 
(Tseng et al., 2013; X. W. Zhao et al., 2011). This action is utilized in normal cellular 
function and tissue maintenance. Immature haematopoietic cells express CD47 to protect 
themselves as they travel to their final destination in the bone marrow (Willingham et al., 
2012). Human neutrophil polymorphonucleocyte (PMN) cell migration is regulated in part 
by CD47 binding to SIRPα (Y. Liu et al., 2002).  
 
Cancer cells expressing the ‘don't eat me signal’ can evade normal immunosurveillance 
systems enabling them to continue to grow and divide (Willingham et al., 2012). The 
development of anti-CD47 antibodies has led to the identification of the phagocytic effect 
of the CD47-SIRPα interaction in AML in vitro and in vivo. The anti-CD47 antibody used in 
vitro preferentially facilitated the phagocytosis of AML stem cells without any increase in 
the phagocytosis of their normal counterparts. The author advocated the use of 
monoclonal anti-CD47 therapy as part of a targeted combination therapy in the elimination 
of leukaemia cells (Majeti et al., 2009).  
 
Willingham et al., found that CD47 expression levels correlated negatively with survival 
times in a range of solid tumours with cancer cells expressing an average of 3.3 fold more 
CD47 than normal, adjacent, noncancerous cells, as assessed by quantitative flow 
cytometry (Willingham et al., 2012). The normal adjacent tissues used in this study were 
sarcoma, ovarian, breast, bladder, colon, liver, pancreatic, lung, kidney, and head and 
neck squamous cell carcinoma. Normal human brain tissue is notably absent from this list. 
The administration of CD47 antibody has been shown to slow tumor progression, prolong 
life and in small tumors antibody therapy halted disease progression completely in in vivo 
xenograft studies. High CD47 mRNA expression levels in patient samples of glioma and 
GBM tumours correlated with shorter progression-free and overall survival times and could 
potentially be a clinically relevant prognostic factor in some tumours (Willingham et al., 
2012).  
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5.5.6 CD47 blocking antibodies prevent the SIRPα interaction and inhibit tumour 
growth 
The blood brain barrier (BBB) provides an effective obstruction to deleterious molecules 
under normal circumstances and significant difficulties in designing therapies capable of 
crossing the BBB to researchers and oncologists. To determine the efficacy of antibody 
therapy on brain cancer, glioblastoma cells were transplanted into the brain of 
NOD/SCID/γ mice, which lack B, T, and NK cells but produce macrophages capable of 
phagocytosis. Purified blocking anti-CD47 monoclonal antibodies (mAbs) were injected 
intraperitoneally resulting in significant reduction in tumor growth (Willingham et al., 2012). 
The response to treatment shows that the CD47 blocking antibody crossed the BBB and 
inhibited tumor growth in orthotopic xenograft glioblastoma tumors when administered and 
absorbed systemically. A recent study into the adaptive immune response of T-cells to 
macrophage antigen presentation that followed anti-CD47 antibody mediated 
phagocytosis of tumor cells revealed a cytotoxic T-cell immune response was launched 
which could be utilized in treating tumours by exploiting adaptive and innate immune 
responses in concert (Tseng et al., 2013). 
 
As a result of the findings from the study by Willingham et al., the anti-CD47 B6H12 
monoclonal antibody is currently in phase-1 clinical trials at Stanford Medical School. The 
study analysed the response to the anti-CD47 antibody in ovarian, breast, colon, and GBM 
cells in vitro and to breast, colon, bladder, ovarian and glioblastoma cells in vivo in 
xenograft models of immune deficient mice resulting in significant inhibition of tumour 
growth. Engraftment of breast cancer cells into fully immune competent mice was 
undertaken to determine the safety and efficacy of antibody therapy administered 
systemically resulting in significant inhibition of tumour growth with no unacceptable 
toxicity (Willingham et al., 2012). The outcome of the clinical trials may be different for 
glioblastoma tumours as the blood brain barrier poses an additional obstacle, however, a 
breach to the integrity of the BBB during surgery or as a result of tumour progression has 
the potential to allow larger than usual molecules past the barrier at least temporarily. 
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5.5.7 The interaction of CD47 with TSP-1 blocks nitric oxide signaling and 
promotes radiation damage 
Thrombospondin-1 (TSP-1) is a matricellular protein ligand that also binds to CD47 (Osz, 
Ross, & Petrik, 2014). Inhibition of the interaction of CD47 with TSP-1 has been shown to 
reduce radiation damage in vivo due to the ability of TSP-1 to block nitric oxide signaling. 
Nitric oxide has a cytoprotective effect on hypoxic soft tissue preventing ischaemic 
damage (Isenberg et al., 2008; Maxhimer, Shih, Isenberg, Miller, & Roberts, 2009). The 
ability to impart radiation resistance could be of benefit to radiotherapy patients by 
protecting surrounding healthy tissue from ischemia while radiosensitivity is required for 
effective therapeutic eradication of tumour cells. For this strategy to be effective, targeted 
interference with the CD47, TSP-1 interaction would be required on healthy non-tumour 
cells while at the same time promoting the interaction between CD47 and TSP-1 on 
tumour cells. 
 
5.5.8 Increased gene expression in cell surface proteins suggests potential 
therapeutic targets in GBM 
We compared the gene expression data of the cohort of 26 cell surface proteins selected 
for further study in GBM tumours above with normal brain tissue using the publically 
available data from The Cancer Genome Atlas Data Portal. We identified five cell surface 
proteins with significantly higher gene expression in all four GBM subtypes, identified by 
Verhaaak et al. when compared to normal brain tissue (Verhaak et al., 2010). All five 
proteins identified were cell surface receptors with roles in cellular processes including cell 
adhesion, activation, and migration.   
 
CD9, also known as motility related protein 1 (MRP-1) a member of the tetraspanin family 
interacts with a number of other proteins including integrins, growth factors and other 
tetraspanins (Hwang et al., 2012; Murayama, Oritani, & Tsutsui, 2015). Through these 
interactions, CD9 is involved in cellular adhesion, migration proliferation and survival 
(Murayama et al., 2015). CD9 was found to be upregulated in in vitro and in in vivo models 
of ovarian cancer acting as an oncogene with an anti-apoptotic action through the 
constitutive activation of NF-κB (Hwang et al., 2012). In this study, the CD9-specific 
monoclonal antibody ALB6 injected into the mouse peritoneum resulted in a reduction in 
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tumour weight compared to that of control mice injected with IgG1 in in vivo models of 
ovarian cancer (Hwang et al., 2012).  
Our analysis of GBM showed, like the ovarian cancer model examined by Hwang et al., 
showed that CD9 expression was significantly higher in tumours compared to normal 
tissue. The role of CD9 in cell adhesion, migration, proliferation and survival (Murayama et 
al., 2015) combined with evidence of significantly higher expression in tumour tissue 
suggests that this protein is likely to be contributing to tumour progression. A CD9-specific 
inhibitor such as ALB6, which reduced tumour burden in in vivo mouse models of ovarian 
cancer, could potentially slow tumour cell proliferation in GBM and in combination with 
other treatments slow disease progression (Hwang et al., 2012).   
 
CD44 is an adhesion molecule that acts as a receptor for a number of molecules including 
hyaluronic acid (Louderbough & Schroeder, 2011). Its function is to mediate cell-cell 
communication and communication between cells and the extracellular matrix thereby 
promoting cell survival, migration, invasion and angiogenesis (Louderbough, Brown, 
Nagle, & Schroeder, 2011). After finding increased CD44 expression in human GBM 
microarray data from the TCGA, we looked for a similar pattern in other solid tumours. Of 
the five genes upregulated in human GBM compared to normal brain tissue, only CD44 
was upregulated in colon adenocarcinoma and rectal adenocarcinoma with respect to 
normal control tissues. The remaining four genes were expressed either at similar or lower 
levels compared to the corresponding control tissue. 
Yoshida et al. showed that CD44 expression levels increased with histopathological 
tumour grade in glioma and that treatment with a CD44 monoclonal inhibitor reduced 
migration in GBM cells in vitro whereas normal brain tissue expressed little or no CD44 
(Yoshida, Matsuda, Naito, & Ishiwata, 2012). This evidence suggests that specific 
inhibition of CD44 positive cells could potentially target cancer cells with little or no effects 
on normal cells. A low molecular weight inhibitor developed from fungus known as F-
19848 A was shown to inhibit the CD44-hyaluronic interaction in vitro in HEK293 cells 
(Hirota-Takahata et al., 2007). More recently, a humanized monoclonal antibody (RG7356) 
specific for CD44 showed specificity and cytotoxicity for leukaemia B cells in immune 
deficient mice engrafted with CLL while having little or no effect on normal B cells (S. 
Zhang et al., 2013). Findings by Birzele et al. indicate that the CD44 inhibitor RG7356 was 
effective in blocking the interaction between CD44 and hyaluronic acid in vivo (Birzele et 
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al., 2015). The results of a phase 1 clinical trial of RG7356 in patients with solid tumours 
have not yet been posted (U.S National Institutes of Health NCT01358903).  
CD44 cell surface protein expression has been shown to be higher in multiple types of 
solid tumours than in the corresponding normal tissue contributing to cellular 
communication, survival, migration and invasion ((Louderbough et al., 2011) which all 
promote tumour progression. The development of a humanized monoclonal antibody that 
was both cytotoxic and specific for leukaemia cells while sparing normal cells is exciting for 
two reasons (Birzele et al., 2015; Y. Zhang et al., 2013). Specificity of a therapy reduces 
the potential side effects for the patient making therapy more tolerable, improving quality 
of life and reducing patient stress. Secondly, clinical trials already underway in the U.S if 
successful, could lead to approval for a CD44 inhibitor in other cancers resulting in the 
potential for the same therapy to be used to slow tumour progression in GBM patients. 
 
CD63, also known as TSPAN30 is a tetraspanin receptor that interacts with many proteins 
including integrins, other tetraspanins (including CD9 and CD151), kinases, adaptor 
proteins and other proteins (Kang et al., 2014; Radford, Thorne, & Hersey, 1996). CD63 is 
involved in regulation of cell development, activation, growth, motility, and survival (Rorive 
et al., 2010). Rorive et al., reported high CD63 expression in glioblastoma, that this 
correlates with a poor prognosis in GBM and that CD63 appears to be involved in cellular 
proliferation (Rorive et al., 2010). A phosphatidylinositol 3-kinase (PI3K) inhibitor, IPI-145 
was introduced in early phase clinical trials and found to be well tolerated by 
haematological patients and healthy control subjects at doses that effectively inhibited 
CD63 (Akinleye, Avvaru, Furqan, Song, & Liu, 2013). Trials with this inhibitor are ongoing. 
 
Our findings that CD63 was more highly expressed in GBM than in normal tissue confirms 
the findings of Rorive et al., that CD63 expression was higher in GBM cells and increased 
with poor prognosis (Rorive et al., 2010). Studies showing that CD63 contributes to cell 
activation, growth, motility and survival suggest that this protein could contribute to a range 
of processes necessary for tumour progression. An effective PI3K inhibitor already being 
trialed in human patients could potentially become a future treatment for GBM patients. 
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CD164 also known as MUC-24 is a transmembrane sialomucin that acts as an adhesion 
receptor (Havens et al., 2006). Doyonnas et al., showed that CD164 functions are 
regulated through cell type-specific post-translational modifications (Doyonnas et al., 
2000). In prostate cancer, CD164 was found to promote metastasis through the 
chemokine receptor type 4 (CXCR4) / stromal cell-derived factor-1 (SDF-1) interaction 
(Havens et al., 2006). A recent study showed that CD164 promoted tumourigenicity 
through the CXCR4/SDF-1 α axis in an in vivo ovarian cancer model (Huang et al., 2013). 
Upregulation of CXCR4/SDF-1 interaction through CD164 induces cellular proliferation, 
migration, and invasion through activation of the PI3 kinase/Akt signaling pathway (Huang 
et al., 2013). PI3K signaling has been shown to be disrupted in a variety of cancers 
including GBM (Lino & Merlo, 2011) Interestingly, CXCR4 was significantly upregulated in 
all GBM subtypes analysed by the TCGA compared to normal brain tissue, as discussed 
below. This suggests that a relationship could exist between CXCR4 and CD164 in GBM. 
Forde et al. showed that knockdown of CD164 inhibited cell migration mediated by the 
CD184 ligand, SDF-1 (Forde et al., 2007). I speculate that inhibiting CD164 might lead to a 
reduction in CD184/SDF-1 mediated cell migration and downregulation of the PI3K/Akt 
signaling pathway thereby reducing tumour cell proliferation and metastasis in GBM. 
 
During normal brain development, CD184 binding to the ligand SDF-1 has been shown to 
mediate hippocampal-neuron survival and cell migration in brain development (Bagri et al., 
2002). CD184 also known as CXCR4 is a chemokine receptor specific for SDF-1 (also 
known as CXCL12). Studies show that CD184 protein contributes to functions that support 
tumour progression. Small-cell lung cancer cells were shown to express high levels of 
CD184, which upon binding the ligand SDF-1 elicited firm adhesion to stromal cells (J. A. 
Burger, Spoo, Dwenger, Burger, & Behringer, 2003). Burger et al. found that disruption of 
CD184 binding to SDF-1 through the introduction of T140, a CD184-specific chemokine 
receptor antagonist sensitized CLL cells in vitro to drug-induced apoptosis increasing the 
efficacy of current therapy (M. Burger et al., 2005). When we analysed the expression of 
CD184 in GBM using the TCGA data we noticed that CD184 expression was significantly 
higher in all four GBM subtypes than in normal brain tissue. Strong CD184 expression in 
human GBM tumours analysed by the TCGA suggests that binding of the ligand SDF-1 
could contribute to tumour cell migration and invasion in human GBM. The receptor 
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antagonist T140 is a potential candidate for in vitro studies to test the effects of CD184 
inhibition in GBM tumour cells.  
 
5.6 Conclusions 
Cell surface proteins contribute to a wide range of cellular functions that can be exploited 
by cancer cells in tumour progression and invasion. One particularly interesting 
mechanism is the ability to evade phagocytosis by the innate immune system. Before 
terminal differentiation, normal circulating cells use this same ‘recognition of self’ marker to 
remain in the circulation during normal development and for the purpose of cell turnover 
for healthy organ maintenance (Willingham et al., 2012). Exploitation of this property 
equips the cancer cell with an advantage, which allows it to circumvent mechanisms, 
which would otherwise have eliminated it from the population. 
 
The survival advantage that CD47 confers upon a cell through its binding with SIRPα 
emitting the ‘don’t eat me’ signal contrasts with the survival disadvantage it imparts when it 
interacts with thrombospondin-1 leading to an increase in radiosensitivity. The ability to 
capitalize on the diversity of receptors with which CD47 interacts by permitting TSP-1 
binding to increase radiosensitivity or inhibiting binding to SIRPα to abrogate the don't eat 
me signal suggests CD47 could be a useful tool in future combination therapies to 
eradicate an aggressive tumour cell population. These opposing actions could be further 
exploited if treatment were to involve inhibition of the SIRPα/CD47 interaction combined 
with permission of the TSP-1/CD47 interaction to radiosensitise tumour cells while in 
normal healthy adjacent tissue blocking the TSP-1/CD47 interaction to impart 
radioresistance. Radiation damage to healthy tissue is recognized as a long-term 
complication for healthy tissue that has historically been unavoidably negatively impacted 
by localized radiotherapy treatment (Brandes et al., 2008).  
 
Evidence suggests that the majority of GBM cells exhibit strong CD59 and CD47 
expression and that these proteins are viable therapeutic targets in the treatment of tumor 
progression and disease recurrence. CD59 antibody therapy could potentially enhance the 
effects of CD47 antibody therapy by exposing protected cells to complement cell lysis in 
combination with existing surgical and chemotherapeutic treatments. 
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This study found that five cell surface proteins exhibited a significant increase in gene 
expression in comparison to normal human brain tissue based on the TCGA microarray 
data. Recent literature has reported that the ratio of glial cells to neurons in the normal 
human brain is approximately 1:1 in contrast to historical estimations of a glial to neuron 
ratio of 10:1 (Hilgetag & Barbas, 2009) (Azevedo et al., 2009). Based on this data we 
consider normal brain tissue to be a most suitable tissue for comparison of cell surface 
protein expression in GBM The genes we identified are all involved in functions that can 
potentially increase tumour aggression, invasion, and metastasis suggesting that they are 
potential targets for anti tumour therapies. It is of particular interest that for some of these 
proteins, inhibitors are available which could be deployed in neurosphere and mouse 
models to determine their ability reduce intratumoural heterogeneity and/or slow disease 
progression. Overall, my work has identified a cohort of viable targets, some with existing 
inhibitors that have the potential to reduce subpopulations of tumour cells that may 
contribute to disease progression and at the same time increase the cytotoxic response to 
commonly used chemotherapeutics. As the tenure of my PhD candidature has expired, it 
was not possible to test these inhibitors myself. Instead, in the final discussion I have 
outlined my recommendations for future directions arising from this work. 
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CHAPTER SIX 
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6 General discussion and conclusions 
 
The aim of this thesis was to identify new therapeutic targets in human GBM using “close 
to patient” models of human GBM. Using these models, we have identified a population of 
cells within human GBM capable of contributing to therapeutic resistance and tumour 
relapse after therapy. Furthermore, this work identified a small cohort of cell surface 
proteins of potential clinical value in GBM that could be exploited in targeted approaches 
to GBM treatment. The key findings from this work are summarized in Figure 6.1 and its 
accompanying table. 
 
Figure 6-1 GBM is a heterogeneous tumour. A simple schematic summarizes our data showing 
that GBM tumours are heterogeneous and consist mostly of fast cycling cells and a small 
population of slow cycling cells. Intratumoural heterogeneity in cell surface protein expression is 
indicated by different coloured spots in cells. The slow cycling cell population consisted mostly of 
euploid cells and a small fraction of hyperdiploid cells. 
121 
 
 
 
 
Table 6-1 Table of summary of findings. Table briefly outlines findings including characteristics 
identified for each cell population of interest. 
 
 
6.1 Tumour initiating hyperdiploid cells are present in GBM 
A major finding of this thesis was that a hyperdiploid population of tumour initiating cells 
existed in primary cultures of human GBM. Tumour initiating hyperdiploid cells have been 
identified in other cancers. One recent study showed that diploid mouse ovarian cancer 
cells failed cytokinesis (Lv et al., 2012). The product of the failed cytokinesis was 
tetraploidy which resulted in the generation of aneuploid cells following chromosomal mis-
segregation. The subsequent intraperitoneal injection of mouse ovarian surface epithelial 
cells revealed that only late passage aneuploid cells were able to form tumours in contrast 
Cohort of cells Characteristics identified 
 
Total GBM cell population 
 
Cell surface protein expression was highly variable 
 
A small number of proteins were highly expressed in vitro and in vivo 
 
The highly expressed proteins have known roles in cellular 
proliferation, adhesion, migration, invasion, metastasis, drug 
resistance and immune system evasion 
 
Inhibitors have been developed for some of the identified proteins 
 
Comprised of fast cycling and slow cycling cells 
 
 
Slow cycling cells 
 
Not quiescent but actively cycling 
 
More proficient at tumour formation than fast cycling cells 
 
Comprised of euploid and hyperdiploid cells 
 
 
Hyperdiploid cells 
 
Capable of tumour initiation 
 
Resistant to conventional therapy 
 
Sensitive to metabolic inhibition – a potential point of fragility 
 !
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to diploid cells, which did not form tumours (Lv et al., 2012). Thus, ploidy status was a 
selection pressure that generated aneuploid tumour initiating cells. Our search for 
therapeutic targets in GBM led us to the identification of a tumour initiating hyperdiploid 
subpopulation of GBM cells that possess a potential point of fragility which could be 
exploited to slow disease progression. 
 
6.2 Cancer cells are sensitive to metabolic inhibition 
An important finding from this work was the novel observation that specific inhibitors of 
metabolism could deplete hyperdiploid GBM cells. This suggests that the dependence of 
hyperdiploid cells on the glycolytic pathway may be a viable therapeutic target in GBM. We 
hypothesize, based on our work with slow cycling cells, that hyperdiploid cells may be 
endowed with superior tumour initiating ability. Therefore, I hypothesize that a low 
carbohydrate diet could have maximum impact on hyperdiploid human GBM cells while 
also impeding metabolism in euploid cancer cells and increasing tumour cell sensitivity to 
other therapies without damaging normal cell metabolism. 
 
It is noteworthy that, the Ketogenic diet that is currently in use to treat children with 
refractory epilepsy was given to mice with brain tumours. The results showed that when 
the diet was administered in restricted amounts, tumour growth and vascularity were 
significantly reduced and progression free survival was significantly increased (W. Zhou et 
al., 2007). As this diet is already in clinical use to treat another pathological condition, it is 
conceivable that it could be implemented to compliment current treatment regimes and 
has the potential to improve therapeutic response and progression free survival (Schwartz 
et al., 2015). The following patents have also been generated: Ketogenic diet composition 
for the treatment of chemo therapy and/or radiation therapy. WO2012113572 A1, 
Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy 
patients. US20140011749 A1, Regulation of cancer using natural compounds and/or diet. 
WO2014159500 A1, Targeting cancer with metabolic therapy and hyperbaric oxygen. 
WO2014085652 A1. In addition to this, clinical trials are currently underway into the 
ketogenic diet in adults with GBM. As an example: Calorie-restricted, ketogenic diet and 
transient fasting during reirradiation for patients with recurrent glioblastoma (ERGO2). 
NCT01754350. 
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Normal cells use oxygen and glucose to generate adenosine triphosphate (ATP) to store 
energy in a process known as oxidative phosphorylation (Garber, 2006). Cancer cells 
have an increased reliance on glucose for ATP production even in the presence of oxygen 
(anaerobic glycolysis). This is known as the “Warburg effect” (Warburg, 1956b). The 
increased glucose requirements of cancer cells present a potential therapeutic target that 
could specifically inhibit cancer cell metabolism without negatively impacting normal cell 
metabolism. Ketones are produced in the liver as an energy source when carbohydrate 
(glucose) is in short supply. They are produced from fatty acids and oxidized in the 
mitochondria bypassing glycolysis (W. Zhou et al., 2007).  
 
The Ketogenic diet is low in carbohydrates and high in fats providing energy for normal 
cells that can utilize ketones for energy production and starves cells that cannot 
metabolize ketones (W. Zhou et al., 2007). Results from studies utilizing high fat, low 
carbohydrate diets suggest that cancer cells could be specifically targeted with therapies 
that reduce glucose availability leading to cell death and tumour regression while normal 
cells continue to generate ATP through oxidative phosphorylation. A study of tumour 
progression in mice on a carbohydrate restricted diet showed a reduction in tumour 
progression and an increase in tumour cell sensitivity to antitumor therapies (Ho et al., 
2011). The finding that human GBM tumours contain a tumour initiating subpopulation of 
hyperdiploid cells that rely on increased energy requirements above those of both euploid 
cancer cells and healthy non cancerous cells suggests that carbohydrate restriction might 
improve response to treatment in patients with GBM. 
 
6.3 Hyperdiploid human GBM cells are sensitive to proteasome inhibition 
Previous studies have shown that proteasome activity in aneuploid cells can be targeted 
specifically without negatively impacting euploid cell populations (Tang et al., 2011). 
MG132 is a peptide aldehyde that inhibits proteasome activity by binding to the active site 
of the beta subunits in the 20S core of the 26S proteasome complex (Guo & Peng, 2013). 
MG132 promotes cell cycle arrest and induces apoptosis through the regulation of reactive 
oxygen species and subsequent defects in mitochondrial function as a result of 
proteasome inhibition (J. J. Chen, Huang, & Chen, 2005; Guo & Peng, 2013; Han, Moon, 
You, & Park, 2009). Nuclear factor kappa-B (NF-κB) regulates the expression of the 
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antiapoptotic genes BCL-2 and BCL-XL (Ortiz-Lazareno et al., 2014). Treatment with 
MG132 interferes with NF-κB function (Ortiz-Lazareno et al., 2008). Inhibitory protein 
kappa-B (IκB) inhibits NF-κB function through its association with the NF-κB dimer in the 
cytoplasm. This association maintains NF-κB in an inactive form (Gilmore & Herscovitch, 
2006). The degradation of the NF-κB inhibitor, IκB is prevented by treatment with MG132 
(Nakajima, Kato, Takahashi, Johno, & Kitamura, 2011). Colon cancer cells underwent 
apoptosis following treatment with MG132 as a result of mitochondrial induction of 
proapoptotic factors (W. X. Ding et al., 2007). Similarly, leukaemia cells entered apoptosis 
at the highest frequency when MG132 treatment was combined with another cytotoxic 
agent, either paclitaxel or Doxorubicin (Bravo-Cuellar et al., 2013; Ortiz-Lazareno et al., 
2014). These data suggest that administering MG132 in combination with other treatments 
could produce a targeted effect on therapy resistant hyperdiploid tumour cells.  
 
6.4 Limitations to in vitro and in vivo studies 
It was not possible to obtain normal human brain tissue as a comparator for in vitro and in 
vivo assays therefore we used publically available data on normal human brain cells to 
determine normal protein expression levels where possible. Despite this limitation, we 
were able to show significant differences in gene expression between human GBM 
tumours and normal human brain tissue for a small cohort of candidates.  
 
Xenotransplantation assays are an established method used to examine tumour 
progression and complexity in vivo. However, due to the necessity for animals to be 
immunodeficient to some degree, transplanted cells are not within the environment 
normally experienced by primary tumour cells in a human patient. Immunodeficiency is 
necessary to ensure that transplanted cells survive but also masks any potential 
contribution to tumour cell survival that may have been otherwise present with an intact 
immune system. It should be noted that even “immunodeficient” mice retain remnants of 
immunity (albeit unbalanced) resulting in the possibility that relevant human tumourigenic 
cells are eliminated by the residual xenogenic eradication system (Meacham & Morrison, 
2013). These limitations are unavoidable and common to the vast majority of cancer 
studies. Despite these limitations, we were able to generate xenograft tumours that 
resembled primary human GBM tumours histopathologically. 
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Orthotopic xenograft models of human GBM are labour intensive, time-consuming 
experiments. Murine brain tumours in our mouse model took up to ten months to fully 
develop and required constant monitoring. Time constraints prevented limiting dilution 
injections of hyperdiploid clonal cell populations into mice to determine the tumour 
initiation efficiency of hyperdiploid tumour cells. It is conceivable that superior tumour 
initiation shown in slow cycling cells in chapter two was due to an enrichment of 
hyperdiploid cells within the slow cycling fraction rather than the total population of slow 
cycling cells. We hypothesize that fewer hyperdiploid human GBM cells than euploid 
human GBM cells are required for in vivo tumour initiation. The majority of tumour cells are 
eradicated at the completion of therapy in patients however, human GBM tumours 
invariably regenerate. A population of cells with the capacity to regenerate tumours from 
very small numbers would pose a serious threat to complete remission of the disease. 
Superior tumour initiating ability would establish hyperdiploid cells as a target for treatment 
with the potential to increase progression free survival or inhibit tumour regrowth 
completely.  
 
6.5 Future directions 
To extend the findings discussed in this thesis, glucose deprivation in in vivo hyperdiploid 
tumour models could potentially reveal changes in therapeutic response to current 
treatment protocols. Following intrastriatal injection of hyperdiploid cells mice would be 
placed on either a normal diet or a low glucose diet and monitored for signs of tumour 
development. At the end of the experiment tumour size for the two groups and survival 
curves would be compared to assess differences in time for diploid and hyperdiploid cells 
to form large tumours. Future work should also include other anti-hyperdiploid therapies 
and the impact they have on the response to TMZ treatment. Tang et al. showed that 5-
aminoimidazole-4-carboxamide riboside (AICAR) and 17-allylamino-17demethoxy-
geldanamycin (17-AAG) were able to inhibit aneuploid tumour cell proliferation while 
sparing euploid cells in vitro and in vivo (Tang et al., 2011). I would like to test these 
therapies on human GBM hyperdiploid cells in vitro and orthotopic xenograft tumour 
models generated from euploid and hyperdiploid cells.  
 
Cell surface proteins can serve as specific therapeutic targets when they are differentially 
expressed on normal cells and tumour cells. The CD9-specific monoclonal antibody ALB6 
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effectively reduced proliferation in tumours generated in mice from an ovarian cell line 
(Hwang et al., 2012). RG7356 inhibited the interaction between CD44 and hyaluronic acid 
in in vivo tumours generated from eight cancer cell lines (Birzele et al., 2015) and was 
approved for use in a phase 1 clinical trial in the U.S. A PI3K inhibitor, IPI-145 was 
effective in inhibiting CD63 activity in phase 1 clinical trials in haematological patients 
(Akinleye et al., 2013). The T140 CD184 receptor antagonist sensitized CLL cells to 
existing therapy (M. Burger et al., 2005). To extend the results discussed in this thesis and 
the work of others I would like to test these inhibitors in vitro using human GBM cells and 
then in vivo using orthotopic xenograft tumour models of GBM. The ultimate goal of this 
research was to provide new insight into therapeutic resistance in GBM. These findings 
have revealed a subpopulation of GBM cells and a small cohort of proteins that represent 
potential treatment targets. My hope is that this work leads to the validation of new 
treatment regimes that will improve therapeutic outcomes in this aggressive and incurable 
disease.  
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